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Abstract 
Expression of the stem cell antigen-1 (Sca1) denotes cardiac progenitors in the adult mouse 
heart and a clonogenic subset (CSP) is identified by the side population phenotype. Clonal 
CSP cells differentiate to cardiomyocyte, endothelial and smooth muscle lineages when 
grafted in vivo; however, the instructive signals directing adoption of these fates are 
unknown. Similarly, in vitro conditions for directed differentiation of CSP have yet to be 
defined. To facilitate high content screening approaches for the investigation of signals 
directing cardiomyocyte differentiation, a lentiviral fluorescent reporter assay based on the 
5.5 kb Myh6 promoter was developed. In validation experiments comparing expression in a 
range of differentiated cell types, the Myh6-based construct demonstrated superior specificity 
for the cardiomyocyte fate than a TNNT2-based construct that was assessed as a potential 
alternative. However, in proof of concept, high content screens, Myh6 reporter gene induction 
was observed in the absence of endogenous Myh6 gene expression. Ectopic expression of 
lentiviral reporter constructs based on tissue specific promoter is reported elsewhere and 
these findings highlight the potential for false positive induction in screening applications. 
Unexpectedly, cardiomyocyte differentiation was not observed under any of the conditions 
tested, although smooth muscle differentiation occurred under conditions of low serum. The 
discrepancy between in vivo and in vitro lineage capacity suggests that the methods for 
differentiation investigated here were inadequate. Before phenotypic screens of cell fate can 
be instigated for CSP clones, further studies are required to better define which CSP clones 
are most cardiogenic and to establish methods for culture that better recapitulate the 
endogenous microenvironment. 
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Nppa  atrial natriuretic peptide      ANP, Anf 
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Overview 
Impact of cardiovascular disease and heart failure 
Cardiovascular disease remains the leading cause of mortality in the industrialized world 
despite considerable advances in treatment over recent decades. The prevalence of heart 
failure is increasing as a consequence of improvements in survivorship, together with 
demographic shifts towards an aged population; amongst US adults, an estimated increase 
of 25% is anticipated in the next two decades; from 6.6 million to 9.6 million cases 
(Heidenreich et al., 2011). The prognosis for patients presenting with decompensated heart 
failure is equivalent or worse than that of many of the common malignancies (Stewart et al., 
2001). Current therapies have improved the prognosis somewhat by slowing or preventing 
functional decline, however the imperative for better treatments aimed at restoring lost heart 
function is clear.  
 
Scarring predominates following myocardial injury  
Progression to heart failure typically follows an initial acute injury resulting in impairment of 
ventricular function, such as for myocardial infarction. The acute injury response is 
characterised by inflammatory cell infiltration and fibroblast expansion to clear non-viable 
material and generate scar. Poorly contractile segments result in reduced overall cardiac 
performance that is compensated for by hypertrophy of viable segments and neurohumoral 
activation to maintain cardiac output.  In the longer term, dysregulated cardiac function 
impacts on tissue homeostasis (cardiomyocyte loss and fibrosis) resulting in extension of the 
injury beyond the initial extent. These maladaptive responses underlie adverse left ventricular 
remodelling and fibrosis, which are a poor prognostic marker for patients (Assomull et al., 
2006). If treatments were available that could effectively restore functional myocyte number 
after the initial injury then many of the secondary outcomes could be limited or averted 
completely.  
 
Regenerative deficit of mammalian myocardium  
In the mammal, myocardial injury response characterized by scar formation contrasts to the 
robust regenerative responses observed in related biological systems. The capacity for 
myocardial regeneration differs considerably depending upon the developmental context, as 
well as amongst different species. Lower order veterbrate species such as teleost fish exhibit 
strikingly robust cardiac regeneration following experimental amputation and are able to 
restore the entire cardiac apex to normal function and without scar (Poss et al., 2002). This 
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regenerative potency is echoed in the developing and newborn mammalian heart 
(Drenckhahn et al., 2008; Porrello et al., 2011). In contrast to adult cardiac muscle, adult 
skeletal muscle regenerates robustly following injury to restore normal architecture without 
scar, through the proliferation then differentiation of lineage-committed precursor cells 
(Collins et al., 2005; Seale et al., 2000).  
 
The cardiomyocyte as the limiting factor in cardiac regeneration 
The apparent absence of a regenerative response in the mammalian myocardium 
traditionally has been attributed to the absence of cardiomyocyte renewal since expansion of 
the other important cell compartments has long been established (fibroblasts, smooth muscle 
and endothelial cells). This understanding has been challenged by a number of lines of 
evidence, which collectively point towards renewal of the cardiomyocyte compartment during 
adult life both in humans and in rodent species, prompting intense interest into the cellular 
origins of new cardiac myocytes, both during normal homeostasis and after injury.  
 
Cardiomyocye progenitors 
The discovery of multipotent cardiovascular progenitors as the basis for developmental 
cardiogenesis (Garry and Olson, 2006), has promoted the search to adult stem cells with 
equivalent characteristics. A number of stem-like populations have been described in adult 
rodent and human hearts that are able to differentiate to cardiomyocytes when grafted to 
injured myocardium (Beltrami et al., 2003; Messina et al., 2004; Oh et al., 2003). Better 
understanding of the cellular system(s) underlying low-level cardiomyocyte turnover in 
humans may assist in identifying novel targets for therapies aimed at enhancing reparative 
healing. Advances in the mechanistic understanding of mammalian cardiomyocyte renewal 
derive predominantly from investigations of rodent species but also from the study and 
manipulation of human myocardial biopsy tissue as described in detail below. Unless 
otherwise stated, studies were conducted using mouse or rat model systems. 
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Mammalian cell turnover, tissue homeostasis and regeneration  
Overview  
Tissue homeostasis describes the process by which an organism’s form and function is 
maintained throughout the lifespan. Tissue homeostasis encompasses complex processes 
for the elimination of older differentiated cells by apoptosis and their replacement with newly 
generated cells. In contrast, tissue regeneration refers to the response to a pathological insult 
to restore damaged tissue architecture, typically in the context of inflammation. Thus, 
regeneration represents an alternative pathway to somatic cell turnover in adulthood, distinct 
from tissue homeostasis where incremental replacement of defunct cells occurs through 
programmed cell death and limited renewal as illustrated in Figure 1.1. 
 
 
 
Integrity of form 
and function!
Regeneration/ tissue 
homeostasis!
Replenishment!
-  Proliferation!
-  Adult stem cells  !
Injury/ tissue 
turnover!
Elimination!
-  Apoptosis!
-  Necrosis !
-  Amputation!
 
 
Figure 1.1  Tissue homeostasis, regeneration and somatic cell turnover. To maintain integrity of form and 
function, cell loss must be balanced by the genesis of new differentiated cells types. Elimination of cells by 
programmed apoptosis occurs during tissue homeostasis whereas injury may result in loss of cells through 
amputation, necrosis and apoptosis. Replenishment may occur through the proliferation and differentiation of 
adult stem cells, the self-duplication of differentiated cells, or the dedifferentiaion and subsequent amplification of 
differentiated cells.  
 
In classical studies of mammalian tissue homeostasis by auto-radiography in rats and mice, 
Leblond et al., classified organs based the extent of turnover and the mechanisms of renewal 
(Leblond, 1964; Messier and Leblond, 1960). They demonstrated the contribution of adult 
stem cells in tissues with high rates of cell turnover (i.e. self-renewing: blood, gut epithelium) 
and of proliferation of differentiated cells where the rates are lower (i.e. expanding tissues: 
liver, vascular smooth muscle and endothelium). The heart and the central nervous system, 
for which turnover could not detected, were considered to be static. Although the framework 
provided by this seminal work remains instructive, more recent observations have suggested 
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greater overlap of the contrasting mechanism for renewal. In particular, the observation that 
stem cells exist in most if not all mammalian adult tissues has led to a fundamental refiguring 
the understanding of the biology involved (Raff, 2003). It is interesting to note that the extent 
of turnover during normal homeostasis correlates poorly with regenerative capacity, 
suggesting context specific pathways to renewal (Rando, 2006). For example in mice, robust 
regeneration of skeletal muscle following injury contrasts markedly with the low rates of cell 
turnover observed under normal conditions (Collins et al., 2005). 
 
The cellular basis for somatic cell turnover  
The three main pathways for renewal across species and organ systems may be 
summarized as follows:  
 
(i) the differentiation of adult stem cell cells;  
(ii) self duplication of differentiated cells;  
(iii) dedifferentiation and subsequent amplification of differentiated cells.  
 
Each of these pathways results in the genesis of progenitors, i.e. cells that are able to 
differentiate to a particular lineage. Exquisite regulation is required to precisely match 
renewal to cellular attrition to avoid dysregulated growth. In this respect, the parallels with 
development are striking.  
 
(i) Adult stem cells 
Classically described as restricted to self-renewing tissues such as blood and gut epithelium, 
adult stem cells (or somatic stem cells) are now known to reside almost all tissues, across 
mammals and including humans (Dor and Melton, 2004; Pellettieri and Sanchez Alvarado, 
2007). Typically, a reservoir of undifferentiated stem cells is maintained throughout life in 
anatomically or functionally defined niches where behaviour is regulated by 
microenvironmental cues.  Displacement from the niche is thought to be an important step in 
determining the fate of stem cell progeny as they are exposed to external signals to which 
they respond by dividing and differentiating. Local signalling within the niche perpetuates the 
undifferentiated state by stimulating self-renewal when division occurs. 
 
A hierarchy of stem and progenitor cells exists in which lineage is restricted progressively 
through a stepwise process of lineage restriction known as commitment (Figure 1.2). Cells at 
intermediate stages in this hierarchy serve as transient amplifying cells and are often referred 
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to as progenitors. These cells have a more limited capacity for self-renewal than the stem 
cells from which they descend. Although there is a lack of consensus as to how to use these 
terms, most researchers would agree that progenitor cells are oligopotent and are further 
downstream in lineage commitment than adult stem cells. 
 
True stem cells are defined by a capacity for indefinite self-renewal and for differentiation into 
multiple lineages. In contrast to embryonic stem cells (ESCs) which give rise to specialized 
cells from all three germ layers (pluripotent), adult stem cells are typically give rise to 
differentiated cells of different types from a single layer (multipotent). Certain adult stem cells, 
such as the well-characterized satellite cells of skeletal muscle, are committed to a single cell 
fate, in this case skeletal muscle (oligopotent, as discussed below).  
 
 
TA/ progenitor cells!
Stem cell niche!
Multipotent stem cell!
Differentiated cells!
?Undifferentiated !
adult stem cell!  
 
Figure 1.2 The classical stem cell hierarchy. Schematic of the classical hierarchy illustrating progressive fate 
restriction from undifferentiated adult stem cell, to multipotent stem cells, transiently amplifying (TA) progenitor 
cells arriving at the differentiated cell type. Stem cells when activated in the stem cell niche divide by asymmetric 
cell division to generate one mother cell that is identical to the original stem cells and a daughter cell that goes on 
to generate multipotent stem cells and ultimately differentiated cell type. Facultative stem cells may be generated 
by the de-differentiation of existing differentiated cells (dashed arrows). Blue arrows indicate self-renewal; red 
arrows, lineage specification; green arrows, differentiation; dashed arrows. Adapted from (Rawlins and Hogan, 
2006). 
 
Dedifferentiation and self-duplication 
For many tissues, as cells differentiate during embryonic development, their rate of 
proliferation decreases until arrest occurs in the quiescent (G0) stage of the cell cycle (Coller 
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et al., 2006). Certain cell types were thought to have exited the cell cycle irreversibly, whilst 
others are able to re-enter the cycle under certain stimuli. Cells which are G0 are arrested 
reversibly, such as hepatocytes in the liver, and are able to divide to replace lost cells 
(Fausto et al., 2006), whereas terminally differentiated cells such as keratinocytes are not 
(Allombert-Blaise et al., 2003). This method for cellular replenishment is known as self 
duplication and is exemplified in the mouse by the regeneration of β cells in the pancreas 
(Dor et al., 2004). 
 
Dedifferentiation describes the process by which a differentiated cell reverts back to an 
earlier developmental stage, usually as part of a regenerative process. Dedifferentiation 
based regeneration is exemplified by urodela and segmented worms (Brockes, 1997; Fontes 
et al., 1983); in response to injury, existing specialised cells are returned to an early 
progenitor state before proliferating and redifferentiating into the relevant components of the 
affected part. In this manner, lobular bile duct cells of the mouse liver can de-differentiate to 
form progenitors to replenish hepatocytes leading to the concept of facultative stem cells 
contributing to regeneration (Alison et al., 2004). 
 
Contrasting mechanisms may coexist in particular organ systems with one pathway 
predominating under certain conditions. For example, self-duplication underlies normal tissue 
homeostasis in the liver (Sigal et al., 1992), whereas adult stem cell differentiation 
contributes to liver regeneration following injury (Oh et al., 2002; Taub, 2004). There is a 
trend towards reduced cell turnover in mammalian organs that apparently lack tissue-specific 
stem cells. However the model of alternative mechanisms active under different biological 
contexts is gaining increased credence.  Whether pre-existing or generated through de-
differentiation, stem-like progenitor cells underlie many regenerative processes in mammals 
as shown in Figure 1.3 
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Figure 1.3 Classification of mammalian tissues based on the rate of cellular turnover and regenerative 
capacity. Tissues may be characterised according to the rate of cellular turnover during normal homeostasis, 
which in turn is correlated to regenerative capacity following injury. Tissues with the highest rates of turnover 
(blood, gut epithelium) have a significant and highly active stem cell compartment that in turn translates to a high 
regenerative capacity. In the liver, replenishment of hepatocytes occurs by the self-duplication of differentiated 
cells in normal homeostasis however stem cell based regeneration is observed following injury. Adapted from 
(Rando, 2006) 
Myocardial tissue homeostasis and regeneration  
Overview 
The embryonic mammalian heart has a potent regenerative capacity which is reminiscent of 
that observed in lower order organisms. In a genetic mouse model based on random, cardiac 
specific ablation of cardiomyocytes, a robust regenerative capacity has been demonstrated 
through the expansion of the myocyte compartment (Drenckhahn et al., 2008). The capacity 
for cell division of mouse cardiomyocytes declines sharply as they undergo cell cycle arrest 
and become binucleate as a result of uncoupled karyokinesis (Li et al., 1996a; Walsh et al., 
2010). Withdrawal from the cell cycle has long been regarded as permanent with cells 
arriving in a state of terminal differentiation; however recent reports have reported cell 
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division of cardiomyocytes in mice, implying that at least a proportion remain in a G0 arrested 
state (Bersell et al., 2009; Engel et al., 2005; Kuhn et al., 2007). 
 
Using conventional experimental methods, it has not been possible to confirm conclusively or 
refute low-level turnover in adult mouse myocardium (Steinhauser and Lee, 2011). Given the 
observation of a low incidence of cardiac tumours in humans and the seeming irreversibility 
of cardiac injury, tissue turnover and/or regeneration in mammals has been assumed to be 
negligible or absent. By contrast, lower order vertebrate species such as the zebrafish 
demonstrate robust cardiac regeneration in the face of experimental injury (Poss et al., 
2002). There appears to be a trend towards a diminished capacity for differentiation with 
increasing organismal complexity, although the evolutionary drivers remain poorly 
understood (Bely, 2010).  
 
The apparent absence of new cardiomyocyte formation during adult mammalian life contrasts 
with other myocardial lineages (endothelial, vascular and fibroblast) for which renewal is well 
established (Rensen et al., 2007; Souders et al., 2009; Urbich and Dimmeler, 2004; Virag 
and Murry, 2003). These observations spotlight cardiomyocyte regeneration as the limiting 
factor in myocardial repair. Emerging evidence for cell turnover, along with understanding 
about developmental and adult stem cell systems, is prompting a thorough re-evaluation of 
the biology of myocardial tissue.  
 
Evidence for cardiomyocyte turnover in mammals 
In principle, cardiomyocyte turnover may arise as a result of normal tissue homeostasis or 
from wholesale regeneration following injury. Studies in this area can be grouped into 
observational studies of physiological turnover in normal life and interventional studies 
investigating the regenerative response to experimental injury. 
 
A mainstay of both interventional and observational studies has been the application of 
histology-based methods for the detection of cardiomyocyte cell division. This approach 
relies on the proxy of nuclear division (karyokinesis) to detect cellular division (cytokinesis) by 
tracing the fate of synthetic nucleotides incorporated into newly formed DNA 
(bromodeoxyuridine, BrdU), or by detection of markers such as Ki-67 (Walsh et al., 2010). 
Baseline variability in the degree of cardiomyocyte polyploidy in mammals complicates this 
approach, as does the accurate identification of cardiomyocyte nuclei from the numerically 
predominant non-cardiomyocytes (Banerjee et al., 2007). Data from experiments on mice are 
conflicting, with some studies indicating on-going mitosis through adult life (Anversa and 
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Kajstura, 1998) and others declaring it absent (Soonpaa and Field, 1997; Steinhauser and 
Lee, 2011) 
 
The most compelling evidence for mammalian cardiomyocyte turnover has come from post-
mortem examination of human myocardial tissue using radiocarbon dating of cardiomyocyte 
nuclei to determine cell age. During the mid 20th century, prior to the Partial Test Ban Treaty 
of 1963, nuclear bomb testing generated a spike of Carbon-14 that was incorporated into 
CO2 and ultimately the food chain. The proportion of Carbon-14 present in the biosphere was 
then used to Carbon date nuclear DNA in human cardiomyocytes. These studies 
demonstrated convincingly the genesis of new cardiomyocytes in post-natal life and 
estimated a rate of cellular turnover in normal tissue homeostasis of 1% per year at age 25, 
falling to 0.45% at age 75 (Bergmann et al., 2009). Collectively, these studies support the 
case for cardiomyocyte renewal in adult mammals including humans, although only to a 
limited extent.  
 
The origin of new cardiomyocytes in mamallian adult life 
Emerging evidence for cardiomyocyte renewal in adult life has prompted intensive study to 
uncover the origin of these cells. Evidence for each of the pathways outlined above has been 
generated in vertebrate animal models (adult stem cells, de-differentiation and self-
duplication).   
 
For teleost zebrafish, cardiac regeneration occurs by the de-differentiation of existing 
cardiomyocytes to form an expanding progenitor pool to repopulate lost cells 
(Jopling et al., 2010; Kikuchi et al., 2010). In mice, several groups have reported that adult 
cardiomyocytes are able to reenter the cell cycle and contribute to regeneration under FGF1, 
periostin and neuregulin-1 stimulation (Bersell et al., 2009; Engel et al., 2005; Kuhn et al., 
2007). The effect of periostin on myocyte division was not replicated in vivo in a transgenic 
model of over expression (Lorts et al., 2009). Walsh et al. developed a flow cytometry based 
approach to investigate cardiomyocyte division in mice, using nuclear cardiac Troponin T 
staining to robustly identify cardiomyocytes (Walsh et al., 2010). By this approach, they were 
able to circumvent some of the pitfalls associated with histological analysis of proliferation 
and concluded that adult cardiomyocytes do not enter the cell cycle beyond early neonatal 
life.  
 
Evidence for the contribution of an adult stem cell population to cardiomyocyte renewal in the 
mouse is provided by Hseih et al. (2007), in studies using complex transgenesis for lineage 
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fate mapping. The system comprises the Myh6 promoter driving tamoxifen-inducible Cre 
recombinase used to indelibly label adult cardiomyocytes in ZEG reporter mice. By 
examining changes in the percentage of labelled cardiomyocytes following experimental 
infarction, the investigators were able to infer a contribution from an Myh6 negative stem cell 
population. In an alternative approach, Senyo et al. (2013) combined the Cre/Lox lineage fate 
mapping system above with a 15N pulse chase approach whereby nuclear incorporation of 
isotopic nitrogen assessed by multi-isotope mass spectroscopy was used to confirm cell 
division. Newly formed mononuclear cardiomyocytes (15N positive) where found to be GFP 
positive suggesting cardiomyocyte renewal from the self-duplication or de-differentiation and 
re-differentiation of existing cardiomyocytes.  
 
Although radiocarbon dating of human cardiomyocytes strongly supports the existence of 
cardiomyocyte renewal throughout adult life, there is no consensus as to the mechanism by 
which this occurs. The evidence from mouse models is conflicting and no consensus has yet 
emerged. It is possible that multiple pathways co-exist in the mammalian myocardium, as for 
the liver where the source of new cellular material is dependent upon the biological context 
(tissue homeostasis versus regeneration).  
 
Resident cardiac stem/ progenitor cells 
Overview 
Resident cardiomyocyte progenitor cells derived from the adult mammalian heart have been 
identified by the Supervisor and others in rodents, and have been shown to be capable of 
proliferation and differentiation to cardiomyocytes and in some cases other cardiac lineages 
(Beltrami 2003, rat; Oh 2003, mouse; Pfister 2005, mouse; Oyama 2007, rat; reviewed in 
Segers 2008). Human analogues of these populations are described (see below), however 
the characterization and functional examination of mammalian adult cardiac progenitors has 
been conducted in mouse and rat model systems.  
 
Despite such study, is not determined conclusively whether these populations represent or 
encompass true tissue stem cells or whether they represent progenitors derived from these 
cells. Furthermore, the developmental origin is unknown, with postulated sources including: 
developmental stem cells sequestered and maintained since embryogenesis; mesenchymal 
stem cells (MSCs) from the bone marrow; and facultative stem cells arising from de-
differentiated myocytes.  
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Some populations of putative cardiac stem/ progenitor cells are reported to differentiate to 
multiple cardiac lineages (multi potent, (Beltrami et al., 2003); for others the lineage potential 
beyond cardiomyocyte fate is not fully explored and may be more limited (unipotent, (Oh et 
al., 2003)). As a minimal characteristic, however, is a cardiac stem/ progenitor cell that has 
the capacity to generate the cardiomyocyte lineage.  
 
When considering resident cardiac stem/ progenitor cells, it is instructive to consider stem-
based homeostasis and repair in mammalian skeletal muscle where the contribution of 
satellite cells is comparatively well understood. Satellite cells are resident stem cells that are 
usually quiescent but are activated by injury, promoting proliferation and differentiation to 
skeletal myocytes (Zammit, 2008) Satellite cells underlie a robust regenerative response by 
which tissue architecture is restored following injury (Whalen et al., 1990). Satellite cells are 
able to self renew to maintain the stem cell/ progenitor pool throughout adult life (Collins et 
al., 2005). Quiescent satellite cells can be identified by their expression of number of 
molecular markers including Pax7 (Seale et al., 2000) and M-Cadherin (Irintchev et al., 
1994). Upon the appropriate stimulus, activation is marked by expression of MyoD, the 
master regulator of skeletal muscle differentiation (Yablonka-Reuveni and Rivera, 1994).  
 
In contrast to skeletal muscle, where activated satellite cells are identified by expression of 
MyoD, no equivalent single factor has been found to identify cells destined to adopt the 
cardiomyocyte fate. Instead, identification of adult cardiac progenitors has relied upon 
examination of functional potential through assays of clonogenicity, self-renewal and lineage 
potential. Nevertheless, evolutionary conserved transcription factors essential for normal 
mammalian heart formation are enriched in some of populations described (see Table 1.1). 
Adult cardiac progenitor cells may be defined as clonogenic, self-renewing cells that are able 
to differentiate to the cardiomyocyte lineage under appropriate stimulation (directed 
differentiation in vitro or following grafting to injured mammalian myocardium).  
Mammalian multipotent cardiovascular progenitors in heart development 
Mammalian heart development is based upon the specification and proliferation of a pool of 
lineage restricted progenitors that divide and differentiate to populate the organ (Brade et al., 
2013; Garry and Olson, 2006). Based on the assumption that renewal in adult life is likely to 
recapitulate developmental processes, one approach to determining the identity of adult 
cardiac stem cells is to explore parallels with developmental heart formation. Three sources 
of developmental cardiac progenitors are described, the cardiac mesoderm, the cardiac 
neural crest and the proepicardial organ (PE). Each of these distinct populations is essential 
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to normal development, contributing complimentary cell lineages to a variety of structural 
components of the heart.  
 
In the mouse, cardiac mesodermal progenitors are the source of most, it not all, 
cardiomyocytes, as well as contributing epicardial, endocardial, endothelial and vascular 
smooth muscle cells (Brade et al., 2013). Progenitors emerge from the anterior region of the 
primitive streak (PS) during gastrulation (Brade et al., 2013) and the timing and position of 
this transition the first step towards establishing cardiac specification (Garcia-Martinez and 
Schoenwolf, 1993; Tam et al., 1997). At this stage, cardiac mesodermal progenitors are 
marked by the transient induction of mesoderm posterior 1 (Mesp1), (David et al., 2008; 
Lindsley et al., 2008). Mesp1+ progenitors migrate away from either side of the PS and adopt 
an anterolateral position under the head folds (mouse embryonic day 6.5, E6.5).  
 
Subsequently, the downregulation of Mesp1 corresponds to the induction of transcription 
factors that regulate the expression of genes directing the differentiation of cardiac cells 
(Bondue et al., 2008). No single factor has been identified as sufficient for this process. 
However, a core set of evolutionary conserved transcription factors are known to play a 
specific and essential role in normal heart development. These factors are often described as 
cardiac transcription factors however expression is not restricted to the developing heart 
(Olson, 2006). Cardiac transcription factors include GATA binding protein 4 (Gata4); GATA 
binding protein 6 (Gata6); NK2 homeobox 5 (Nkx2.5); myocyte enhancer factor 2A (Mef2a); 
myocyte enhancer factor 2C (Mef2c); T-box 5 (Tbx5); T-box 20(Tbx2); and heart and neural 
crest derivatives expressed transcript 1 and 2 (Hand1/ Hand2) (Bruneau, 2002). 
Interestingly, ectopic expression of Gata4, Mef2c, Hand2 and Tbx5 in fibroblasts is sufficient 
to prompt reprogramming to the cardiomyocyte fate highlighting the importance of this subset 
of factors (Song et al., 2012). How these factors relate to the specification and lineage 
commitment of specific populations of developmental cardiac progenitors is incompletely 
understood. However, the expression of Nkx2.5 is reported to mark biopotent cardiac 
progenitors committed to cardiomyocyte and smooth fates (Wu et al., 2006). 
 
After commitment, cardiac mesodermal progenitors expand and transition to the heart-
forming region in the midline. Two successive migratory waves of cells constitute the first 
heart field (FHF) and second heart field (SHF) respectively. Fusion of FHF masses across 
the midline generates the cardiac crescent from which the beating heart tube emerges at 
E8.5 (Buckingham et al., 2005). FHF progenitors form the left ventricle and contribute to the 
atria and inflow tract. Following this, progenitors of the SHF migrate to the poles of the 
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developing heart and progressively contribute to rapid growth and elongation during heart 
looping. The SHF arises from pharyngeal mesoderm which lies medial and anterior to, (but 
contiguous with) the first heart field. SHF progenitors generate the outflow tract, right 
ventricle and contribute in part to the atria (Buckingham et al., 2005). 
 
No genes have yet been identified that are uniquely expressed in FHF progenitors, though 
Tbx5 is preferentially expressed in developing left ventricle (Brade et al., 2013; Takeuchi et 
al., 2003). Within the developing heart, Isl1 are expressed progenitors of the SHF and not 
those of the FHF (Cai et al., 2003; Kelly, 2012). Isl1-Cre recombinase lineage fate mapping 
has been used to investigate SHF progenitors in developmental models and in differentiation 
ESCs. In both systems, Isl1+ cells differentiate to cardiomyocyte, endothelial and smooth 
muscle cells (Moretti et al., 2006; Sun et al., 2007). It should be noted that Isl1 is also 
expressed in other embryonic tissues such as the endocrine pancreas (Karlsson et al., 1990) 
and motor neurons (Tsuchida et al., 1994), and is consequently not a specific marker for 
cardiac progenitors.  
 
A second subset of cardiac progenitors originate from the PE, a transitory mesenchymal 
structure in proximity to the venous pole of the heart tube at E8.5 (Manner et al., 2001). PE 
derived progenitors migrate around the heart tube and form the epicardium. Some undergo 
epithelial to mesenchymal transition (EMT) and infiltrate the myocardium, contributing 
smooth muscle cells to the vasculature and fibroblasts to the interstitium (Brade et al., 2013). 
PE progenitors are marked by expression of Tbx18 (Cai et al., 2008; Kraus et al., 2001), Wt1 
and Isl1 (Zhou et al., 2008b). Conditional reporter based studies using Tbx18 and Wt1 to 
lineage trace cells of epicardial origin have suggested cardiomyocyte, endothelial and 
smooth muscle differentiation (Cai et al., 2008; Smart et al., 2011; Zhou et al., 2008a). Whilst 
consensus for vascular lineages and fibroblasts is established, the capacity for 
cardiomyocyte differentiation is disputed given observations of Wt1 expression in SHF 
(Jongbloed et al., 2011), and Tbx18 in other cardiac progenitor populations (Christoffels et 
al., 2009; Jongbloed et al., 2011). 
 
A third and distinct population of progenitor cells originate from the neuroectoderm of the 
dorsal neural tube. These cells migrate to surround the anterior pole of the heart and are 
essential to normal outflow tract development, cardiac septation and patterning of the aortic 
arteries (Hutson and Kirby, 2007). In addition to their essential signalling role, neural crest 
progenitors also make essential contributions of vascular smooth muscle to the cardiac 
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valves and provide the parasympathetic innervation for the heart (Brade et al., 2013; Jiang et 
al., 2000).  
 
Multipotent cardiac stem cells in adulthood – coming of age? 
In vivo genetic fate mapping and embryonic stem-cell based models of cardiogenesis have 
contributed considerably to the understanding of cardiac lineage diversification from 
developmental progenitors in mice (Martin-Puig et al., 2008). By contrast, understanding of 
the biology of adult cardiac progenitors remains in its infancy.   
 
In the search for adult analogues of developmental cardiac progenitors, investigators have 
employed a range of enrichment criteria such as those cell surface markers and phenotypic 
assays established to indentify stem cell populations in other adult rodent tissues. These 
include, cell surface haemopoietic stem cell markers stem cell antigen 1 (mouse Sca-1, (Oh 
et al., 2003) and kit oncogene (rat Kit, (Beltrami et al., 2003); mouse transcription factor Islet-
1 (Laugwitz et al., 2005); selective culture of human and mouse cardiac tissue to form 
‘cardiospheres’ (Messina et al., 2004); and phenotypic characteristics such as Hoechst dye 
exclusion (Hierlihy et al., 2002; Pfister et al., 2005). A summary of the characteristics of these 
populations is given in Table 1.1.   
 
In spite of seemingly divergent methods for isolation and propagation, considerable 
similarities are observed between the populations of adult mammalian cardiac progenitors 
with respect to gene expression. As above, several of the populations above share a pattern 
characterised by simultaneous expression of core cardiogenic transcription factors (Gata4, 
Nkx2.5, Mef2) and stem cell associated markers (Sca1, Kit), in the absence of cardiac 
structural genes (Beltrami et al., 2003; Oh et al., 2003; Pfister et al., 2005). [For review of 
cardiogenic transcription factors see (Davidson and Erwin, 2006)]. In this respect, these 
populations resemble committed progenitors of the cardiac mesoderm (Komuro and Izumo, 
1993; Wu et al., 2006). This observation has led to the suggestion that the regulatory 
networks that guide heart development may have relevance to adult cardiac progenitors 
(Mercola et al., 2011). 
 
Much of the characterisation studies of adult cardiac progenitors have been based on 
enrichment from enzymatically dissociated heart tissue and culture ex vivo (Sturzu and Wu, 
2011). To determine whether a population possesses stem cell properties, assays of 
clonogenicity and self-renewal in vitro are described; the former by determining the capacity 
to re-establish populations from a single isolated cell, and the latter by determining whether a 
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population retain the stem cell associated markers or phenotypic characteristics used for 
their isolation (Beltrami et al., 2003). To examine the lineage potential of putative cardiac 
progenitor populations, investigators report differentiation under defined conditions in vitro 
and in vivo following grafting to the infarcted myocardium (Oh et al., 2003; Pfister et al., 
2005). Cell transplantation is considered the most robust assay for lineage, however 
differentiation is difficult to quantify in vivo (Mercola et al., 2011); in addition  factors affecting 
the survival of grafted cells along with fusion with host cardiomyocytes complicate the 
assessment (Oh et al., 2003). 
 
A further consideration for characterisation studies of putative adult cardiac progenitors 
relates heterogeneity of stem cell populations isolated from whole heart preparations. 
Enrichment according to expression of a particular marker may capture stem cells of diverse 
origins with divergent lineage potential, such as cells from the blood pool and vasculature. To 
determine multi-lineage potential conclusively for such populations, it is necessary to 
examine the progeny of clonally isolated cells (Hope and Bhatia, 2011). 
 
Pioneering studies of cardiac regeneration highlighted the role of the stem cell antigen 1 
(Sca1) as a marker of resident cardiomyocyte progenitors in mice. When injected to the tail 
vein following experimental infarction, Sca1+ cells homed to injured myocardium and 
differentiated into cardiomyocytes (Oh et al., 2003). The cardiac Sca1 population and the 
sub-population defined by the side population phenotype are the subject of this thesis and 
are discussed in detail below.   
 
Beltrami et al., reported isolating a population of rat heart derived cells expressing Kit (c-Kit) 
but were negative for blood lineage markers (Lin-); these cells were clonogenic, self-renewing 
and capable of differentiation to cardiomyocyte, endothelial and smooth muscle cells 
lineages following grafting in vivo or directed differentiation in vitro (Beltrami et al., 2003). As 
well as being an established marker of haematopoietic stem cells, Kit is also a marker of 
developmental cardiovascular progenitors for cardiomyocyte, smooth muscle and endothelial 
lineage (Christoforou et al., 2008; Ikuta and Weissman, 1992; Wu et al., 2006). Ellison et al. 
report robust cardiomyocyte differentiation in a mouse injury model using a lentivirally 
delivered Cre recombinase under the control the Kit upstream regulatory element (Ellison et 
al., 2013); however uncertainty over the specificity of the Cre driver complicate the 
interpretation of these findings (Molkentin and Houser, 2013). Jesty et al., employed a 
bacterial artificial chromosome (BAC) transgenic mouse harbouring a Kit reporter gene to 
assess the contribution of Kit+ cells to cardiomyocyte renewal following injury. They reported 
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a partial contribution of Kit+ cells to cardiac regeneration in the neonate and no contribution in 
the adult (Jesty et al., 2012). Furthermore, using c-Kit cells from mice harbouring transgenes 
for enhanced green fluorescent protein (eGFP) expression under the β-actin promoter (ACT-
eGFP) and cardiomyocyte restricted nuclear β-galactosidase (Myh6-nLac), Zaruba et al., 
reported a near total absence of cardiomyocytes derived from c-Kit+ progenitors under 
conditions of neonatal cardiomyocyte coculture or cell grafting (Zaruba et al., 2010). Given 
conflicting reports of their contribution to cardiac regeneration, a contribution of c-Kit+ 
progenitors to cardiac regeneration has yet to be conclusively determined (Molkentin and 
Houser, 2013).  
 
Laugwitz et al. reported the existence of neonatal Isl1 progenitors in the mouse heart that 
share the lineage potential of embryonic equivalents (cardiomyocyte, smooth muscle and 
endothelial). Although this population does not persist beyond neonatal life, it is possible that 
these cells give rise to related Isl1- progenitors that do persist into adulthood (Cai et al., 2003; 
Laugwitz et al., 2005). Suspension culture of human myocardial biopsies generates cell 
clusters termed ‘cardiospheres’ which contain cells expressing c-Kit and markers of 
endothelial progenitors. Cells from these clusters are reported to differentiate to 
cardiomyocyte, endothelium and smooth muscle lineages upon grafting to the infracted 
myocardium. Although the beneficial effect on myocardial function is attributed in part to 
paracrine effects (Chimenti et al., 2010; Messina et al., 2004), others have challenged these 
findings and demonstrating the potential for cardiomyocyte contamination to confound 
assessment of cardiomyocyte differentiation (Andersen et al., 2009).  
 
Finally, populations of murine epicardium-derived progenitors have been described during 
embryogenesis and adult life termed EPDC. Based on transient re-expression of the 
embryonic marker Wt1, a population of adult progenitors contributing interstitial fibroblasts, 
vascular smooth muscle and cardiomyocytes has been described (Smart et al., 2011; 
Wessels and Perez-Pomares, 2004; Zhou et al., 2008a). However, as for embryonic PE 
progenitors, controversy persists over the specificity of Wt1 as a marker EPDC in activated 
epicardium (Gittenberger-de Groot et al., 2012). Chong et al., have employed the colony-
forming assay to identify multipotent cardiac progenitors of epicardial origin that express 
Sca1 and Pdgfra and demonstrate tri-lineage potential (cardiomyocyte, endothelial and 
smooth muscle cell) following grafting and directed differentiation in vitro (Chong et al., 2011; 
Wessels and Perez-Pomares, 2004).  
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Table 1.1 Summary of adult cardiac progenitor populations 
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Adult mouse cardiac Sca1+  and CSP progenitors 
As indicated above, amongst the first adult cardiac progenitors reported were isolated 
according to expression of Sca1 (Matsuura et al., 2004; Oh et al., 2003). Sca1 is an 18-kDA 
mouse glycosyl phosphatidylinositol-anchored cell surface receptor first identified on 
activated lymphocytes (Yutoku et al., 1974). Although the function of Sca1 has yet to be fully 
elucidated, it is known to be involved in cell signalling and adhesion (Holmes and Stanford, 
2007). Sca1 is expressed in embryonic, foetal and adult haematopoietic stem cells and is 
essential for normal hematopoiesis (Bradfute et al., 2005). Enrichment for this marker has 
been used to identify adult stem cells from a wide range of tissues, including skeletal muscle 
(Lee et al., 2000), liver (Petersen et al., 2003), and mammary gland (Welm et al., 2002).  
 
Sca1 identifies populations of stem-like cells from adult mouse hearts (Matsuura et al., 2004; 
Oh et al., 2003). Cardiac Sca1+ cells express cardiogenic transcription factors (Gata4, Mef2c) 
along with markers of stemness such as telomerase. In vitro cardiomyocyte differentiation is 
reported in a small percentage (<5%) of cells following treatment with azacytidine or oxytocin 
followed by culture for 4 weeks, and determined by the expression of Nkx2.5 and sarcomeric 
proteins (Matsuura et al., 2009; Oh et al., 2003). Matsuura et al. reported sarcomeric 
organization and spontaneous contraction that was chronotropically responsive to 
pharmacological stimulation with isoprenaline (Matsuura et al., 2004). Oh et al., 
demonstrated that cardiac Sca1+ cells, when transplanted following ischaemia-reperfusion 
injury, home to the infarct border zone heart where they were detectable after 2 weeks. Using 
a Cre/ LoxP doner-recipient pair (Myh6-Cre/ R26R), they demonstrated activation of Myh6-
Cre in grafted cells which was only attributable in part to cell fusion. All cells expressing Cre 
were found to stain for cardiac α-actin, cardiac troponin I, and connexin-43 confirming 
cardiomyocyte differentiation (Oh et al., 2003). More recently, genetic deletion of Sca1 has 
been found to result in cardiac hypocontractility in early life and later to cause age-related 
hypertrophy; interestingly, these findings were associated with a reduction in the number of 
cardiac c-Kit+ cells (Bailey et al., 2012). 
 
Often, Sca1 expression is associated with side population (SP), a phenotypic marker used to 
identify adult stem cells in a range of tissues including hematopoietic stem cells (Goodell et 
al., 1996; Holmes and Stanford, 2007). SP marked cells are distinguished by flow cytometry 
based on their capacity to efflux Hoechst dye which is determined by expression of ATP-
binding cassette transporter proteins, Abcg2 and Abcb1b (Golebiewska et al., 2011). A 
number of research groups have used the SP assay to isolated progenitor populations from 
adult mouse hearts (Hierlihy et al., 2002; Martin et al., 2004; Pfister et al., 2005). Pfister et 
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al., demonstrated cardiomyocyte differentiation of cardiac SP cells in vitro following coculture 
with rat neonatal cardiomyocytes, evidenced by expression of sarcomeric proteins, cellular 
contraction and intracellular calcium transients (Pfister et al., 2005). Oyama et al., 
demonstrated the multi-lineage potential of neonatal rat cardiac SP cells by in vitro 
differentiation to cardiomyocytes, osteocytes and adipocytes (Oyama et al., 2007).   
 
The cardiac Sca1+ population is enriched 100-fold for SP cells and similarly, 93% of the 
cardiac SP population express Sca1. As such, the cardiac SP represents a sub-group of the 
cardiac Sca1+ population (Oh et al., 2003). In unpublished work from the supervisor’s 
laboratory, the side population phenotype has been shown to prospectively identify the 
clonogenic fraction of cardiac Sca1+ cells (CSP) (Figure 1.4A). CSP clones were cultured for 
over 10 months without replicative senescence (Figure 1.4B-C), or loss of Sca1 or the SP 
phenotype suggesting self-renewal (Figure 1.4D). The efficiency of secondary clone 
formation from culture CSP primary clones is high (Figure 1.4F).  
 
Similar to the parent Sca1+ population, CSP cells express several of the core cardiac 
transcription factors (Mef2a, Gata4, Gata6, Tbx2, Tbx5, Tbx20, Hand2) and the absence of 
genes coding for cardiac structural proteins (Figure 1.4F). Gene expression of clonally 
isolated CSP populations reveals heterogeneous expression patterns of core cardiac 
transcription factors (Figure 1.5A). The significance of these differences is unknown, 
however it is possible that they may represent different states of differentiation or lineage 
commitment. Across 20 CSP clones tested, expression of key heart forming transcription 
factors Gata4, Mef2c, Tbx5 and Hand2 (Song et al., 2012) demonstrates considerable 
heterogeneity (Figure 1.5B).  
 
Amongst 20 CSP clonal populations generated, CSP clones 3 and 16 were selected for 
further study as representative of complementary gene expression profiles observed in the 
population (CSP clone 3: Gata4POS, Nkx2.5POS; CSP clone 16: Gata4NEG, Nkx2.5NEG). The 
lineage potential of CSP clones 3 and 16 was examined by grafting of mOrange labeled cells 
to the infracted mouse myocardium immediately following coronary artery ligation. When 
hearts were examined after 12 weeks, striated donor cells were present expressing cardiac 
Troponin T and cardiac α-actin (Figure 1.6A), as well as vessel associated doner cells 
expressing smooth muscle myosin heavy chain (Figure 1.6B) and endothelial marker von 
Willebrand factor (Figure 1.6C). These results suggest that CSP clones 3 and 16 are multi-
potent cardiac progenitors however a contribution from cell fusion cannot be excluded. The 
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efficiency of differentiation to cardiac lineages was equivalent between CSP clones 3 and 16 
despite the contrasting expression patterns of cardiac transcription factors described above.  
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Human adult cardiac progenitors  
The existence of cardiac progenitors in the adult rodent heart has prompted studies to 
identify human analogues. Several such populations have been described including human 
c-Kit cells (Urbanek et al., 2003), SP (Sandstedt et al., 2012), cardiospheres (Messina et al., 
2004) and cells isolated using antibodies to mouse Sca1 (Smits et al., 2009a). Since no 
known human homologue for murine Sca1 is known, the identity of the human ‘Sca1’ 
population remains uncertain (Sturzu and Wu, 2011).  
 
There is no consensus on the best marker for the identification of adult cardiac progenitors in 
either the human or the mouse, and none yet described is specific to adult stem cells of 
cardiac lineage potential. Adult cardiac progenitors have been studied extensively in mouse 
and rat model systems, using a variety of approaches to track cell fate in vivo; whether 
homologous human cardiac stem cell populations serve similar functions in tissue 
homeostasis remains unknown.  
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In vitro differentiation of adult cardiac progenitors: therapeutic enabler 
Much interest has been generated in the therapeutic potential of cardiac progenitor cells to 
address the regenerative deficit observed in humans (Ptaszek et al., 2012). A variety of 
conceptual strategies exist: 
 
• Transplantation of cardiac progenitors expanded ex vivo, either as a cell suspension 
or as a component of engineered cardiac tissue 
• Biopharmaceutical therapies promoting the expansion and differentiation of 
endogenous progenitor populations in situ to augment self-repair 
 
Although the directed differentiation of embryonic stem cells (ESC) to cardiomyocyte has 
advanced greatly the understanding of developmental cardiogenesis, the potential 
therapeutic applications of ESC-derived cardiac progenitors, or differentiated 
cardiomyocytes, is limited by allogenicity and ethical considerations (Dai et al., 2007). 
Furthermore, the relative immaturity of ESC derived cardiomyocytes, reflected by 
disorganized sarcomeric structure and electrical properties, is of concern given the potential 
for arrhythmogenesis (Chen et al., 2009b) and teratoma formation (Cai et al., 2007). The use 
of patient-derived induced pluripotent cells (iPSC) would overcome the immune and ethical 
issues, however several technical challenges, such as low reprogramming efficiency, must 
be overcome to realize this potential (Yoshida and Yamanaka, 2011).  
 
Adult cardiac progenitors have a number of a priori advantages over ESC/ iPSC derived 
therapies for applications in transplantation. Over and above the potential for autologous 
therapy with attendant advantages, adult cardiac progenitors are already poised to a cardiac 
fate and, as such, may be expected to demonstrate superior efficacy and safety 
characteristics. The relative efficacy of ESC and adult cardiac progenitor-based therapy for 
cardiac repair can only be evaluated empirically and remains to be determined. Both ESC/ 
iPSC and adult cardiac progenitor based approaches are contingent upon a complete 
understanding of cellular phylogeny and the networks which regulate self-renewal and 
differentiation (Sturzu and Wu, 2011). In the case of ESC differentiation, considerable 
advances have been made, however understanding of the regulation of adult cardiac 
progenitors is still in its infancy (Noseda et al., 2011). 
 
A more complete understanding of the networks regulating the function of adult cardiac 
progenitors may permit the elaboration of therapies to enhance adult progenitor function in 
situ. Zaruba et al., describe an analogous strategy to enhance recruitment of endothelial 
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progenitors from the bone marrow following myocardial infarction. A granulocyte-colony 
stimulating factor was introduced to promote mobilization of stem cells from the marrow and 
subsequent recruitment to the myocardium was enhanced using with a small molecule 
inhibitor of CD26 (Zaruba et al., 2009). A similar approach might be envisaged for targeting 
cell fate in progenitor cells to increase expansion or enhance differentiation (Li et al., 2012). 
Augmentation of adult stem cell function in situ is a conceptually appealing strategy for 
cardiac repair, but will depend the achievement of significant advances in knowledge of 
lineage maps and signalling cues.  
 
Signals regulating the differentiation of adult CSP 
Little is yet known about the signals that regulate cell fate in adult cardiac progenitors and 
there is a lack of methodological consensus regarding the  directed cardiomyocyte 
differentiation in vitro (Chamuleau et al., 2009). For cardiac Sca1+ cells, reports have shown 
cardiomyocyte differentiation in response to azacytidine, a demethylating agent that non- 
specifically activates genes, (Mercola et al., 2011). In addition, oxytocin, a natural hormone of 
known relevance to heart development, has been employed successfully to induce 
differentiation (Jankowski et al., 2004; Matsuura et al., 2004). Frequencies of differentiation in 
vitro are typically low and variable across reported studies (Hoch et al., 2011; Matsuura et al., 
2004; Oh et al., 2003; Tateishi et al., 2007). For cardiac SP cells, cardiomyocyte 
differentiation has been reported following co-culture with neonatal cardiomyocytes; however 
the signalling factors mediating this effect are unknown (Martin et al., 2004; Pfister et al., 
2005). Although some studies indicate the potential for cardiac Sca1+ cells to differentiate to 
other cardiac lineages (e.g. endothelial, smooth muscle cell), the question as to whether 
cardiac Sca1+ and cardiac SP are true multi-potent cardiovascular progenitors remains open 
(Goumans et al., 2007; Oh et al., 2003). To demonstrate multi-potency conclusively, it must 
be proven for clonally isolated progenitors, given the possibility that multiple uni-potent 
progenitors all expressing Sca1+ or SP may exist in the heart. Conditions for the in vitro 
differentiation of CSP, isolated by enrichment for both Sca1+ and SP, are currently unknown 
and form the basis of this study. Investigation focused on two clonally isolated CSP lines so 
that multi-potency could be explored.  
 
Whilst the mechanisms for the cardiac differentiation of adult cardiac progenitors may differ 
from those active in embryonic cardiogenesis, it is likely that understanding of the 
developmentally relevant cues will be informative (Bondue et al., 2008; Mercola et al., 2011; 
Noseda, 2011a). Stepwise activity of diffusible proteins such as the Wnt proteins, FGFs, and 
members of the TGF-β superfamily, effect mesoderm formation and patterning, and 
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subsequent cardiac specification and differentiation (for review see (Noseda, 2011b). During 
development, morphogenic signals frequently arise from adjacent tissues such as the 
anterior endoderm (Liu et al., 2007), the epithelial surfaces of the heart (Lavine et al., 2005), 
and from cardiac fibroblasts dispersed throughout the myocardium (Ieda et al., 2009). The 
action of individual cardiogenic factors is often context specific; for example canonical Wnt 
signalling is essential for mesoderm formation (Liu et al., 2007), but subsequent inhibition by 
dickopf-1 is required to release onward differentiation (Ueno et al., 2007). 
 
Despite the above factors being well-poised candidates to regulate adult progenitor function, 
the complex combinatorial and temporally specific relationships essential in heart 
development limit the scope of hypothesis-driven investigation based on a priori assumptions 
(Noseda et al., 2011). Furthermore, adult cardiac progenitors and their development 
analogues may differ significantly in how they respond to particular signals. For example, 
epigenetic modifications of skeletal muscle satellite cells occurring during development have 
been shown to alter the responsiveness of extracellular signalling molecules (Lepper et al., 
2009; Mohn and Schubeler, 2009). Equally, it may be that other molecules implicated in the 
late cardiogenesis, such as the FGFs and retinoic acid, are essential to the differentiation of 
progenitor cells (Lin et al., 2010; Rosenblatt-Velin et al., 2005). Two strategies have been 
suggested to overcome the complexities described and achieve a better understanding of the 
regulation of stem cell fate (Noseda et al., 2011): a systems–based approach using 
computational modelling to integrate experimental data and model regulatory networks 
(Macarthur et al., 2009); and ‘higher throughput’ approach to the empirical testing of 
extracellular proteins, including diffusible growth factors, morphogens and hormones 
(Noseda et al., 2011). For cardiomyocyte differentiation from ESCs, screens of small 
molecule libraries have generated encouraging results, with certain molecules found to 
increase efficiency (Sadek et al., 2008; Willems et al., 2011; Wu et al., 2004). It is possible 
that high-throughput phenotypic screens of differentiation (and also self-renewal) in adult 
cardiac progenitors similarly may be informative and could yield results that are translatable 
as the basis for regenerative drugs for enhanced endogenous repair. However, such an 
approach pre-supposes that these cells are the predominant basis for regeneration and this 
has yet to be determined conclusively (Steinhauser and Lee, 2011). 
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High content screens for CSP cardiomyoctye differentiaton  
The objects of study in this research are cloned CSP cells from the mouse heart. The focus 
was on the cardiomyocyte differentiation, although other lineages were also  considered. 
Conditions for the in vitro differentiation of CSP are unknown. For the related cardiac Sca1 
and cardiac SP, reported methods result in frequencies of differentiation that are low and 
variable (see above). Clonally isolated CSP cells were selected for study as purified 
populations in which multi-lineage might be determined conclusively. In addition, the 
combination of two related markers of cardiac progenitors cells was hypothesized to provide 
greater enrichment for stem cells. Better defined conditions for cardiomyocyte differentiation 
in a better defined starting population (CSP clones) may provide further evidence for the 
contribution of adult cardiac progenitors to post-natal cardiopoiesis. Conditions themselves 
may highlight pathways for therapeutic manipulation to enhance endogenous function or 
otherwise form the basis for discovery platforms for novel factors directing cardiogenesis (i.e. 
signalling proteins, RNAi, small molecules). Furthermore, it is possible that enhanced 
differentiation in vitro may facilitate the production of differentiated cardiomyocytes for use in 
engineered cardiac tissue.  
 
High content screening (HCS) refers to automated microscope or flow cytometry based 
screening where the outcome measure is a change in the phenotype of a cell or model 
organism measured by image analysis (Buchser et al., 2004). Such approaches are typically 
based on epifluorescence or confocal microscopy and allow for the temporal and spatial 
resolution of phenotypic modulation. Fluorescent assays to mark a particular cellular process 
may take the form of fluorescent stains, immunofluorescence of cell surface markers or fixed 
cells, and fluorescent reporter genes. High content screening has a number of advantages 
over more traditional cell-based high throughput screens, such as those employing plate 
readers. In contrast to plate readers that measure fluorescence signal for the well overall, 
high content methods (automated microscopy/ flow cytometry) have dramatically higher 
sensitivity and dynamic range. This level of sensitivity is likely to be necessary for the 
detection of the low frequency differentiation events expected here. In addition, there is 
scope to design experiments and assays to evaluate multiple parameters of cell status, often 
in live cells (Bushway and Mercola, 2006). Automated microscopy represents the most 
established high content screening modality, since the ability to measure cells in situ in 
culture vessels is immediately scalable. Only recently has the introduction of microwell-based 
sampling made this approach possible with flow cytometry (Black et al., 2011).  
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Fluorescent reporter genes offer a number of advantages over other available technologies, 
such as luciferase and β-galactosidase for high content screening. These reporter genes 
offer the possibility to monitor differentiation events without the need for cell lysis or substrate 
addition. Towards the establishment of large-scale screens of cardiac progenitor 
differentiation, this thesis describes the development of optical assays for cardiomyocyte 
differentiation in which fluorescent reporter genes are under the transcriptional control of 
cardiomyocyte specific promoters. Such an approach has successfully been employed 
(Myh6-eGFP reporter) in small molecule screens for factors improving the efficiency 
(frequency of differentiation) and has led to the discovery of novel small molecule enhancers 
(Willems et al., 2012; Willems et al., 2011). An additional advantage is the potential to 
combine quantitative assessment of reporter induction in live cells, with subsequent analyses 
of gene expression; this is particular relevant to studies of primary cells where there is the 
potential for numbers to be limited. Furthermore, given the expected low frequency of 
differentiation events for adult cardiac progenitors, fluorescence reporters enable enrichment 
of differentiated cells and more comprehensive analyses such as microarray. Automated 
fluorescence microscopy using a Cellomics Arrayscan Automated Imaging Platform was 
used to facilitate combined high content screening and gene expression analysis 
 
Prerequisite to large-scale screening for factors driving cardiomyocyte differentiation in CSP 
is confirmation of the lineage potential in the target cells; this is particularly relevant for clonal 
lines where heterogeneity of molecular signature may reflect a divergent lineage potential. As 
discussed above, the conditions required for the differentiation of CSP are currently 
unknown; further differentiation conditions for related cardiac progenitor populations are 
imperfect. Azacytidine treatment is reported to promote Sca1+ differentiation in vitro (Oh et 
al., 2003), however the utility of this method for determining lineage is limited; cardiac 
differentiation of mesenchymal stem cells is induced by azacytidine (Makino et al., 1999; 
Zhang et al., 2009), despite an emerging consensus that these cells do not transdifferentiate 
to cardiomyocytes in vivo (Balsam et al., 2004; Murry et al., 2004). For the related cardiac SP 
population, co-culture with neonatal cardiomyocytes has been used to induce differentiation. 
However, reported methods describe admixtures of both cell types (Martin et al., 2004; 
Pfister et al., 2005) and do not adequately control for the possibility of cell fusion (Zaruba et 
al., 2010). 
 
Consequently, there is a lack of adequate conditions for assessing the cardiomyocyte 
potential of CSP by in vitro assays; instead, this capacity has been determined by in vivo 
grafting (Figure 1.6). For in vitro assays, it is expected that the prevalence of differentiation of 
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clonal derivatives of CSP will be greater than or equal to that of the cardiac Sca1+ for which 
conditions for differentiation are established. Notwithstanding the need for caution stated  
above, azacytidine is the most frequently used agent to induce cardiomyocyte differentiation 
of cardiac Sca1+ (Matsuura et al., 2004; Oh et al., 2003; Smits et al., 2009b). Here the effect 
of azacytidine treatment on CSP differentiation was assessed; although this method may be 
imperfect for the determination of lineage potential, azacytidine induced differentiation of CSP 
may serve as positive control conditions for validation of reporter constructs under 
development and for use in exploratory screens. Once positive control conditions for the in 
vitro differentiation of CSP are established, and suitably sensitive and specific fluorescent 
reporter assays are available, a series of low–throughput, high-content screens of CSP 
cardiomyocyte differentiation can be performed. These initial screens were focused on 
investigating the potential roles of morphogens from established developmental pathways in 
stimulating differentiation. The eventual aim is  the availability of high throughput, high 
content screens employing a range of interventions such as small molecule libraries (Willems 
et al., 2011), RNA interference (Kim et al., 2004), and libraries of recombinant extracellular 
proteins (Lin et al., 2008). However, given the expected biological complexity of the signalling 
networks directing differentiation, it is considered unlikely by some that a single factor will be 
sufficient to cause cardiomyocyte differentiation of adult cardiac progenitors (Segers and 
Lee, 2010). To account for the expected biological complexity, multi-step combinatorial 
screens are envisaged.  
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Aims  
The aims of the research are stated as follows, with primary and supporting objectives: 
 
• To investigate whether azacytidine treatment is effective at promoting cardiomyocyte 
differentiation of CSP (Chapter 3) 
i. To establish positive control conditions for CSP differentiation to enable 
development fluorescent reporter assays of cardiomyocyte cell fate. 
ii. To establish positive control conditions for CSP differentiation for use in 
exploratory screens 
iii. To use gene expression arrays to simultaneously screen for differentiation to 
other cardiac lineages (endothelial and smooth muscle cells) 
 
• To develop fluorescent reporter assays of cardiomyocyte differentiation (Chapter 4) 
i. To generate a reporter construct for use in CSP where the expression of a 
fluorescent reporter gene is coupled to promoter fragments of cardiomyocyte 
restricted genes (Myh6 and TnnT2) 
ii. To compare the sensitivity and specificity of reporter constructs in a range of 
differentiated cell types, including CSP and differentiating embryonic stem 
cells. 
 
• To conduct ‘proof of concept’ high-content screens of CSP cardiomyocyte 
differentiation (Chapter 5) 
i. To investigate the role of morphogens from established developmental 
pathways in stimulating cardiomyocyte differentiation  
ii. To investigate the potential for co-culture with neonatal cardiomyocytes to 
stimulate cardiomyocyte differentiation 
iii. To investigate instances of reporter induction by gene expression array to 
validate the fidelity for cardiomyocyte lineage and to screen for other cardiac 
lineages. 
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Chapter 2: Methods 
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Tissue culture routine  
All cell lines were maintained in Tissue Culture Treated vessels (BD Biosciences), at 37oC 
and 5% CO2 in humidified incubators, avoiding confluence greater than 70%. To passage, 
cells were rinsed with phosphate buffered saline (PBS) and then incubated with Trypsin-
EDTA solution to detach and disperse cells. 10x volume of media was then used to 
resuspend cells before replating at the appropriate density. As summarized in Table 1 below, 
for particular cell types an vessels were prepared with additional matrix substrate: Collagen, 
for culture of CSP and Lin-/ Sca1+ cell, vessels were coated with 50 μg/ml collagen type I 
(BD Bioscience). Collagen was dispersed in acidified water and incubated for 60 min at room 
temperature before rinsing with PBS; Fibronectin: For culture of neonatal cardiomyocytes 
and where indicated for differentiation screens, vessels were coated with fibronectin 10 or 
200 ug/ml respectively. Stock solution of 1 mg./ ml Fibronectin (Sigma F1141) was diluted in 
PBS and then incubated for 60 min at room temperature or overnight at 4oC; and for human 
embryonic stem cell culture and differentiation vessels were coated in Matrigel Matrix Growth 
Factor Reduced (BD Biosciences). 
 
Isolation of primary cardiac cells  
Cardiac Sca1+ and CSP 
Whole hearts were isolated from male C57BL6 mice of 8-12 weeks age, finely minced with a 
razor blade, and washed with Base Solution [Hanks Balanced Salt Solution (Invitrogen) 
supplemented with 10 mM HEPES (Invitrogen) and 30 mM taurine (Sigma)]. Sequential 
enzymatic digestions were performed by incubating the tissue for 5 min at 37oC with 50 µg/ml 
DNase (Roche) and 0.1 mg/ml liberase (Roche) in Base Solution and the supernatant 
collected following each of 5 iterations. Digestion was stopped by adding 1x volume of 
Stopping Solution at 4oC [Base solution with 20% fetal bovine serum (FBS, Hyclone, Thermo 
Scientific)].  
 
The resulting single cell suspension was then centrifuged at 300g for 10 min at 4 oC and then 
washed once with Stopping Buffer. The sample was then depleted of cells of haematopoietic 
lineage and enriched for Sca-1+ cells by iterative magnetic sorting using the Lineage Cell 
Depletion Kit, Anti-Sca-1 Microbead Kit and a MACS Separator (all Miltenyi Biotec). Cardiac 
Sca1+ cells were derived at this stage.  
 
To isolate the Lin-, Sca1+ SP, cells were then incubated with 5 µg/ml Hoechst 33342 (Sigma) 
in DMEM Plus [Dulbecco’s Modified Eagle’s Medium (Invitrogen) supplemented with 2% 
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FBS, 10 mM HEPES (Invitrogen) and 2 mM L-Glutamine (Invitrogen) for 90 min at 37 oC. 
Additionally, cells where stained with 2 µg/ml Propidium Iodide (Sigma) in DMEM Plus to 
enable to exclusion of nonviable cells. Lin-/ Sca1+ SP cells were deposited by flow activated 
cell sorting (FACS) as single cells into each well of a 98-well plate to generate clonal 
derivates (FACSAriaII, BD Biosciences). 
 
Cardiac Sca1+ and CSP cells were established and maintained in culture on collagen-coated 
culture vessels in cardiosphere growing medium (CGM). 
 
Cardiosphere growing medium, CGM (Messina et al., 2004)   
Iscove's Modified Dulbecco's Medium 35%, Dulbecco's Modified Eagle's Medium 
32.5%, Ham’s F12 32.5% (All Invitrogen) 
Supplements  
Bovine growth serum (Hyclone) 3.5% 
Penicillin-Streptomycin (Invitrogen) 100 U/ml 
L-Glutamine (Invitrogen) 2mM 
β-Mercaptoethanol (Sigma) 0.1mM 
B27 (Invitrogen) 1.3% 
Recombinant human epidermal growth factor (Peprotech) 6.5 ng/ml 
Thrombin (Roche) 0.0005 U/ml  
Human cardiotrophin-1 (Cell Sciences) 0.345 ng/ml 
Basic fibroblast growth factor (Peprotech) 13 ng/ml 
 
Complete Explant Medium CEM (Messina et al., 2004) 
Iscove's Modified Dulbecco's Medium  
Supplements  
 Bovine growth serum (Hyclone) 10% 
Penicillin-Streptomycin (Invitrogen) 100 U/ml 
L-Glutamine (Invitrogen) 2mM 
 2-mercaptoethanol 0.1 mmol/L 
 
The isolation of Cardiac Sca1+ and CSP cells was performed as a collaborative undertaking 
between members of supervisor’s laboratory under the leadership of Dr M Noseda (second 
supervisor). Cardiac Sca1+ and CSP were generated from regular, serial isolation procedures 
performed in the laboratory. I contributed to all aspects of the isolation process except for 
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Hoecsht staining, flow cytometry assisted cell sorting and clonal expansion that were 
performed by Dr M Noseda. From this collaborative effort, a number of cell lines were 
established, expanded by serial passage and cyropreserved.  
 
Cell type Term  Passage  
Entire population Uncloned Cardiac Sca1+ 3  
Uncloned CSP 13 
Clone 3 untransduced CSP Clone 3 14 - 18 
Clone 3 transduced with 
Myh6-mCherry/ PGK-
BSNr   
CSP Clone 3 Δ Myh6-
mCherry 
17 - 18 
Clone 16  CSP Clone 16 16 - 19 
 
 
 
Lin-/ Sca1+ 
 
 
 
 
 
Side population 
Clone 16 transduced with 
Myh6-mCherry/ PGK-
BSNr   
CSP Clone 3 Δ Myh6-
mCherry 
17 - 18 
 
Table 2.1 Summary of adult cardiac progenitor populations under study  
 
Neonatal cardiomyocytes and cardiac fibroblasts 
Neonatal rat cardiomyocytes were isolated from 2-day-old Sprague-Dawley rats as 
previously described (Akli et al., 1999). Cardiomyocytes were purified by Percoll density 
gradient centrifugation, and pre-plating on non-coated culture vessels. Cells were maintained 
in DMEM/Ham's nutrient mixture F-12 (1:1) and 5% horse serum. Cardiac fibroblasts were 
expanded from adherent cells in the pre-plating steps and were cultured in the same 
medium.  
 
Other cell lines 
A number of cell lines were used for lentiviral viral production, comparative expression 
analyses, and as positive and negative controls. Cell culture conditions are summarized in 
Table 2.1. Unless otherwise stated, all cultures were supplemented with 100 U/ml Penicillin-
Streptomycin (Invitrogen) and 2mM L-Glutamine (Invitrogen). 
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Cell type 
 
Species Abbreviation 
or line 
number 
Cell culture 
medium 
Cell culture 
substrate 
Reference 
 
Embryonic 
kidney cells  
Human  HEK293T DMEM + 10% 
FBS 
None  (Graham et al., 
1977) 
Neonatal 
cardiomyocytes 
Rat nCM DMEM/ F-12 
+ 5% Horse 
serum  
Fibronectin  (Akli et al., 1999) 
Neonatal cardiac 
fibroblasts  
Rat nCF DMEM/ F-12 
+ 5% Horse 
serum 
None (Akli et al., 1999) 
Umbilical vein 
endothelial cells  
Human HUVEC M199 + 10% 
FBS  
None ATCC CRL-1730 
 
Aortic vascular 
smooth muscle 
Mouse  MOVAS-1 DMEM + 10% 
FBS 
None ATCC CRL-2797 
ESC  Human hESC 
(H7p77) 
mTeSR™1 
(Stemcell 
Technologies) 
Gelatin (Brito-Martins et 
al., 2008; 
Thomson et al., 
1998) 
MSC * Mouse  n/a DMEM + 10% 
FBS 
None (Friedenstein et 
al., 1970) 
Embryonic 
fibroblasts 
Mouse  MEF DMEM + 10% 
FBS 
None Brito-Martins et 
al., 2008 
Leukaemic 
monocyte 
macrophage 
cells  
Mouse RAW 264.7 DMEM + 10% 
FBS 
None ATCC TIB-71 
 
* mouse bone marrow derived MSCs were a gift from Dr M Hahnel and Professor S Rankin, 
Imperial College London. 
 
Table 2.2 Summary of cell lines and culture conditions  
 
Exploratory protocols for cardiomyocyte differentiation of CSP 
Media supplements 
 
Azacytidine 
Sterile 5’ Azacytidine powder (A1287 Sigma) was reconstituted in phosphate buffered 
saline to give a stock solution of 500uM. Appropriate dilutions were made to achieve 
target concentrations in the differentiation media. Given the instability of the agent, 
solutions were shielded from direct light during preparation and used immediately 
following reconstitution.   
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Oxytocin  
Oxytocin (H2510, Bachem) was dissolved in PBS to 0.001M stock solution which was 
then filter sterilized, aliquoted and stored at -20oC for no longer than 4 weeks. To treat 
cells, stock solutions were diluted in media to a concentration of 100nM.  
 
IWR 
IWR-1 (I0161, Sigma was reconstituted in dimethyl sulfoxide (DMSO) and warmed to 
37oC for 5 min to dissolve. Aliquots were stored at -20oC for up to 6 months. To treat 
cells, stock solutions were diluted in media to a concentration of 4μM.  
 
 Recombinant factors 
Recombinant proteins were reconstituted in PBS containing 0.1% bovine serum 
albumin (BSA) and aliquots stored at -20oC for up to 3 months. For use, stock 
solutions were diluted in media as follows: human fibroblast growth factor-basic (154 
aa, Peprotech), 10μg/ml; mouse Dkk1 (5897-DK, R&D Systems), 200ng/ml; mouse 
BMP4 (314-BP R & D Systems), 100ng/ml. 
 
Azacytidine treatment protocol (Chapter 3)  
 
Conditions for cardiomyocyte differentiation of cardiac Sca1+ cells (Oh et al., 2003) were 
applied to the CSP subpopulation, bone marrow derived MSCs were included as a control 
treated according to the methods described by (Makino et al., 1999). Cryopreserved CSP 
(uncloned, sample 144) were thawed and expanded in CGM media as described above. CSP 
cells at passage 13 were pre-plated in CGM media, using 100mm dishes coated with 200 
μg/ml fibronectin (Sigma), at a density of 5000 cells/cm2. Similarly, MSCs at passage 13 
were pre-plated in maintenance medium on uncoated 100mm dishes at a density of at 5000 
cells/cm2 (Table 2.2). 48 hours after pre-plating, cells were washed in PBS and cultured in 
differentiation culture media for the remainder of the experiment. For the first 3 days of 
culture, cells were treated with freshly prepared azacytidine at 0, 5 and 10 µM. Subsequently 
medium was refreshed every 2 days (Figure 3.1A) until analysis for gene expression.  
 
Cardiac progenitor differentiation medium (Oh et al., 2003)  
M199 (Invitrogen) 
Supplements 
FBS 2% 
Antibiotic-Antimycotic (Invitrogen) 1x 
L-Glutamine (Invitrogen) 2mM  
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Serum free differentiation medium (Noseda et al., unpublished data) 
DMEM (Invitrogen) 
Supplements 
Antibiotic-Antimycotic (Invitrogen) 1x 
L-Glutamine (Invitrogen) 2mM  
Insulin-Transferrin-Selenium X (Invitrogen)  
Albumax (Invitrogen) 1mg/ml 
 
MSC differentiation medium (Makino et al., 1999) 
IMDM (Invitrogen)  
Supplements 
 FBS 20%  
Antibiotic-Antimycotic (Invitrogen) 1x 
L-Glutamine (Invitrogen) 2mM  
 
Exploratory combinatorial screen (Chapter 5, Screen 1) 
 
Cyropreserved CSP clone 3 transduced with Myh6-mCherry/PGK-BSNr passage 18 and CSP 
clone 3 untransduced was reanimated in CGM medium. For differentiation, cells at passage 
18 were allocated to collagen-coated plates at 10,000 cells/cm2. After 48 hours, cells were 
washed in PBS and cultured in CEM medium for the remainder of the experiment. For 3 
consecutive days media containing azacytidine 10 μM or 100 nM oxytocin or vehicle were 
applied daily. For the remainder of the experiment, cells cultures were supplemented by 
Dkk1, IWR or vehicle as described above, with media refreshed every 2-3 days (Figure 5.1). 
CSP clone 3, untransduced, passage 14, treated in CEM medium only was included as the 
negative gating control for flow cytometry. 
Co-culture with rat neonatal cardiomyocytes (Chapter 5, Screen 2)  
 
Conditions for cardiomyocyte differentiation of cCFU-Fs by coculture with neonatal rat 
cardiomyocytes were applied to the CSP clone 3 and 16, and cardiac Sca1+ (Chong et al., 
2011). CSP clones 3 and 16 transduced with Myh6-mCherry/PGK-BSNr were reanimated 
from cyrostorage into CGM medium. For differentiation, reanimated CSP clone 3 and 16 at 
passage 18, and cardiac Sca1+ at passage 3 were allocated to collagen coated six well 
plates at 10,000 cells/cm2 for 3 days prior to coculture. Neonatal rat cardiomyocytes were 
isolated as described above and plated directly at a density of 105,000 cells/cm2 onto 
collagen-coated 0.4 μm pore PTFE membrane inserts (Corning 3491 Transwell®) and left 
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overnight to attach. To begin coculture, CGM medium was removed from the CSP cultures 
and replaced by differentiation medium with or without BMP4 supplementation at 100ng/ml. 
Cardiomyocyte coated transwell inserts were then added to the CSP cultures and media 
were refreshed every 48 hours for a total of 14 days prior to analysis (see Figure 5.4).  
 
Rat neonatal cardiomyocyte coculture differentiation medium (Chong et al., 2011) 
DMEM: F12 (Invitrogen)  
Supplements  
 FBS 5% 
Antibiotic-Antimycotic (Invitrogen) 1x 
L-Glutamine (Invitrogen) 2mM  
 
Combination treatment with azacytidine and FGF2 (Chapter 5, Screen 3) 
 
Conditions for cardiomyocyte differentiation of cCFU-Fs by treatment with azacytidine and 
FGF2 were applied to the CSP clone 3 and 16 (Chong et al., 2011). CSP clones 3 and 16 
transduced with Myh6-mCherry/PGK-BSNr were reanimated from cyrostorage into CGM 
medium. For differentiation, cells at passage 18 were allocated to collagen coated six well 
plates at 10,000 cells/cm2 for 3 days prior to addition of azacytidine and FGF2. Cells were 
treated for 14 days with differentiation medium supplemented with FGF2 10 ng/ml. For the 
first 2 days, fresh medium containing 10μM azacytidine was applied (Figure 5.10).    
 
Azacytidine/ FGF2 differentiation medium (Chong et al., 2011) 
DMEM (Invitrogen) 
 FBS 10% 
Antibiotic-Antimycotic (Invitrogen) 1x 
L-Glutamine (Invitrogen) 2mM  
 
Smooth muscle differentiation of CSP  
 
CSP clones 3 and 16 were reanimated from cyrostorage into CGM medium. For 
differentiation, cells at passage 18 were pre-plated to collagen coated six well plates at 
10,000 cells/cm2 for 3 days prior to treatment. Cells were treated for 18 days with 
differentiation medium with or without BMP4 supplementation at 100ng/ml (Figure 6.2).  
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DMEM: F12 (Invitrogen)  
Supplements  
 FBS 5% 
Antibiotic-Antimycotic (Invitrogen) 1x 
L-Glutamine (Invitrogen) 2mM  
 
Cardiomyocyte differentiation of hES  
 
Embryoid body based differentiation of hES was performed as described by (Brito-Martins et 
al., 2008) except mouse embryonic fibroblast conditioned medium was replaced with 
Nutristem XF/FF (Stemgent, Massachusetts). Briefly, human ESCs (H7 line) were maintained 
on Matigel-coated culture vessels in Nutristem XF/FF with media refreshed daily. Prior to 
subculturing or differentiation, spontaneously differentiated fibroblast-like cells were removed 
by treatment with collagenase (10 min, 37oC). Embryoid bodies (EBs) were generated by 
mechanical disruption of ESC colonies using a 5 ml pipette tip, followed by culture in non-
adherent plates for 4 days in hES Differentiation Medium. The EBs were then transferred to 
gelatin-coated culture vessels and cultured in same conditions for 10 days or until 
spontaneous contraction was observed. hESC culture was performed under the supervision 
of Nadire Ali, with assistance from Alex Kareh. 
 
hES Differentiation Medium  
Knockout Dulbecco’s Modified Eagle’s Medium (Invitrogen) 
Supplements  
 FBS 20% 
 L-Glutamine (Invitrogen) 1 mM 
 β-Mercaptoethanol 0.1mM 
 non-essential amino acids 10 mM (Invitrogen) 
 
 	  
	  
58 
Microscopy and flow cytometry 
Antibodies  
 
Antigen Species 
raised/  
conjugate 
Catalogue #/ 
Manufacturer 
Isotype  Conc 
mg/ml 
Dilution 
factor 
IHC 
Dilution 
factor 
FCS 
PRIMARY ANTIBODIES 
 
α smooth 
muscle 
actin 
Mouse A2547/ 
Clone 1A4 
Sigma 
IgG2a 5.3 10000 N/A 
Calponin-
1 
Rabbit 1806-1 
Clone EP798Y 
IgG nd 400 N/A 
SM22 α 
 
Rabbit Ab14106/ 
Abcam/ 
IgG 1.0 16000 N/A 
Cardiac 
Troponin 
T 
Mouse Ab8295/ 
Clone 1C11 
Abcam 
IgG1 2.0 1000 1000 
mCherry Mouse Clontech / 
632496 
IgG 0.5 1000 N/A 
ISOTYPE CONTROLS 
 
Control Mouse ab18448/ 
Abcam 
IgG1 1.0 
Control Mouse ab18449/ 
Abcam 
IgG2A 
 
1.0 
Control 
 
Rabbit 1-1000/ Vector 
Laboratories 
IgG 5.0 
Dilution factor/ 
concentration 
corresponding to primary 
antibody under study 
SECONDARY ANTIBODIES 
 
Mouse 
IgG 
Donkey/  
Dylight 649 
715-496-150/ 
Jackson 
Immunoresear
ch 
nd 1.5 N/A 100 
Mouse  
IgG 
Goat/ 
Alexa 647 
#4410 Cell 
Signaling 
nd 2.0 1000  
Mouse 
IgG 
Goat/ 
Alexa 488 
#4408 Cell 
Signaling 
nd 2.0 1000 N/A 
Rabbit 
IgG 
Goat/ 
Alexa 488   
#4412 Cell 
Signaling 
nd 2.0 1000 N/A 
  
Table 2.3 Summary of isotype control, primary and secondary antibodies 
Abbreviations: cTnT, cardiac troponin; IF, immunofluorescence; FCS, flow cytometry.  
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Antibody validation  
Conditions for Cardiac troponin T and mCherry immunostaining were developed and 
validated for sensitivity and specificity by other members of the Supervisors laboratory (Dr S 
McSweeney and E Maifoshie). Antibody staining conditions for mouse smooth muscle 
proteins were validated using an aortic vascular smooth muscle cell line (MOVAS-1, ATCC 
CRL-2797) as the positive control, and mouse macrophage line (RAW 264.7) as the negative 
control. Serial dilutions of primary antibody were performed, encompassing recommended 
dilution factors, along with corresponding isotype controls (α smooth muscle actin: 1/400, 
1/800, 1/1600, 1/3200; Calponin-1: 1/100, 1/200, 1/400, 1/800; SM22 α: 1/200, 1/400, 1/800, 
1/1600). For each primary antibody concentration, secondary antibodies were tested at two 
dilutions (1/500 and 1/1000), exposure time was fixed at 100ms. Concentrations pairs 
achieving optimum specificity and sensitivity were selected for use in subsequent 
experiments (Table 2.3). No suitably validated antibody for smooth muscle myosin heavy 
chain was identified for use in immunocytochemistry.   
 
Fluorescence microscopy  
For fluorescence microscopy of intracellular antigens, cells were fixed in 6-, 24, or 96- well 
culture vessels with 4% paraformaldehyde (PFA) for 15 min, blocked and permeabilised for 1 
hr in Blocking Buffer (4% FBS, 0.2% Triton X-100 in PBS). Primary antibodies were diluted in 
Blocking Buffer and incubated overnight at 4 oC. Species-specific secondary antibodies 
conjugated with Alexa Fluors (Molecular Probes) were diluted 1:1000 in Blocking Buffer and 
incubated for 1 hr at room temperature. Cells were washed 3x in PBS before secondary 
staining and subsequently 3x with 0.02% Triton X-100 PBS and 3x PBS. Nuclei were stained 
with DAPI at 4 µg/ml in PBS. 
 
Fluorescence microscopy was performed using an Axio Observer.Z1 microscope and 
AxioVision software (Zeiss, Jena, Germany). Appropriate filters for immunofluroscence were 
employed and images acquired at exposure times for comparative studies. All image fields 
illustrated represent the full, uncropped field for either 10x or 20x magnification. 
Automated image acquisition and analysis 
Live cell imaging was performed using an ArrayScanTM VTi automated microscope and 
image analysis system (Cellomics Inc.). For nuclear staining, media containing Hoechst 
33342 0.5 μg/ml was applied for 20-30 min and subsequently exchanged for normal media 
(Sigma B2261). Cell nuclei were identified by Hoechst fluorescence and the nuclear 
boundary demarked (nuclear mask). Proprietary algorithms were used to exclude debris. The 
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nuclear mask was dilated to define a cytoplasmic area (mask) in which mean fluorescence 
intensity was calculated (Figure 5.5A). 49 fields were acquired per condition and each 
condition was run with triplicate biological samples; a minimum of 10, 000 cells per replicate 
were analysed (Figure 5.BA). 
 
The threshold for mean mCherry fluorescence defining reporter positive objects was 
determined manually for each experiment. Individual fields were assessed manually and 
subsequently using the automated algorithm; the threshold for determining positivity for 
expression was determined by an iterative process comparing frequencies generated 
manually to those generated by automated analysis. Following this, the distribution and 
threshold levels were examined using frequency histogram plots for all data in each condition 
(for example, see Figure 5.5C).  
Flow cytometry  
Flow cytometry analysis and cell sorting were performed using a the LSRII flow cytometer 
and FACSAriaII respectively, each equipped with 355 nm UV, 405 nm violet, 488 nm blue, 
561 nm yellow-green and 638 nm red lasers (Becton Dickinson).  
 
For immediate analysis, live cells were harvested from culture vessels using Typsin EDTA, 
washed and resuspended in PBS at 105 to 5 x 107 cells per mL. To stain for cardiac Troponin 
T, approximately 106 cells were harvested and resuspended in 100uL PBS. An equal volume 
of Fix and Perm Reagent A (Invitrogen, GAS003) was then added and cells incubated for 15 
mins at room temperature. The cells were then washed with 3ml of Wash Medium (PBS, FBS 
5%, NaN3 0.1%) before centrifugation at 350 x g for 5 min and aspiration of supernatant. The 
cells were then resuspended in Fix and Perm Reagant B containing the appropriate 
concentration of primary antibody and incubated at room temperature for 30 min. Following 
this, cells were re-washed and incubated with secondary antibody diluted in PBS for 5 min 
before washing and resuspending in Wash Medium for analysis.  
 
Debris and cell couplets were excluded by gating against forward and side scatter 
parameters as illustrated in Figure 4.8. Viability was assessed with Sytox Blue Dead Cell 
Stain (Invitrogen), a high affinity nucleic acid stain that is able to cross the cell membrane of 
non-viable cells. Sytox Blue Cell Stain was added to cell suspension from 105 to 5 x 107/ mL 
to a final concentration of 1 µM. Samples were incubated for 5 min and then analysed 
immediately by flow cytometry.  
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For multi-colour experiments, control samples were included to facilitate subsequent data 
compensation (HEK 293T ∆ pLVX mCherry; HEK 293T ∆ pLL38 eGFP, HEK 293T ∆ pLL38 
mOrange; and BD Compbeads with relevant fluorophores). Compensation and data analysis 
were performed using FlowJo versions 9.3.1 (Tree Star, Ashland, Oregon). 
 
Gene expression analysis 
RNA extraction and cDNA production  
0.5-2 million cells were harvested directly from cell culture plates and homogenized using Tri 
Reagant (Molecular Research Centre) and RNA extracted and treated with TurboDNase 
(Applied Biosystems). Alternatively, RNA was extracted from Tri Reagant using the PureLink 
RNA Mini Kit followed by Purelink DNAse Treatment (Invitrogen).  
Control tissues  
Reverse-transcribed cDNA for embryonic heart, adult heart, and undifferentiated ESCs were 
a gift from Dr M Noseda. Neonatal heart and mouse aorta samples were generated by 
microdissection and placed in Tri-Reagant. Tissues were immediately homogenized 
mechanically and RNA extracted.  
 
RNA was quantified using a Nanodrop 8000 Spectrophotometer (Thermo Fisher Scientific). 
cDNA was generated by reverse transcription using the High Capacity cDNA kit (Applied 
Biosciences).  
Quantitative real time polymerase chain reaction 
Quantitative real time polymerase chain reaction (qRT PCR), was performed using the 
7900HT Fast Real-Time PCR System and Taqman Gene Expression Assays (Table 2.3), 
and custom Taqman Low Density Array cards (Applied Biosystems). Comparative threshold 
(Ct) values for each gene and sample were extracted from the product amplification curve 
based on a threshold of 0.2 using RQ Manager 1.2.1 (Applied Biosystems). For uniplexed 
assays, gene expression was determined manually by the dCT method (Livak and 
Schmittgen, 2001). 
Multiplexed gene expression assays  
Gene expression analysis for cardiomyocyte differentiation screens was performed using 
multiplexed custom Taqman low-density array cards designed by the supervisors (Applied 
Biosystems).  
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Raw CT data were processed in R/ Bioconductor platform (Gentleman et al., 2004) using an 
existing coded workflow developed by Thomas Leja, Imperial College London. The stability of 
the loading controls was assessed visually and quantitatively across all samples for each 
experiment. The M-test method was used to determine the most stable combination of 
endogenous controls with which to normalize CT data and generate dCT (Vandesompele et 
al., 2002). Density plots and heatmaps were generated using R packages (beanplot and 
gplots, Comprehensive R Archive Network. For each experiment, the Pearson correlation (r) 
was determined for dCT values for each sample pair. Heatmaps were then plotted with 
samples arranged by hierarchical clustering.  
 
Taqman Assays  
Gene  TaqMan Assay Gene  TaqMan Assay 
Abcb1b Mm01324120_m1 Mesp1 Mm00801883_g1 
Abcg2 Mm00496364_m1 Myh11 Mm00443013_m1 
Actc1 Mm01333821_m1 Myh6 Mm00440359_m1 
Bmp2 Mm01340178_m1 Myl2 Mm00440384_m1 
Bmp4 Mm00432087_m1 Myog Mm00446194_m1 
Cdh5 Mm00486938_m1 Nanog Mm02019550_s1 
Cer1 Mm03024044_m1 Nkx2-5 Mm00657783_m1 
Cnn1 Mm00487032_m1 Nppa Mm01255748_g1 
Eomes Mm01351986_m1 Pdgfra Mm01211685_m1 
Foxa1 Mm00484713_m1 Pln Mm00452263_m1 
Gata2 Mm00492300_m1 Pou5f1 Mm03053917_g1 
Gata4 Mm00484689_m1 Ryr2 Mm00465877_m1 
Gata6 Mm00802636_m1 Acta2 Mm00725412_s1 
Hand1 Mm00433931_m1 Tagln Mm00441661_g1 
Hand2 Mm00439247_m1 Sox17 Mm00488363_m1 
Hhex Mm00433954_m1 T Mm00436877_m1 
Hmbs Mm01143545_m1 Tal1 Mm01187033_m1 
Isl1 Mm00627860_m1 Tbx2 Mm00436915_m1 
Kdr Mm00440111_m1 Tbx20 Mm00451515_m1 
Kit Mm00445212_m1 Tbx5 Mm00803518_m1 
Klf4 Mm00516104_m1 Tert Mm01352136_m1 
Ly6a Mm00726565_s1 Ubc Mm01201237_m1 
Mef2c Mm01340842_m1  Vwf  Mm00550376_m1 
Mef2a Mm01318991_m1   
 
Table 2.4 Taqman gene expression assays 
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Molecular cloning 
Restriction enzyme digestion 
Unless otherwise stated, a total reaction volume of 20 µL was used comprising 2 µg of DNA,      
1 µL of each restriction enzyme or enzymes (all obtained from New England Biolabs), 
buffers, bovine serum albumin and nuclease free water (Qiagen) . The reaction was 
incubated at 37oC for 60 min and inactivated at 65oC for 20 min or by agarose gel 
electrophoresis.  
 
Ligations 
Ligations were performed using T4 DNA Ligase and T4 ligase buffer (New England Biolabs). 
A total reaction volume of 10 µL was used, comprising 1 µL of plasmid DNA (50-100ng), an 
amount of oligonucleotide corresponding to a molar ration of vector to insert of 10:1 or 5:1, 
and nuclease free water (Qiagen). The reactions were incubated at 4oC for 16 hr and 5 µL of 
each ligation product were transformed described below.  
 
Transformations  
Plasmid DNA was transformed into competent E. Coli (OneShot Stbl3, Invitrogen). 50 uL of 
bacteria were thawed on ice and 5 uL plasmid DNA was added and incubated for 30 min. 
The sample was then heat shocked at 42oC for 30 sec and then cooled on ice for 2 min. 250 
uL of pre-warmed SOC media (Invitrogen) was then added and before plating 50 uL or 200 
uL on appropriate bacterial selective plates (100 µg/ml ampicillin or 50 µg/ml kanamycin) and 
incubated for 16 hr at 37oC 
 
Plasmid purification  
Appropriate volumes of LB broth were inoculated with single colonies derived as described 
above, incubated in shaker for 16 hr at 37oC. Plasmid DNA was then isolated using by 
Miniprep (Promega A1223) or Maxiprep (Promega A2392).  
 
Spectrophotometry 
Concentrations of nucleic acids were measured using a Nanodrop spectrophotometer 
(Thermo Scientific).  
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Agarose gel electrophoresis  
Agarose gels were prepared by dissolving agarose in Tris/Acetate/EDTA (TAE) buffer to the 
desired concentration (1-2%).  GelRedTm nucleic acid dye (Biotium 41002) was added to 
cooled agarose and gels cast in Mini-Gel casters (Bio-Rad). Electrophoresis was performed 
in Mini-Gel tanks at 75-100 V in 1x TAE buffer. Sample volumes ranging from 20 to 40 µL for 
diagnostic and purification gels respectively using between 1 and 10 µL of DNA, 
BlueJuiceTm gel loading buffer (Invitrogen) and nuclease free water (Quiagen). Nucleic acids 
were imaged by UV transillumination using the Gel-Doc XR+ System (Bio-Rad).  
 
Gel extraction  
Selected bands were excised from agarose gels under UV transillumination and nucleic acids 
purified using the Qiagen Gel Extraction Kit (Qiagen 28704).  
 
Primer design 
Primers for cloning and sequencing were designed using Oligoperfect (Applied Biosciences). 
  
Site directed mutagenesis  
Site directed mutagenesis was performed using the QuckChange II XL Site Directed 
Mutagenesis Kit (Stratagene 200521). 
 
Plasmid maps/ virtual cloning  
Plasmid maps and virtual cloning histories were created with SnapGene software, version 
2.2.2 (Chicago, Illinois). 
 
Lentiviral vector production and transduction 
Production of lentiviral particles  
Viral production protocols were based on relevant publications and technical manuals, 
optimised to ensure adequate viral titer (Kutner et al., 2009). 293FT cells were plated at a 
density of 70,000 cells per cm2 in 100 mm dishes the afternoon prior to transfection to 
achieve a confluence of 50-80% at transfection. For transfection, the antibiotic supplement 
was omitted from standard media to optimise the efficiency of gene transfer. A combination 
of 6 µg of shRNA-encoding lentiviral vector, 4.5 µg of packaging vector psPAX2 and 3 µg of 
envelope vector pMD2.G (Didier Trono, University of Lausanne) in 40.5 µl Fugene6 (Roche) 
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were diluted in 6 ml medium and applied to the cells. The medium was replaced after 12 hr 
with 10ml of standard medium. Culture supernatants containing lentiviral particles were 
collected at 24 and 36 hours and passed through 45 µm filters to remove debris.  
 
Lentiviral particles were concentrated and purified by ultrafiltration. 26ml of lentiviral 
supernatant was overlaid on 4ml sucrose cushion into sterile conical centrifuge tubes 
(sucrose cushion: 20% sucrose, 100mM NaCl, 20mM HEPES, 1mM EDTA). Loaded tubes 
were centrifuged at 82,700 x g for 2 hours and 20 min at 4oC following which the supernatant 
was discarded. Lentiviral particles were resuspended in 260 µl PBS (100-fold final 
concentration of 26ml starting supernatant) by serial pipetting before aliquoting and storage 
at - 80 oC.  
Lentiviral transduction  
A schematic overview of the transduction procedure for all cells, other than hES cells, is 
given in Figure 4.7A, (the adapted procedure for the transduction of hES clusters is detailed 
below).  Cells were plated in 6-well plates in triplicate for each condition 48 hours prior to 
transduction (neonatal cardiomyocytes, 100,000 cells/cm2; other cell types, 10,000 
cells/cm2). For transduction, 40 - 100 µl viral supernatant was diluted in relevant culture 
medium containing 8 μg/ml polybrene (Sigma H9268) and applied to cultures, followed by 
centrifugation at 300 x g for 1 hour at 37oC  and incubation for 12 hours. Cells were 
maintained under normal culture conditions for a further 84 hours (total 4 days) post 
transduction before analysis.  
 
For hES transduction, cells were expanded in 12-well, Matrigel coated plates until 
subconfluent. Medium was replaced with 0.5mL of Collagenase IV and the cells were then 
incubated at 37oC for 5 min following the enzyme preparation and subsequently removed and 
washed. Clusters from each well were then manually broken up into 500 μL mTeSR1 
containing 8 μg/ml polybrene and transferred to a 5 mL tube. Once clusters had settled, 250 
μL of supernatant was exchanged for 250 μL of virus diluted in culture medium to an 
approximate MOI of 2.5. Cells were incubated with the virus medium for 5 hours, agitating 
hourly before seeding to Matrigel coated 6 well plates.  
 
Blastocidin selection of Myh6-mCherry-PGK-Blar transduced cells 
To create purified reporter lines containing the Myh6-mCherry-PGK-Blar reporter, cells were 
selected using Blastocidin S Hcl (Invitrogen) (CSP clone 3 and 16, hES). For each cell type, 
the minimum killing concentration was determined for untransduced cells (hES, 0.5 μg/mL; 
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Clone 3 and 16, 2 μg/mL). 3 days after transduction, cells were cultured in medium 
containing blastocidin at the relevant concentration and refreshed every 48 hours. Wild type 
cells cultured in parallel were used to confirm cell death in those cells not possessing the 
resistance cassette; generalised cell death was observed at 7 days. 
 
Graphing and statistical analysis 
Graphing and statistical analysis were performed using Prism 5, version 5 (Graph pad 
Software Inc.; San Diego, California). Unless otherwise stated, data are expressed as mean 
± SEM. Data were analysed using paired t-tests or by analysis of variance (ANOVA), 
followed by Bonferroni multiple-comparisons test. p values less than 0.05 were considered 
significant. ns, p > 0.05; *, p ≤ 0.05; **, p ≤ 0.01; *** p ≤ 0.001. 
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Chapter 3: Gene expression analysis of CSP cells at 
baseline and under conditions of directed differentiation. 
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Background 
 
Conditions for the in vitro differentiation of CSP, isolated and propagated by the methods 
described, have not been determined. A summary of the reported methods for in vitro 
differentiation of other/ complimentary cardiac progenitor populations is given in Table 3.1. 
Treatment with azacytidine has been shown to stimulate cardiomyocyte differentiation in 
cardiac Sca1+ progenitors (Oh et al., 2003) and in marrow stromal cells (Makino et al., 1999), 
as well as to enhance differentiation of ESCs by the ‘hanging drop’ method (Yoon et al., 
2006).  
 
First described in 1974, azacytidine is a chemical analogue of cytosine (Cihak, 1974) which 
can selectively activate gene expression. When incorporated into DNA, azacytidine functions 
as an inhibitor of 5-methylcytosine methyltransferases. Through this mechanism it may 
cause the reactivation of genes formerly suppressed by DNA methylation (Jones, 1985; 
Jones et al., 1982). Azacytidine is also incorporated into RNA altering processing and 
consequently protein synthesis.  
 
Azacytidine treatment converts the mouse embryonic cell line 10T1/2 into three mesodermal 
phenotypes (skeletal muscle, adipocytes and chondrocytes), suggesting that these cells 
represent a multipotent mesodermal precursor (Taylor and Jones, 1979). Although 
azacytidine is reported to promote cardiomyocyte differentiation, the effect to other cardiac 
lineages (endothelial and smooth muscle) is not described. 
 
In this thesis the effect of azacytidine treatment on CSP in comparison with MSC was 
investigated. Custom gene arrays (Taqman Low Density Array, TLDA) were employed to 
simultaneously assess for the emergence of a range of mesoderm-derived phenotypes 
(cardiac, skeletal, and smooth muscle; haemopoietic lineages, and endothelium), as well as 
for effects on expression of stem cell markers and cardiogenic transcription factors.  
 
Although azacytidine treatment may be of limited value in determining lineage potential, it 
represents the most established method for the in vitro differentiation of the parent cardiac 
Sca1+ population. It may be of utility to provide positive control conditions for the 
development of genetic reporters of cardiomyocyte differentiation and for use in subsequent 
high content screens. The availability of reliable positive and negative control conditions are 
important references in determining the Z-factor for screens, which in turn allow for 
comparisons between experimental runs (Al-Ali et al., 2004).
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Table 3.1 Summary of in vitro differentiation protocols for cardiac progenitors
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Aims 
 
1. To investigate whether azacytidine treatment is effective at promoting cardiomyocyte 
differentiation of CSP  
 
i. To establish positive control conditions for CSP differentiation to enable the 
development fluorescent reporter assays of cardiomyocyte cell fate. 
ii. To establish positive control conditions for CSP differentiation for use in 
exploratory screens 
 
2. To investigate the effect of azacytidine treatment on differentiation to other cardiac 
lineages (endothelial and smooth muscle cells). 
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Results  
Taqman Low-Density Array (TLDA) analysis was employed to define the gene expression 
profile of uncloned CSP (CSP, passage 13) and bone marrow derived MSC (MSC, passage 
13) under conditions of normal growth and following treatment with azacytidine. A schematic 
overview of the azacytidine treatment protocol is given in Figure 3.1A. To confirm the 
sensitivity and specificity of the assay format, a panel of control tissues was included in the 
analysis (adult neonatal cardiomyocytes, adult whole heart, 10-day embryonic heart, skeletal 
muscle, and undifferentiated embryonic stem cells; gift from M Noseda, second supervisor). 
Brightfield images of CSP and MSC at baseline are given in Figure 3.1B. All CSP, MSC and 
control samples at baseline and following azacytidine were analysed for gene expression 
concurrently. 
Selection of endogenous control genes and validation of TLDA gene assays 
To determine the optimum combination of endogenous control genes for normalization, CT 
values for Hmbs, Ubc, 18S and combinations thereof were plotted for all samples (Figure 
3.2A). The endogenous control gene(s) should reflect the amount of RNA present in the 
polymerase chain reaction and should not vary according to the tissues sampled or in 
response to experimental treatment (azacytidine).  
 
To quantitatively evaluate the stability of control genes expression, Vandersomple et al. 
development an algorithm for calculation of the gene stability measure based on non-
normalised gene expression levels of multiple control genes (Vandesompele et al., 2002). 
This method is based on the assumption that the ratio of stable control genes should not vary 
between cell types and experimental conditions. Gene stability measures (M values) were as 
follows, Hmbs 0.09451985; Ubc 0.09896045; 18S 0.11719179. The geometric mean of 
Hmbs and Ubc gave the most stable M value indicated by the lowest score (0.07628851), of 
all endogenous control genes tested singularly or in combination. The geometric mean of 
these two genes was then used for normalisation to generate dCT values.  
 
To confirm the sensitivity and specificity of gene expression by Taqman Low-Density Array, 
bar plots organized by individual genes were plotted, with scaling to facilitate comparison 
between CSP, MSC and control samples at baseline (Figure 3.3). The results confirm the 
expected pattern of tissue and stage -specific gene expression, suggesting utility of this 
assay format in screening multilineage differentiation events in CSPs.   
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The molecular identitiy of CSP  
To determine whether CSPs possess a unique molecular signature with respect to MSC and 
control tissues, hierarchical clustering was applied to a Pearson correlation matrix for all 
samples (reference cell types, untreated CSPs, and treated CSPs). The results demonstrate 
that CSPs (both treated and untreated) are grouped as a distinct molecular entity. Amongst 
the control tissues, the MSC were the most similar with respect to the pattern of gene 
expression (Figure 3.2B).  
  
To facilitate direct comparison of the baseline gene expression profiles of CSP (uncloned, 
passage 13) and MSC (uncloned, passage 13), all genes were plotted for each sample with 
identical scaling (Figure 3.4). The pattern of gene expression for the CSP uncloned 
population is consistent with unpublished data for the mean expression from 20 clonally 
derived CSP cell lines (Figure 1.4), and contrasted with that observed for MSCs. Cardiac 
transcription factors Gata4, Gata6, Hand2, Mef2a and Mef2c were detected in CSP, whereas 
Mef2a was the only cardiac transcription factor expressed in MSC.  
 
As expected the MSC- and cardiogenic mesoderm-associated marker Pdgfra was expressed 
in both MSC and CSP (Kattman et al., 2011). CSP expressed little or no message for 
markers of differentiated cardiac lineages and overall the molecular profile of transcription 
factors present was similar to that described for the cardiac Sca1+ population in general (Oh 
et al., 2003). 
 
Effet of azacytidine treatment on the differentiation status of CSP and MSC 
To determine whether azacytidine treatment is effective in inducing the cardiomyocyte 
differentiation of uncloned CSP, cells were treated according to published methods reported 
to be effective in the cardiac Sca1+ population (Oh et al., 2003); bone marrow derived MSCs 
were included as a control and were treated according to the methods described by (Makino 
et al., 1999). Cells were analysed by TLDA gene expression array at baseline, and then at 7, 
14 and 28 days following induction (Figure 3.1A). 
 
A dose responsive induction of cardiomyocyte associated cardiac α-actin (actc1) at 28 days 
was observed following azacytidine treatment in MSC but not CSPs; other markers of 
cardiomyocyte differentiation were not induced (Myl2, Nppa), (Figure 3.5). These results 
contrast with the activation of multiple cardiomyocyte genes reported elsewhere (MSC: 
Myh6, Myh7, Actc1, (Makino et al., 1999). Low levels of Cdh5, Vwf, Myog induction were 
observed in MSCs, but not in CSP (Figure 3.6). Smooth muscle associated genes were 
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induced in CSP (Cnn1, Myh11) under conditions of low serum with no relation to azacytidine 
dose (Figure 3.6).  
Selection of CSP clones 3 and 16 for use in subsequent differentiation studies 
Given the absence of cardiomyocyte differentiation of the uncloned CSP population (CSP, 
passage 13), two complementary CSP clonal populations (CSP clones 3 and 16) with proven 
tri-lineage differentiation potential in vivo (Figures 1.4-1.6) where selected for use in 
subsequent studies of in vitro differentiation. Cardiac Sca1+ cells at low passage were 
included in subsequent studies as a complementary control. 
 
To facilitate quantitative comparison of the baseline gene expression of these populations 
were re-examined by qRT PCR with all genes for each sample plotted with identical scaling 
(Figure 3.7). The molecular signature of expression of cardiac transcription factors in the 
absence of cardiac structural genes was consistent across samples (CSP clones 3 and 16, 
cardiac Sca1+). Cardiac transcription factors Gata4, Gata6, Hand2 and Mef2a were detected 
in all samples except for CSP clone 16, where Gata4 was absent. Nkx 2.5 was expressed in 
CSP clone 3 and cardiac Sca1+ only. 
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Discussion 
CSP share a similar gene expression profile with the parent cardiac Sca1+ population  
The baseline gene expression profile of uncloned CSP (passage 13) was comparable to that 
of the cardiac Sca1+ parent population (Oh et al., 2003), and to the mean expression of 
clonally isolated CSP cell lines (Figure 1.4F). All express cardiac transcription factors (Gata4, 
Gata6, Hand2, Mef2a) in the absence of cardiac structural proteins, suggesting that the SP 
phenotype identifies a clonogenic subset of these cells, rather than a distinct population.  
 
The pattern of gene expression is similar to that observed for other putative cardiac 
progenitor populations, namely cardiac Kit+ and cardiac SP (see Table 1.1), but differ from 
those more recently described. Specifically, Chong et al. reported a clonogenic, multi-potent 
subpopulation of the cardiac Sca1+/CD31- population identified by the colony forming unit 
fibroblast assay, termed cCFU-Fs. These cells did not express cardiogenic transcription 
factors at baseline; however these genes were induced under conditions of directed 
differentiation (Chong et al., 2011).  
 
The relationship of cCFU-Fs to the clonogenic SP of the cardiac Sca1+ fraction is not yet 
clear. It is possible that these populations are related, and that observed differences in gene 
expression reflect different activation of states for a common progenitor population, 
(analogous to the satellite cells where induction of MyoD marks activation in response to 
injury (Le Grand and Rudnicki, 2007)). This would be consistent with CSP being an activated 
state of a cCFU progenitor; alternatively it may be that the two populations have distinct 
origins and potentially alternative functions. The characteristics of cCFU population are 
outlined in Table 3.2 (Chong et al., 2011). 
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Table 3.2 Characterisitcs of cCFU-F progenitors
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Azacytidine treatment of CSP and MSC did not induce cardiomyocyte or endothelial 
genes; however smooth muscle associated markers were expressed under 
conditions of serum starvation  
CSP differentiation to the cardiomyocyte phenotype was not observed under the conditions 
tested. For MSC, a dose responsive between azacytidine concentration and expression of 
cardiac α-actin was observed, however no other cardiomyocyte genes were expressed. 
Importantly, the published method employed by Makino et al., involves the subcloning of 
spontaneously beating cells and re-exposure of these cells to azacytidine. It is not clear from 
the published report at what point cells were subcloned and the details of this procedure are 
unavailable (Makino et al., 1999). It is possible that the conditions employed here were 
insufficient to enable activation of the full cardiac program, although the dose-responsive 
relationship of cardiac α-actin with azacytidine is an indication that the agent itself was 
biologically active.  
  
The absence of cardiomyocyte differentiation represents an unexpected result given reports 
of differentiation for the main cardiac Sca1+ population (Oh et al., 2003). The lack of detailed, 
published protocols describing essential aspects for azacytidine-induced differentiation (e.g. 
cell confluence), make accurate replication of a particular system problematic. Smits et al., 
published such a protocol for human heart derived Sca1+ cells, however it remains to be 
determined whether these methods are translatable to mouse derived cells (Smits et al., 
2009b).   
 
In their protocol, Smits et al. list some of the potential factors that may prevent cardiac 
progenitors from differentiating to cardiomyocytes in vitro. These include, serum batch 
variability, use of cells of high passage (>23) or culture at high (>90%) or low (≤50%) 
confluence during expansion. For human cardiac Sca1+ cells, successful differentiation 
depended upon initiation of azacytidine treatment at a cell density of 80-90% confluence 
(Smits et al., 2009b). In these experiments, confluence at initiation was 20-30% and this may 
have prevented cardiomyocyte differentiation. Pfister et al. highlighted the potential 
importance of juxtracrine signalling based on the observation that cellular coupling with adult 
cardiomyocytes was required for functional differentiation of cardiac SP cells (Pfister et al., 
2005). 
 
As outlined in Table 3.1, for all mouse cardiac progenitor populations except Kit cells, 
cardiomyocyte differentiation was performed on freshly isolated cells. Under the stringent 
conditions for isolation employed in the research reported herein, the yield from a single 
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mouse heart was approximately 10,000, limiting the scope of experiments without prior 
expansion in culture. It is possible that the passaging procedure negatively selects for cells 
with differentiation capacity or that capacity is lost as cells adapt to culture conditions.   
 
Alternatively, it may be that the details of the azacytidine treatment schedule were insufficient 
to promote differentiation. Azacytidine is unstable in aqueous solution and is light sensitive 
with t½ of 90 min in phosphate buffered saline (Chatterji, 1982). Therefore azacytidine 
solutions should be prepared freshly for each experiment. Despite this, some studies report 
the long-term storage of aqueous solutions at -20o; consequently effective concentrations 
may vary considerably between studies purporting to use the same dose. To account for this 
potential effect a range of concentrations were examined: 3uM as per (Oh et al., 2003); 5uM 
(Smits et al., 2009b); 10uM (Matsuura et al., 2004). 
 
In a clonal analysis of azacytidine treated 10T½ cells, Konieczny et al., determined that the 
effect of azacytidine treatment was to generate stable, committed progenitors for 
mesenchymal cell lineages, and that subsequent differentiation depended upon the 
appropriate cell culture conditions (Konieczny and Emerson, 1984). It was using this system 
that Davis et al., identified MyoD as the master regulator of skeletal muscle differentiation 
expressed in progenitors committed to this fate (Davis et al., 1987). For 10T½ , azacytidine 
treatment did not directly induce genes for the differentiated phenotype, but instead induced 
those which led to the formation of progenitor populations. By comparison, for CSPs, 
expression of many of the core cardiac transcription factors was confirmed at baseline and 
levels were not significantly altered with azacytidine treatment.  Hence, by analogy, the 
expression of cardiogenic transcription factors may indicate an activated progenitor state, 
suggesting that the key factor for differentiation may be the cell culture conditions.  
 
The interpretation of gene expression data to assess differentiation events in heterogeneous 
or stochastically responsive cultures is limited by a lack of information about cellular 
frequency and hence is potentially thwarted by dilutional effects. Importantly, it is not possible 
to discern whether a particular transcript’s abundance reflects low levels of expression in 
many cells, or high levels in a few. This supports the case for optical reporter based assays 
of differentiation as the basis for higher throughput screens. Conceptually, this approach 
enables quantification of the frequency of differentiation events and offers the potential to 
isolate differentiated cells from heterogeneous cultures for further analysis.  
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Concerning the induction of other cardiac lineages, markers associated with endothelial 
lineage were not expressed. However, induction of smooth muscle associated genes Myh11 
and Cnn1 was observed in CSPs after serum starvation. Serum starvation is recognised to 
induce smooth muscle differentiation from de-differentiated human umbilical vascular smooth 
muscle cells (Han et al., 2006). The induction of genes associated with smooth muscle 
differentiation in CSP is discussed further in Chapters 5 and 6. 
Selection of CSP clones for use in high content screens of cardiomyocyte 
differentiation 
It was hypothesized that clonal purification of CSP may enrich for stem-like cells and 
potentially increase the frequency of differentiation in subsequent in vitro screens. In addition, 
clonal analysis of putative adult stem cell populations is the only means of proving a true 
multi-lineage potential ((Hope and Bhatia, 2011), see Figure 3.8 for schematic of clonal 
analysis approach for CSP).  
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Figure 3.8. Clonal analysis of CSP. A schematic overview of the clonal analysis approach for the determination 
of multi-lineage potential of CSP progenitors in vivo, and for investigation of conditions for differentiation in vitro. 
The clonal subset of the cardiac Sca1+ population is prospectively identified by side population assay (CSP cells), 
and used to establish clonal CSP lin s in cell culture. Following expansion to generated sufficient numbers of cell 
numbers, CSP clones are investigated by in vivo grafting to determine lineage potential (Figure 1.6). CSP clones 
with proven lineage potential are then used in for in vitro screens as a platform for investigated the signals 
directing differentiation.  
 
As discussed in Chapter 1, analysis of clonally isolated CSPs demonstrates heterogeneity 
with respect to the expression of cardiogenic transcription factors. Two complimentary lines 
(CSP clones 3 and 16) were selected for further study to span the range of gene expression 
profiles, each with in vivo data to suggest cardiomyocyte, smooth muscle, and endothelial 
cell differentiation (Figure 1.6). Gene expression of CSP clones 3 and 16 was re-examined 
here and confirmed notable heterogeneity with respect to expression of cardiac transcription 
factors Gata4 and Nkx2.5 (CSP clone 3: Gata4POS, Nkx2.5POS; CSP clone 16: Gata4NEG, 
Nkx2.5NEG). The potential functional significance of these differences is incompletely 
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understood. In the research reported herein two contrasting clones were selected for further 
study as a strategy to mitigate the risk of selecting a non-cardiogenic CSP clone. 
 
Since CSP did not differentiate to the cardiomyocyte lineage under the conditions tested. It 
was determined therefore to validate novel genetic reporters of cardiomyocyte fate in a range 
of differentiated cell types, (including neonatal cardiomyocytes), and also in ESCs derived 
cardiomyocytes. A suitable optical reporter construct could then be used in small-scale 
screens to explore and develop alternative protocols for the cardiomyocyte differentiation of 
CSPs.  
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Chapter 4: Fluorescent reporters of cardiomyocyte 
differentiation 
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Background  
High-content screening (HCS) has emerged as a valuable tool for investigating complex 
biological processes (Almaca et al., 2013). Such screening refers to the extraction of multi-
parameter optical data from cell-based assays, using automated microscopy or flow 
cytometry in large-scale screens. Depending upon the probes employed, high content image 
analysis allows for the quantification at the single-cell level of metrics such as morphology, 
differentiation status, nuclear morphology and DNA content, protein localisation, proliferation 
status and viability (Al-Ali et al., 2004; Breier et al., 2008; Mundy et al., 2010). 
 
HCS has been employed to investigate the developmental logic of neuronal progenitors 
using assays for multiple lineage fates monitored in live cells (Ravin et al., 2008). The 
development of fluorescent reporters of cardiomyocyte fate for use in high content 
applications is described herein. The eventual goal of this research path would be to develop 
reporters for multiple lineages (endothelial and smooth muscle cell), as well as reporters for 
developmental intermediaries (Nkx2.5) for use in multiplexed assays to investigate lineage 
commitment in adult cardiac progenitors. 
 
The development of a genetic reporter of cardiomyocyte differentiation is discussed below. In 
the case of CSP, where the conditions and timescales for cardiomyocyte differentiation are 
unknown, the ability to monitor differentiation events in live cells is potentially of great utility to 
facilitate the development of novel differentiation protocols.  
 
Fluorescent protein reporter gene assays for high content screening  
Reporter gene assays are based on gene labels whose expression is controlled by cis-
regulatory elements such promoter sequences, or response and enhancer elements.  
The role of the reporter gene is to generate a signal that can be identified clearly and reliably. 
A wide range of reporter genes is available, each with specific advantages and 
disadvantages including: ease of detection; kinetics of induction and decay of signal; and 
sensitivity and dynamic range. Report genes can be divided broadly by secreted products 
(for example, secreted placental alkaline phosphatase and β-lactamase) and those which are 
retained intracellularly (for example, luciferase, green fluorescent protein and 
chloramphenicol acetyltransferase), (reviewed in (Liu et al., 2009)). 
 
Fluorescent protein reporter assays offer a number of advantages for use in high content 
imaging applications. Unlike for traditional reporters, quantification does not require cell lysis 
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or substrate addition and allows for serial analysis of living cells. Furthermore, signal intensity 
is analysed at the single cell level and therefore is independent of the total cell number in the 
sample (Gasparri and Galvani, 2010). In some instances, high content analysis using a 
fluorescent reporter gene is reported to show higher sensitivity and specificity that traditional, 
luciferase based, assays (Unterreiner et al., 2009). 
 
In differentiation assays, fluorescent reporter genes facilitate the enrichment of differentiated 
cells from heterogeneous cultures (Muller et al., 2000); enable live cell imaging to track 
differentiation status; and are suitable for use in high throughput applications (Willems et al., 
2011). Given reports of the autofluorescence of cardiomyocytes in the spectrum of eGFP 
(Laflamme and Murry, 2005), derivatives of red fluorescent protein (mOrange and mCherry) 
were selected for use in the reporter gene assay used in the research reported herein.  
 
Choice of tissue specific promoters for cardiomyocyte lineage 
The choice of a regulatory element to drive expression of a reporter gene for use in screens for 
CSP cardiomyocyte differentiation, involves a number of important considerations: 
 
• High degree of specificity for the cardiomyocyte lineage  
• Expressed in cardiomyocytes early in heart development  
• Expression maintained through maturation and in mature cardiomyocytes 
 
The selection the regulatory element for a gene expressed early in cardiomyocyte 
differentiation ensures the detection of immature cardiomyocytes that may arise and may 
also decrease the time frame for their detection in HCS screens. It is equally important that 
expression is maintained in the fully differentiated, mature cardiomyocyte in order to capture 
the multiple developmental stages that may arise during screening. Finally, it is desirable that 
the regulatory element for tissue specificity is applicable across species and translatable 
from the rodent to human tissue. Although this thesis concerns mouse CSP, it is possible that 
the screening platforms developed herein may be translated to human cardiac progenitor 
populations in the future. Based on these criteria, the promoters for the cardiomyocyte-
specific sarcomeric proteins alpha myosin heavy chain (Myh6) and cardiac troponin T 
(TNNT2) were selected for study.   
 
Tissue-specific regulation of the Myh6 gene promoter (- 5446 to - 4 DNA base pairs relative 
to ATG, bp) has been demonstrated in transgenic mice (Subramaniam et al., 1991). This 5.5 
kilobase promoter sequence was the basis for the first cardiac-specific Cre deleter line for 
which cardiomyocyte lineage specificity is well established (Agah et al., 1997). In the mouse, 
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Myh6 and Myh7 are expressed in the developing embryonic heart between 7.5 - 8 days 
(Lyons et al., 1990). However, following the formation of the ventricular chambers, 
expression of Myh6 in ventricular myocytes progressively decreases (Morkin, 2000), until 
shortly after birth when increased levels of thyroid hormone result in rapid induction (Lompre 
et al., 1984). Myh6 is the predominant isoform in adult life although pathological stimuli, such 
as pressure overload, promote increased expression of Myh7 (Haddad et al., 2010).  
 
In the human, MYH6 and MYH7 are expressed from development through to adult life when 
MYH7 predominates and MYH6 levels are decreased in failing hearts (Miyata et al., 2000). In 
spite of these considerations, an mouse Myh6 based reporter has been employed 
successfully in screens of cardiogenic factors in differentiating human embryonic stem cells, 
with durable expression reported in differentiated cells (Kita-Matsuo et al., 2009; Willems et 
al., 2012; Willems et al., 2011). The vector backbone for this construct is the SIN18.WPRE, a 
self-inactivating (SIN) lentiviral vector itself based on human immunodeficiency virus-1 (Kita-
Matsuo et al., 2009; Zufferey et al., 1998). The construct was selected and adapted for in 
CSP (Figure 4.3; gift from Dr M Mercola, Sanford-Burnham Medical Research Institute). 
 
In the mouse, Tnnt2-Cre deleters are expressed earlier and more uniformly during 
development than those based on the Myh6 (Chen et al., 2006; Jiao et al., 2003). A novel 
TNNT2-based lentiviral reporter construct, based on the human analogue of the rat Tnnt2 
promoter (Jiao et al., 2003; Wang et al., 1994) was developed by Dr O Tolmachov in the 
Supervisor’s laboratory and was selected for validation as an alternative, having potentially 
greater specificity and sensitivity than the Myh6 based constructs (Figure 4.2). The lentiviral 
backbone from pLL3.7 was engineered to include the phosphoglycerate kinase (PGK) 
promoter driving expression of nuclear localized eGFP; and a 777 bp fragment of the human 
TNNT2 promoter driving expression of membrane targeted mOrange. The performance of 
this novel TnnT2 promoter based reporter had not yet been established.  
 
Delivery of reporter gene assays to target cells 
A number of methodologies are established for the delivery of reporter transgenes to primary 
cell cultures. Transfection by lipofection or electroporation is possible in some primary cells; 
however, despite the elaboration of numerous methodologies, efficiency remains low and 
procedures can be cytotoxic (Zeitelhofer et al., 2007). Integrating viral vectors are able to 
overcome these issues and establish stable, long-term and heritable trangene expression in 
cells, including those which are post-mitotic (Thomas et al., 2003). Lentiviral vectors 
pseudotyped with the vesicular stomatitis G protein (VSV-G) were selected for use in the 
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research given their advantages over other viral vector systems. These vectors combine a 
large packaging capacity with the ability to infect non-dividing cells, such as neonatal 
cardiomyocytes, a unique property amongst retroviruses (Poeschla et al., 1998). In addition 
they are readily applicable for  use in human primary cells, making possible their application 
in adult human cardiac progenitor cells.  
 
Dual expression cassettes were incorporated to facilitate the purification of lentivirally-
transduced cells harbouring the reporter gene assay for validation studies and for the 
establishment of reporter cell lines (Figure 4.1). The extended capacity of lentiviral vectors 
was particularly relevant here given the large size of these components. A schematic of the 
integrated proviruses demonstrating the dual expression cassettes for the proposed reporter 
constructs is shown in Figure 4.1. 
 
 
Tissue specific 
promoter !
Fluorescent 
reporter gene!
Ubiquitous !
promoter !
Selection !
marker !
Selection cassette ! Reporter cassette!
 
 
Figure 4.1. Dual cassettes for selection of transduced cells and lineage reporting 
Schematic of a lentiviral reporter scheme based on dual expression cassettes. The ubiquitous promoter selected 
that is constitutively active in the target cell type. This sequence drives the expression of a selection marker gene 
that is used to identify and purify successfully transduced cells. The reporter cassette contains a tissue specific 
promoter sequence that drives the expression of a second reporter gene, in this case a fluorescent marker gene. 
 
Choice of reporter genes as selection markers: complementary constructs for 
validation studys and high content screening applications 
To facilitate the selection of lentivirally transduced CSP cells, the constitutively expressed 
mouse phosphoglycerate kinase 1 promoter (PGK) was selected to drive the selection 
marker. For the establishment and maintenance of purified CSP reporter lines, the 
blastocidin resistance gene (BSNr) was chosen as the selection marker. Originally isolated 
from the Bacillus cereus K55-S1 strain, BSNr confers resistance to blastocidin S, an antibiotic 
that inhibits protein synthesis causing cell death in dividing eukaryotic and prokaryotic cells 
(Izumi et al., 1991). The advantage of BSNr as the selection marker is that it permits the 
purification and maintenance of pure reporter cell lines for use in screens, avoiding the need 
for flow cytometry cell sorting. In addition, the use of this marker preserves a greater 
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proportion of the optical spectrum for additional optical assays than may be required in HCS 
applications, such as immunostaining with fluorescent dyes. 
 
To facilitate validation, and for other applications including flow cytometry-based purification, 
an alternative configuration with eGFP as the selection marker was also generated. This 
approach enabled the rapid assessment of reporter expression in diverse cell types without 
the need for extensive normalization for transduction efficiency or time-consuming selection 
based on blastocidin sensitivity.  Furthermore, the lethality of blastocidin is dependent upon 
cell division and consequently was not suitable for selection of transduced neonatal 
cardiomyocytes that were to be the principal positive cell control for validation studies. 
 
Although promoter sequences for sarcomeric proteins have been shown to confer 
cardiomyocyte specificity in transgenic animal models, (Anderson et al., 2007; Huber et al., 
2007), the tissue specificity of viral vectors incorporating these promoter sequences may be 
significantly affected by interaction with elements of the viral backbone (Barth et al., 2008). 
These considerations necessitate a thorough evaluation of performance for any novel 
lentiviral reporter construct.  
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Aims 
1. To develop lentiviral reporter constructs for use in CSP based on the Myh6 promoter 
and to compare this with a novel TNNT2 promoter based construct.  
 
2. To validate the sensitivity and specificity of the constructs generated in Aim 1 across 
a panel of differentiated cell types including primary cardiomyocytes. 
 
3. To examine further the performance of constructs validated in 2., in directed 
cardiomyocyte differentiation of hESCs. 
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 Results  
Construction of Myh6-mCherry/ PGK-eGFP and Myh6-mCherry/ PGK-BSNr vectors  
To adapt the Myh6-mCherry/ REX-BSNr lentiviral vector (Kita-Matsuo et al., 2009) for use in 
CSP, the REX promoter was substituted with the PGK promoter since only a subset of 
pluripotency genes are expressed in CSP (Figure 1.4F). The cloning history for this 
modification is given in Figure 4.4. Briefly, the constraints of the starting vector were such 
that the introduction of a unique restriction site to flank the REX promoter was required (a 
flanking Asc1 site was already available). It was determined that Nhe1 was not present in the 
starting vector and this restriction site was selected for introduction at the 3’ end of the REX 
sequence. The PGK promoter was then copied from pLL3.8 GFP (Liu et al., 2007; Rubinson 
et al., 2003) construct using primers incorporating restriction sites corresponding to the 
existing and engineered sites flanking the REX promoter. Appropriate digests and ligation 
steps were undertaken to excise the REX promoter and to introduce PGK. Successful 
ligations were determined by restriction enzyme digest and gel electrophoresis, followed by 
DNA sequence verification. The plasmid map for the resulting vector (Myh6-mCherry/ PGK-
BSNr )  is given in Figure 4.6A.  
 
To facilitate the validation of tissue specificity and sensitivity of Myh6-mCherry vectors 
incorporating PGK (instead of REX1) in a range of cell types including neonatal 
cardiomyocytes, the selection marker BSNr was substituted with eGFP. The cloning history 
for this modification is given in Figure 4.5. Briefly, the Myh6-mCherry/ PGK-BSNr construct 
(Figure 4.6A) was engineered by site-directed mutagenesis to introduce a unique BstB1 
restriction site at the 3’ end of the blastocidin resistance gene (BSNr). The enhanced green 
fluorescence protein gene (eGFP) was copied from pLL3.8 GFP (Liu et al., 2007; Rubinson 
et al., 2003) construct using primers incorporating restriction sites corresponding to the 
existing and engineered sites flanking the BSNr gene. Appropriate digests and ligation steps 
were undertaken to excise BSNr and to introduce eGFP. Successful ligations were 
determined by restriction enzyme digest and gel electrophoresis followed by DNA sequence 
verification. The plasmid map for the resulting vector (Myh6-mCherry/ PGK-eGFP) is given in 
Figure 4.6B. A schematic diagram of the integrated provirus for each of the resulting lentiviral 
vectors is given in Figure 4.7B. 
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Assessment of sensitivity of Myh6-mCherry/ PGK-eGFP and TNNT2-mOrange/ PGK-
eGFP for labelling neontal rat cardiomyocytes 
To assess the sensitivity of Myh6-mCherry/ PGK-eGFP and TNNT2-mOrange/ PGK-eGFP 
for the cardiomyocyte lineage, neonatal rat cardiomyocytes were transduced with lentiviral 
particles and examined by immunofluorescence microscopy and flow cytometry after 4 days 
in culture (Figure 4.7A).  
 
To ensure that lentiviral transduction of neonatal cardiomyocytes did not result in significant 
cell death, the viability of transduced and control untreated cells was compared using the 
Sytox Blue Dead Cell Stain and flow cytometry analysis. Debris and cell couplets were 
excluded by gating on forward and side scatter parameters as illustrated in Figure 4.8A. 
Viability ranged from 70.1 - 73.65 % and was unaffected by lentiviral transduction (Figure 
4.8C). Non-viable fractions of transduced and control untreated cells were examined for 
eGFP and mOrange/ mCherry expression by epifluorescence microscopy, to determine 
whether dead matter led to false positive events on the basis of autofluorescence. False-
positive staining was not observed (Figure 4.8B).  
 
Next, the efficiency of cardiomyocyte labelling was assessed for each of the reporter 
constructs. Neonatal cardiomyocytes were transduced as described above and analysed 
after 4 days in culture. Despite enrichment of primary cardiomyocytes by Percoll density 
gradient centrifugation, fibroblast growth was observed with time and the cultures were 
therefore heterogeneous containing cardiac fibroblasts. To identify cardiomyocytes, cells 
were subsequently fixed and stained with antibodies for cardiac Troponin T. Reporter 
expression in Troponin T labelled cells assessed qualitatively by immunofluorescence 
(Figure 4.9) and quantitatively by flow cytometry (Figure 4.10). Flow cytometry was selected 
for over automated fluorescence microscopy for the facility of excluding debris and accurately 
compensating for spectral overlap during multi-fluorescence analysis (Sytox Blue, eGFP, 
mCherry/ mOrange, Dylight 649). The TNNT2 based construct labelled a greater proportion 
of cardiomyocytes than the Myh6 based construct (TNNT2: 58.8 ± 2.71 %; Myh6: 50.1 ± 2.94 
%), however greater non-myocyte expression was also observed (TNNT2: 9.85 ± 0.42 %;  
Myh6: 0.06 ± 0.06 %). 
 
Assessment of the specificity of reporter constructs for labeling cardiomyocytes 
To determine the specificity of Myh6-mCherry/ PGK-eGFP and TNNT2-mOrange/ PGK-
eGFP for the cardiomyocyte lineage, expression was quantified in a panel of 6 differentiated 
cell types (neonatal cardiomyocytes, cardiac fibroblasts, human umbilical vein endothelial 
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cells, CSP, human embryonic kidney cells and mouse embryonic fibroblasts), transduced as 
described above. Immunofluorescence was used to visualise reporter transgene expression 
in transduced live cells (4.11B, 4.12B) and, for quantification, live cells were analysed by flow 
cytometry (representative flow cytometry plots, 4.11A, 4.12A; quantification 4.13). 
 
For each cell type, gating for expression eGFP identified transduced cells; within the eGFP 
population, the percentages of cells expressing the respective reporter genes were 
calculated (Myh6-mCherry and TNNT2-mOrange). A summary of this quantification is given 
in Figure 4.13. For Myh6-mCherry/ PGK-eGFP (Figure 4.13A), a higher percentage of 
transduced cardiomyocytes expressed the reporter gene than for TNNT2-mOrange/ PGK-
eGFP (Figure 4.13B), (Myh6: 44.9 ± 5.62 %; TNNT2: 23.3 %). These low values of 
expression are a likely reflection of the fact that neonatal cardiomyocyte cultures contained a 
considerable proportion of cardiac fibroblasts.  
 
The Myh6-mCherry/ PGK-eGFP construct demonstrated high fidelity for the cardiomyocyte 
lineage, and its expression across all non-cardiomyocyte lines was ≤1% (CSP, 0.52 ± 0.03 
%; cardiac fibroblasts, 0.13 ± 0.08 %; human embryonic kidney cells, 0.03 ± 0.03 %; human 
umbilical vein endothelial cells, 0.01 ± 0.08 %; mouse embryonic fibroblasts, 0.26 ± 0.074 
%), (representative microscopy images and flow cytometry plots, Figure 4.11; quantification 
Figure 4.13A). The cardiomyocyte specificity of TNNT2-mOrange/ PGK-eGFP was 
comparatively lower, exceeding 2% for human embryonic kidney cells (CSP, 0.44 ± 0.11 %; 
human embryonic kidney cells, 2.08 ± 0.073 %; human umbilical vein endothelial cells, 1.43 
± 0.14 %; mouse embryonic fibroblasts and cardiac fibroblasts, not determined due to low 
transduction efficiency), (representative microscopy images and flow cytometry plots, Figure 
4.12; quantification, Figure 4.13B). Based on these results, the Myh6-mCherry based 
constructs were selected for use in high-content screening applications where specificity of 
expression is of greater importance than sensitivity.  
 
Myh6-mCherry/ PGK-BSNr: line creation and assessment in hESC cardiomyocyte 
differentiation 
To generate non-clonal stable reporter lines for use in validation experiments and in high 
content screening applications, human embryonic stem cells and CSP clones 3 and 16 were 
transduced. Subsequently cells harbouring the integrated provirus were selected with 
blastocidin treatment (treatment protocols: hESC, Figure 4.14A; CSP clones 3 and 16, Figure 
4.14C). For all cell types, generalised cell death was observed at 7 days in the untransduced 
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controls, indicating activity of the blastocidin resistance gene in transduced cells (hESC, 
Figure 4.14B, CSP, data not shown).  
 
To investigate the ability of Myh6-mCherry/ PGK-BSNr to report cardiomyocyte lineage in a 
dynamic, developmentally relevant system, transduced hESCs were differentiated to 
cardiomyocytes by the embryoid body method. After 10 days in culture, reporter expression 
was restricted to beating clusters amongst the transduced cells and reporter signal was 
absent from the untransduced cells, as expected (Figure 4.14B).  
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Discussion 
Myh6-based reporters are sensitive and specific for cardiomyocyte lineage 
Although the TNNT2 -based construct was found to label cardiomyocytes with greater 
efficiency than the Myh6-based constructs, it did so at the expense of selectivity. Very low 
levels of expression of the Myh6 construct were seen the non-cardiomyocyte cells. The 
labelling efficiency compared favourably to that reported for an alternative reporter system in 
which the Myh6 based reporter gene (Subramaniam et al., 1991) was delivered in the 
pRRLsin18.cPPT.CMV.eGFP.WPRE lentiviral vector (Barth et al., 2008). 
 
The Myh6-based lentiviral reporter constructs (Myh6-mCherry/ PGK-eGFP and Myh6-
mCherry/ PGK-BSNr) were selected further study. For creation of cell lines harbouring the 
reporter cassette, it was determined not to isolate transduced cells clonally. The rationale for 
using pooled cells was to minimize potential confounding effects of genome integration, copy 
number variation, and baseline heterogeneities between individual CSPs. CSP and hES were 
successfully transduced and purified by blastocidin selection to generate lines that would 
yield fluorescently labelled cardiomyocytes upon differentiation.  
 
In a ‘proof of principle’ experiment, hESC transduced with Myh6-mCherry/ PGK-BSNr were 
differentiated into cardiomyocytes and selective fluorescent labelling of beating clusters was 
confirmed. Quantitative analysis of these cultures was not possible due to the typical 3D 
aggregation of beating cells at the time-point tested, as an obstacle to conventional imaging, 
and insufficient cell number for analysis by flow cytometry. Further studies are thus required 
to enable staining and analysis by flow cytometry, with confocal microscopy being a potential 
alternative.  
 
Although qualitative assessment of reporter expression in differentiated hESCs suggested 
specific labelling of beating clusters, expression during the intervening stages of 
development, from pluripotency to the differentiated state, was not assessed. It is possible 
that Myh6-mCherry was expressed earlier, in a larger population of hESCs than ultimately 
adopted the cardiomyocyte lineage. To investigate this further, a time-course analysis is 
warranted along with lineage mapping, to identify whether reporter positive cells can arise at 
an intermediate developmental stage. To confirm conclusively the identity of cells expressing 
the reporter immunofluorscence and functional of these cells from dissociated clusters is 
required.  
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TNNT2-mOrange/ PGK-eGFP demonstrates inferior specificity for cardiomyocyte with 
respect to Myh6-mCherry/ PGK-eGFP 
The TnnT2 based reporter construct demonstrated inferior specificity for the cardiomyocyte 
fate. Since the two constructs tested were based on different viral backbones, it is not 
possible to reach a definitive conclusion as to whether the lower specificity is attributable to 
the inherent differences in the tissue specificity of the promoter sequence or factors relating 
to the viral backbone. Barth et al. (2008) determined one cause for the ectopic expression 
from proven cardiospecific promoters was residual activity of the viral 3’-self-inactivation 
long-terminal repeat region (3’-SIN-LTR). They demonstrated that this element alone was 
sufficient to drive a low level of expression of a reporter gene. They observed an inverse 
correlation between the length of the heterologous promoter fragment and the degree of 
ectopic reporter expression. This affect was attenuated and specificity was improved by the 
introduction of an internal ribosomal entry site element as an insulator sequence between the 
reporter gene and the 3’-SIN-LTR (Barth et al., 2008). In these studies, the large Myh6 
promoter (5.5 kilobase) showed the greatest specificity, whereas the smaller TNNT2  
promoter (0.77 kilobase) showed some expression in non-cardiomyocyte lines. One strategy 
to improve the specificity of the TNNT2-mOrange/ PGK-eGFP construct may be to similarly 
introduce a segment of transcriptional silent, insulator sequence.  
 
Future work to further investigate the relative performance of Myh6-mCherry/ PGK-
eGFP and TNNT2-mOrange/ PGK-eGFP 
Although the experimental data suggest improved specificity of the Myh6-mCherry/ PGK-
eGFP reporter construct over TNNT2-mOrange/ PGK-eGFP, further investigation is 
warranted to corroborate these findings. A number of important differences in the 
composition of these vector constructs limit the scope for direct comparison of the relative 
performance of tissue specific promoter fragments for Myh6 and TNNT2. Although both 
constructs shared eGFP as the reporter gene for transduction, in TNNT2-mOrange/ PGK-
eGFP this fluorescent protein is nuclear targeted whereas for Myh6-mCherry/ PGK-eGFP. 
Furthermore the tissue specific reporter genes differ between the constructs and in the case 
of TNNT2-mOrange/ PGK-eGFP, the TNNT2-mOrange reporter gene is targeted to the cell 
membrane. In future work it would be instructive to substitute the novel TNNT2 promoter 
sequence for that of Myh6 in Myh6-mCherry/ PGK-eGFP to enable direct comparison of 
performance.  
 
To improve the quality of the comparison, there is scope to refine the experimental 
approaches for transducing differentiated cell types and measuring expression levels in live 
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cells. From the data presented in Figures 4.11 and 4.12 it may be observed that transduction 
efficiency varied considerably between the various cell types. Although cells were pre-plated 
at the same density prior to transduction and received the same number of lentiviral particles, 
differences in growth rate were apparent and would have affected the multiplicity of infection. 
Furthermore, certain cell types are intrinsically more susceptible to transduction than others. 
In the future, it would be instructive to optimise transduction across all the cell lines to ensure 
that consistent and higher proportions of cells were transduced.  
 
For fixed cells presented in Figure 4.9, the levels of fluorescence the tissue specific promoter 
were relatively lower for Myh6-mCherry/ PGK-eGFP (Figure 4.9 B) with respect to TNNT2-
mOrange/ PGK-eGFP (Figure 4.9C). In both cases the image quality is sub-optimal and may 
relate to the procedure for sample processing. Highly pure paraformaldehyde (PFA) is 
required to ensure the absence of methanol that can denature fluorescent proteins (FP). 
Further it is possible that fixation for 15 min with 4% PFA was excessive and led to distortion 
of the FP through too much crosslinking. It is notable that the quality of the samples prepared 
for flow cytometry analysis was notably higher (Figure 4.10) were an alternative, 
commercially sourced fixation solution was employed (Fix and Perm, Invitrogen). Finally, to 
improve the quality of the FP signal in fixed cells, it would be prudent to use an appropriate 
anti-FP antibody to enhance the signal.  
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Chapter 5: Optical screens of cardiomyocyte differentiation  
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Background  
CSP cardiomyocyte differentiation was not observed under the established conditions 
described for the cardiac Sca1+, as described in Chapter 3 (Matsuura et al., 2004; Oh et al., 
2003). Positive control conditions therefore were not available for the conduct of large-scale 
high content screens of cardiogenic factors as planned. Instead, a series of small-scale 
screens were undertaken using CSP clones 3 and 16 lines harbouring the Myh6-mCherry/ 
PGK-BSNr reporter to explore alternative protocols for in vitro cardiomyocyte differentiation. 
The results of two separate Myh6-mCherry/ PGK-BSNr reporter based screens are 
described: 
 
a. An exploratory combinatorial study using a small and tractable set of conditions 
guided in part by those reporter genes known to be active in the parent cardiac Sca1+ 
population. - namely, the inductive effect of the established inducers azacytidine and 
oxytocin (Matsuura et al., 2004; Oh et al., 2003), used in combination with canonical 
Wnt inhibition with both small molecule IWR and recombinant dickopf-1 (Dkk1) 
(Zelarayan et al., 2008).  
 
b. Application of the conditions of differentiation reported for the cCFU-F population, 
including co-culture with neonatal cardiomyocytes (with and without BMP4) and 
azacytidine treatment in combination with FGF2 supplementation (Chong et al., 
2011). These protocols have the potential advantage of a short (14 day) incubation 
period for differentiation. 
 
The aims of these studies were: to confirm the cardiomyocyte lineage potential of CSP 3 and 
16 in vitro; to establish positive control conditions for larger scale screens of cardiogenic 
factors; and to evaluate the performance of the Myh6-mCherry/ PGK-BSNr reporter in CSP 
under conditions of directed differentiation. 
 
Combinatorial screen investigating the cardiogenic potential of azacytidine, oxytocin 
and canonical Wnt inhibition in CSP 
As discussed in Chapter 1, heart development is directed by a number of extracellular cues 
that regulate the expression and activity of cardiac transcription factors, culminating in the 
production of cardiac muscle. The transcriptional profile of CSPs resembles that of 
embryonic progenitors in the developing cardiac heart fields. It is hypothesized that 
morphogens and growth factors known to drive cardiomyocyte differentiation at this 
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developmental stage have relevance to adult CSP progenitors. Of the numerous signalling 
pathways described in this context, the essential role of Wnt signalling in development and 
adult tissue homeostasis is perhaps the most thoroughly defined (reviewed in Noseda, 
2011). 
 
Wnt signalling is essential for mesoderm formation (Liu et al., 2007), however inhibition by 
Dkk1 is later required for cardiomyocyte differentiation (Ueno et al., 2007). Similarly, Wnt 
inhibition is required for cardiomyocyte differentiation of cardiovascular progenitors generated 
from hESC by ectopic expression of Mesp1 (David et al., 2008; Lindsley et al., 2008). 
Furthermore, pharmacological inhibition the Wnt pathway with IWR (inhibitor of Wnt response 
(Chen et al., 2009a) was sufficient to drive cardiomyocyte differentiation of Pdgfra+/ Mesp1+ 
hES cells (Willems et al., 2011). 
 
Modulation of the Wnt pathway is known to regulate cell fate in a number of adult stem cells 
systems, for example, crypt progenitor cells of the gut epithelium; bulge stem cells of the hair 
follicle; haematopoietic stem cells; and osteoblasts of the bone (reviewed in (Clevers, 2006). 
Qyang et al., have demonstrated that, for postnatal Isl1+ progenitors, Wnt signalling prevents 
cardiomyocyte differentiation and promotes expansion (Qyang et al., 2007). In an 
experimental model of myocardial infarction, down-regulation of Wnt signalling promoted 
differentiation of cardiac Sca1+ progenitors in vivo (Zelarayan et al., 2008). 
 
In the research reported herein, it was decided to investigate the potential role of Wnt 
inhibition in stimulating the differentiation of CSP clones 3 and 16. Wnt inhibition was 
achieved by supplementation of the culture medium with Dkk1 or the small molecule IWR 
(Willems et al., 2011). Taking advantage of the higher throughput permitted by a reporter 
gene based assay, a combinatorial approach was adopted to include pre-treatment 
azacytidine and also oxytocin, (an alternative inducer of differentiation from the literature 
(Matsuura et al., 2004; Oyama et al., 2007)). The oxytocin receptor is expressed in the 
developing mouse heart from embryonic day 6.5 (Mukaddam-Daher et al., 2002) and 
oxytocin treatment is reported to induce cardiomyocyte differentiation of P19 embryonic 
carcinoma cells (Paquin et al., 2002) and cardiac Sca1+ cells (Matsuura et al., 2004). For this 
screen, flow cytometry was selected to evaluate Mhy6-mCherry reporter expression and to 
assess viability during treatment. 
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Application of protocols for c-CFU-F cardiomyocyte differentiation described by 
(Chong et al., 2011) to CSP cells 
Coculture with neonatal cardiomyocytes 
Coculture with neonatal cardiomyocytes is reported to promote cardiomyocyte differentiation 
of cardiac SP cells (Martin et al., 2004; Pfister et al., 2005). It is possible that the isolation 
and culture of primary cardiomyocytes mimics injury and leads to the secretion of diffusible 
factors that stimulate progenitor cells. Pfister et al., reported that direct cell-cell signalling was 
essential for cardiomyocyte differentiation of cardiac SP cells (Pfister et al., 2005). Critics of 
admixture-based methodologies highlight the potential for misleading results to arise from 
cell fusion and marker transfer via nanotubes (Koyanagi et al., 2005; Zaruba et al., 2010). 
Chong et al., report an effective co-culture system in which cardiomyocytes and cCFU-F 
progenitors are physically isolated with a micropore membrane which permits free exchange 
of diffusible signalling molecule, but not cell-cell juxtacrine signalling (Chong et al., 2011).  
 
The frequency of differentiation in c-CFUs by coculture was increased by the addition of 
BMP4 (Chong et al., 2011). BMP4 is a soluble growth factor from the transforming growth 
factor-beta (TGFβ) superfamily, essential for developmental cardiogenesis (reviewed in 
(Noseda, 2011). A role for BMP4 in adult cardiac progenitors is suggested strongly by the 
finding that in vitro differentiation of adult Sca1+ cells is significantly impaired by genetic 
ablation of BMPR1a (Oh et al., 2003). 
 
It was determined therefore to investigate the potential for coculture (with or without BMP4 
supplementation) to stimulate cardiomyocyte differentiation of CSP clones 3 and 16, with low 
passage cardiac Sca1+ cells included as a comparator, as an alternative approach having an 
arguably greater biologically relevance. Given the complexity of the coculture system and the 
dependence on high numbers of primary cardiomyocytes, for the research reported herein , 
automated epifluorescence microscopy was selected to evaluate expression of the Mhy6-
mCherry reporter gene.  
 
Combined azacytidine and FGF2 protocol 
As outlined in Chapter 3, CSP and c-CFUs are both clonogenic sub-populations of cardiac 
Sca1+ cells and may be related. Chong et al., have reported a high frequency of cellular 
differentiation to cardiomyocyte fate and described the experimental procedures in more 
detail than elsewhere. Two protocols are described here, one based upon treatment with a 
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combination of azacytidine and FGF2 and the other on co-culture with neonatal rat 
cardiomyocytes (Chong et al., 2011). 
 
Despite the limited utility of azacytidine for determining lineage potential (for discussion, see 
Chapter 1), if effective at stimulating cardiomyocyte differentiation of CSP, protocols 
incorporating this treatment may form the basis of positive control conditions for future 
screens. Chong et al., reported an azacytidine based protocol incorporating FGF2 
supplementation as being effective at differentiating CSPs. FGF2 is a heparin-binding growth 
factor reported elsewhere to have a role in the differentiation of adult cardiac progenitors; 
cardiac Sca1+ cells isolated from Fgf2-null mice demonstrated defective differentiation in vitro 
that was rescued by exogenous FGF2, which was required in vivo for homing, engraftment 
and differentiation (Rosenblatt-Velin et al., 2005).  
 
In the research reported herein the effect of combined azacytidine and FGF2 treatment on 
the differentiation status of CSP (clones 3 and 16) and low passage cardiac Sca1+ cells was 
determined by gene expression analysis. 
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Aims 
1. To use CSP clones 3 and 6 harbouring the Myh6-mCherry/ PGK-BSNr reporter gene 
assay to explore alternative protocols for cardiomyocyte differentiation; to confirm 
lineage potential in vitro and as a step towards the establishment of positive control 
conditions for use in larger-scale, unbiased screens.  
 
i. To conduct a small-scale combinatorial, flow cytometry-based screen 
combining azacytidine or oxytocin induction with subsequent inhibition of the 
canonical Wnt pathway. 
 
ii. To apply the protocols reported for the cardiomyocyte differentiation of cCFU-
Fs, to CSP clones namely: 
 
a. Co-culture with neonatal cardiomyocytes  
b. Azacytidine treatment combined with FGF2 supplementation. 
 
2. To evaluate and compare the performance of the Myh6-mCherry/ PGK-BSNr reporter 
gene assay in exploratory screens (cf. Aim 1) of cardiac progenitor cardiomyocyte 
differentiation by flow cytometry and automated epifluorescence microscopy. 
 
3. To validate cases of Myh6-mCherry/ PGK-BSNr reporter induction using gene 
expression array; to both confirm endogenous Myh6 and cardiomyocyte associated 
gene expression, and to screen for other cardiac lineages (endothelial, smooth 
muscle cell). 
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Results  
Screen 1: Myh6-mCherry reporter based combinatorial screen to investigate the 
inductive effect of azacytidine or oxtytocin treatement in combination with canonical 
Wnt pathway inhibition  
To investigate the inductive effect of azacytidine and oxytocin, used in combination with 
canonical Wnt inhibition by Dkk1 or IWR, a two-part, combinatorial differentiation protocol 
was devised. Myh6-mCherry reporter gene expression was analysed in CSP clone 3 
(passage 18) by flow cytometry at 3 time-points (days 0, 12.5, 22.5) (Figure 5.1). Debris and 
cell couplets were excluded by gating on forward and side scatter parameters; Sytox Blue 
staining was used to quantify non-viable cells and exclude them from the analyses (Figure 
5.2).  
 
Under conditions of normal growth, viability of the CSP clone 3 was high (98.5 ± 0.57%); 
however progressive cell death was observed with time in culture (87.1 ± 1.4% at 12.5 days; 
to 44 ± 6.8% at 22.5 days), (Figure 5.3). The extent of cell death did not correspond to a 
particular component of the treatment protocol; for untransduced cells cultured in CEM media 
only, viability at 22.5 days was low (39.6 ± 1.5 %), whereas it was high for cells treated with 
azacytidine and IWR (85 ± 3.9 %). Where a significant reduction in viability was observed (≤ 
30% viable cells) these samples with were excluded from subsequent analysis.  
 
At day 0, expression of Myh6-mCherry in CSP was higher than that recorded during 
validation studies (1.52 ± 0.03% versus 0.52 ± 0.03 %), (Figure 5.3B). A statistically 
significant increase in reporter gene expression was observed for only one of the conditions 
tested, and for a single time-point (azacytidine treatment alone at 12.5 days, 1.29 fold 
increase to 2.81% ± 0.04). Otherwise, combinations of azacytidine or oxytocin with canonical 
Wnt pathway inhibition were not sufficient to cause expression of the Myh6-mCherry reporter 
gene, suggesting an absence of cardiomyocyte differentiation.   
 
Screen 2: Assessment of the inductive effect of neonatal cardiomyocyte co-culture on 
cardiomyocyte differentiation of CSP clones 3 and 16, according to the protocol 
described for cCFU-Fs (Chong et al., 2011) 
To explore an alternative method for cardiomyocyte differentiation, not reliant upon treatment 
with azacytidine, a protocol for neonatal cardiomyocyte culture reported for c-CFUs (Chong 
et al., 2011) was tested in CSP clones 3 and 16 transduced with the Myh6-mCherry reporter 
gene. In this co-culture system, primary neonatal cardiomyocytes were plated directly 
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following isolation to 0.4μm collagen-coated membrane inserts and subsequently transferred 
to wells containing cardiac progenitor cells to initiate coculture. After 14 days, cardiomyocyte 
containing inserts were discarded and the progenitor cells analysed (Figure 5.4A). 
Automated epifluorescence microscopy was used, as an alternative to flow cytometry, to 
quantify the frequency of reporter expression in situ in live cells, and to enable subsequent 
paired gene expression analysis (Figure 5.4B). To quantify the proportion of cells expressing 
the Myh6-mCherry reporter, live cells were exposed to Hoechst dye and individual objects 
(cells) identified by nuclear staining according to proprietary algorithms (Cellomics Inc.). The 
nuclear border was dilated to define a cytoplasmic area in which Myh6-mCherry expression 
was quantified by determining the mean fluorescence of mCherry fluorescence. A 
representative 10x field is shown in Figure 5.5A with sub-panels demonstrating automated 
image analysis of an individual cell (blue outline, nuclear mask; green outline cytoplasmic 
mask).  
 
Non-uniform induction of the Myh6-mCherry was observed across individual wells. To 
account for this non-uniformity a high number of fields (49 10x fields) were imaged for each 
replicate of each condition equating to >3000 individual cells. An example of the complete 
image set (49 10x fields) for a single replicate for each condition for an experiment with CSP 
clone 16 is given in Figure 5.5B. For this example, a qualitative increase in reporter gene 
expression was apparent following coculture, and this effect was enhanced with BMP4 
supplementation. To quantify the frequency of reporter induction, thresholds were set 
manually by comparison with untreated (see Methods). A frequency histograms illustrating 
the distribution of mCherry intensity for this example is given in Figure 5.5C. The dashed line 
indicates the Myh6-mCherry intensity threshold; differentiation was observed in reporter 
expression between the co-cultured cells (red, no BMP4; blue, with BMP4), and untreated 
cells (black line).  
 
Using this method to quantify the proportion of cells expressing Myh6-mCherry, the effect of 
coculture with and without BMP4 supplementation on Myh6-mCherry reporter expression 
was compared in CSP clones 3 and 16 (passage 18) harbouring the reporter gene. For 
comparison an early passage, cardiac Sca+ population (passage 3), was included as a 
control cell line for gene expression analyses. The percentage of cells expressing Myh6-
mCherry following treatment is presented in Figure 5.6A. For Clone 3, significant induction of 
the reporter was observed following treatment with coculture, with an additive effect observed 
with BMP4 supplementation (without BMP4: 8.30 ± 1.91, p ≤ 0.05; with BMP4: 17.0 ± 2.17, p 
≤ 0.001); by contrast, no significant induction was observed for the without coculture control 
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both in the presence and absence of BMP4. For Clone 16, significant reporter induction was 
observed for all conditions, both with and without co-culture, and in the presence and 
absence of BMP4. A trend towards increased expression with BMP4 in the non-culture 
control did not reach statistical significance; however with coculture BMP4 was observed to 
have a significant additive effect (without BMP4 3.80 ± 0.382; with BMP4 9.49% ± 0.585). 
For both CSP clones 3 and 16 neonatal cardiomyocyte co-culture resulted in significant 
induction of Myh6-mCherry reporter expression, an effect that was enhanced by BMP4 
supplementation (Clone 3, p ≤ 0.01; Clone 16, p ≤ 0.001); maximal levels of induction were 
1.79 fold higher for CSP clone 3 compared with CSP clone 16.  
 
To investigate whether induction of Myh6-mCherry reporter genes reflected induction of the 
endogenous Myh6 genes, RNA was isolated from all samples for analysis by Taqman Low 
Density Array (TLDA) qRT-PCR. Unexpectedly, no endogenous Myh6 gene expression was 
detected (Figure 5.6B). To investigate whether Myh6-mCherry reporter expression reflected 
an incomplete transition to the cardiomyocyte phenotype, expression of cardiogenic 
transcription factors, markers of cardiomyocyte differentiation, and markers of alternative 
lineage (endothelial, smooth muscle) were examined. For comparison, samples from early 
passage cardiac Sca1+ cells (not harbouring the Myh6-mCherry transgene) were included in 
the analysis. Of the 5 additional markers of the cardiomyocyte lineage examined (Actc1, 
Myl2, Nppa, Pln, Ryr2), Nppa was the only gene expressed above the detection limit of the 
assay for CSP clone 3 (Ct ≤ 35), (Figure 5.7). To determine whether expression of the 
reporter gene expression reflected partial movement towards the cardiomyocyte lineage, 
expression of the core cardiogenic transcription factors was examined (Figure 5.8). Whilst 
Mef2a was expressed at baseline in all cells, a significant increase in the level of expression 
was noted for CSP clones 3 and 16 (p ≤ 0.01). Similarly, Gata factors were induced in all 
conditions when present at baseline (cardiac Sca+/ Clone 3, p ≤ 0.001); however no genes 
were induced that were not present at baseline (Hand1 absent in Clone 3; nkx2.5 absent in 
Clone 16). 
 
To screen for differentiation to other cardiac lineages, expression of endothelial and smooth 
muscle cell associated genes was examined (Figure 5.9). Unexpectedly, significant induction 
of both Cnn1 and Myh11 were observed for all cell types under all conditions. Coculture did 
not consistently increase induction relative to the without coculture controls; however, BMP4 
supplementation resulted in a trend towards increased expression that reached statistical 
significance for Myh11 in a number of cases (Clone 3, with or without coculture, p ≤ 0.001; 
Clone 16, without coculture, p ≤ 0.001; cardiac Sca+ cells, with coculture, p ≤ 0.05). Low 
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levels of Cnn1 were detectable at baseline in cardiac Sca+ and CSP clone 16 permitting 
calculation of fold change for gene expression. For cardiac Sca+, a maximal 5.1-fold change 
was observed (coculture, no BMP4), and for CSP clone 16, a 83-fold increase was noted 
(without coculture, with BMP4). Likewise, Myh11 was detectable in cardiac Sca+ cells and 
increased by up to 17-fold (without coculture, with BMP4). To contextualise transcript 
abundance against that of a cognate tissue, levels of Cnn1 and Myh11 were compared 
neonatal heart (Figure 5.9, right panel). For cardiac Sca+ and CSP clone 3, transcript 
abundance was ≤1.5-fold that of neonatal heart for all conditions; for CSP clone 16, levels 
were up to 9 fold that of neonatal heart (Cnn1, 9.01 ± 1.76; Myh11, 2.94 ± 2.25). Endothelial 
markers were not expressed. For expression data for all genes analysed by TLDA see Figure 
8.1, CSP Clone 3; Figure 8.2, CSP Clone 16; Figure 8.3, Cardiac Sca1+. 
 
Screen 3: Assessment of the inductive effect of azacytidine and FGF2 treatment on 
cardiomyocyte differentiation of CSP clones 3 and 16, according to the protocol 
described for cCFU-Fs (Chong et al., 2011) 
To investigate the utility of an alternative protocol described for cCFU-Fs combining 
azacytidine with FGF2, CSP clones 3 and 16, passage 18 were treated and cell fate 
assessed by TLDA gene expression array (Figure 5.10). In this preliminary screen, the effect 
of each factor in isolation was not assessed. Although induction of cardiac α-actin reached 
statistical significance (p ≤ 0.001), levels of expression were near to the threshold of 
detection (Figure 5.11A). Other markers of the cardiomyocyte lineage were not expressed 
(Myh6, Myl2, Nppa, Pln and Ryr2), and cardiac transcription factors were not induced (Figure 
5.11B). For Clone 3, trends for induction for Myh11, Cnn1, Cdh5 and Myog were observed 
(Cnn1, Cdh5, Myog, p ≤ 0.001). For Clone 16, Cnn1, Myh11, Cdh5 and Vwf were induced 
(Cnn1 only, ≤ 0.001), (Figure 5.11C). These patterns of gene expression were not consistent 
with a single biologically recognisable lineage. For expression data for all genes analysed by 
TLDA see Figure 8.4. 
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Discussion 
To confirm lineage potential in vitro and to move towards the establishment of positive control 
conditions for use in larger-scale unbiased screens, CSP clones harbouring the Myh6-
mCherry/ PGK-BSNr reporter gene was used to explore alternative protocols for 
cardiomyocyte differentiation including methods no reliant upon azacytidine.  
 
Screen1: Azacytidine or oxtytocin induction with inhibition of the canonical Wnt 
pathway did not induce cardiomycoyte differentiation of CSP clone 3 
As reported in Chapter 3, azacytidine treatment according to the conditions described by Oh 
et al., was not sufficient for CSP cardiomyocyte differentiation (Oh et al., 2003). The 
mechanism/ action of azacytidine in stimulating the differentiation of 10T½ cells to skeletal 
myocytes is to generate progenitors for this lineage, with subsequent differentiation 
dependent upon appropriate cell culture conditions (Konieczny and Emerson, 1984). Given 
the expression of cardiogenic transcription factors at baseline for cardiac Sca1+ and CSP, it 
is possible that the key factor for differentiation may be the cell culture conditions.  
 
To investigate this possibility and to reassess for an azacytidine effect, a combinatorial 
screen was devised, making use of the Myh6-mCherry/ PGK-BSNr reporter gene assay in 
CSP clone 3 (passage 18). For this study a small and tractable set of conditions were 
selected, guided in part by those reported to be active in the parent Sca1+ population 
(azacytidine, oxytocin) and by signals reported to effect the differentiation of mesodermal 
cardiac progenitors in development (Dkk1, IWR). None of the factors tested, either singularly 
or in combination resulted in induction of the Myh6-reporter determined by flow cytometry 
(Figure 5.3B).  
 
A highly variable degree of cell death was observed with prolonged culture (22.5 days) in a 
pattern that did not implicate a particular factor or set of factors (Figure 5.3A). The 
differences observed in cell viability limit the scope for timecourse analysis as poor cell 
health may impact the capacity for differentiation. It is possible that minor irregularities 
relating to seeding density were amplified in the course of treatment and determined the 
extent of cell death. To realize a robust and reproducible phenotypic screen based a 
differentiation endpoint, a shorter culture period is desirable, so long as the timeframe is 
sufficient for differentiation to occur.  
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Screen 2: Myh6-mCherry/ PGK-BSNr reporter induction in CSP clone 3 and 16 
following coculture without cardiomyocyte differentiation 
To investigate cardiomyocyte lineage in a system not dependent upon azacytidine treatment, 
a coculture protocol was adopted as described by . In contrast to other reported methods 
(Pfister et al., 2005), here co-cultured cardiomyocytes are maintained in physical isolation 
from cardiac progenitor cells, negating the potential artifactual effects associated with 
admixtures. CSP clones 3 and 16 reporter lines (passage 18) were used to enable 
quantification of the frequency of reporter gene expression by automated microscopy, 
together with subsequent gene expression analysis. For both CSP clones 3 and 16, neonatal 
cardiomyocyte co-culture resulted in significant induction of Myh6-mCherry reporter gene 
expression, an effect that was enhanced by BMP4 supplementation; however maximal levels 
of induction were higher for CSP clone 3 (Figure 5.6). Gene expression analysis did not 
reveal the expected induction of endogenous Myh6, or other markers of cardiomyocyte 
lineage (Actc1, Myl2, Nppa, Pln, Ryr2). Conceptually this observation could have arisen 
because of the imperfect specificity of the Myh6-mCherry reporter gene for the 
cardiomyocyte lineage, or due to inadequate sensitivity of the assay for gene expression.  
 
The Taqman probes, used here for gene expression analysis, were validated against 
cognate tissue and each experimental run included neonatal heart sample as a positive 
tissue control. In the case of CSP clones 3 and 16 transduced with Myh6-mCherry/ PGK-
BSNr, cells were exposed to Hoechst 33342 to facilitate object identification in automated 
microscopy-based analysis or reporter expression. Hoechst 33342 is a cell permeable dye 
which binds non-covalently to the minor groove of DNA; for the related molecule Hoechst 
33258, DNA binding is reported to inhibit the transcription of specific genes (Baraldi et al., 
2004). Furthermore, Hoechst 33342 is reported to interact with messenger RNA molecules 
containing specific aptamers for this compound to affect their translation (Zhang et al., 2011). 
However the possible impact of binding upon message stability or efficiency of PCR are not 
described by Zhang et al. In this case the time-frame between Hoechst 33342 exposure and 
gene expression analysis was such that any effect on transcription would be unlikely to alter 
the results. It is unlikely that interaction with the message itself affected the results, 
particularly given similar findings observed in the cardiac Sca1+ population, which were not 
exposed to Hoechst. Nevertheless, for future studies based on this platform it would be 
prudent to specifically rule out this potential effect. It is likely that the results are explained by 
the greater permissiveness of the heterologous promoter sequence for activation relative to 
the endogenous gene promoter, as considered in more detail below.   
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Screen 3: Azacytidine and FGF2 treatment in combination did not result in 
cardiomyocyte differentiation  
CSP clones 3 and 16 were treated with a protocol combining azacytidine treatment with 
FGF2 stimulation according to the method reported for the cardiomyocyte differentiation of 
cCFU-Fs (Chong et al., 2011). Due to uncertainties regarding the reliability of Myh6-mCherry 
reporter, lineage was determined by TLDA gene expression array alone. Cardiac muscle 
actin (Actc1) was induced in clones 3 and 16 following treatment with azacytidine and FGF2 
(p≤0.001) along with myosin light chain 2 (Myl2) in clone 3 (p≤0.01); however levels of 
expression were close to the limit of detection. Examination of non-cardiomyocyte lineages 
(Figure 5.11C) revealed a non-specific pattern of low-level gene activation, inconsistent with 
any known lineage (Clone 3: Cnn1, Cdh5, Myog, Actc1; Clone 16: Actc1, Cnn1). These 
findings suggest that demethylating agents may not be useful for in vitro determination of 
lineage potential. It is notable that treatment of 10T1/2 cells (mouse embryonic fibroblasts) 
results in differentiation to skeletal muscle; whilst a useful model for gene discovery in that 
context (MyoD, (Davis et al., 1987), the results here question the general utility of azacytidine 
induced differentiation as a means to determine lineage potential.  
 
Myh6-mCherry/ PGK-BSNr reporter expression in the absence of endogenous gene 
activation  
Robust reporter induction was observed for CSP clone 3 and 16 (3>16) under conditions of 
coculture in the absence of message for cardiomyocyte associated genes. This represented 
an unexpected result given that the reporter was extensively evaluated across a range of 
differentiated cell types, including neonatal rat cardiomyocytes and found to be highly 
sensitive and specific for this lineage (see Chapter 4), and that CSP clones 3 and 16 have 
proven cardiomyocyte lineage potential in vivo (Figure 1.6). 
 
Expression of reporter genes driven by the same 5.5 Kb Myh6 promoter fragment 
(Subramaniam et al., 1991) in the absence of endogenous gene expression is not 
unprecedented. Song et al., used fibroblasts isolated from a Myh6-GFP transgenic mouse to 
screen for combinations of cardiac transcription factors to effect direct reprogramming to a 
cardiomyocyte fate. Several combinations of transcription factors led to activation of the 
reporter gene in the absence of expression of endogenous cardiomyocyte associated genes, 
leading to the conclusion that expression reflected incomplete progress towards the 
cardiomyocyte lineage (Song et al., 2012). Similar observations have been noted elsewhere 
(Bruneau, 2012; Chen et al., 2012). 
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It is possible that ectopic expression of the reporter gene construct results from the random 
integration of the trangene to CSP clone genomes. The transgenic reporter cassette 
inevitably lacks the natural regulatory context (epigenetic modifications, the full set of cis- 
regulatory elements) and this may explain the increased susceptibility to activation compared 
to that of the endogenous genes. Whilst selectivity for cardiomyocyte lineage over other 
differentiated cell types is established, they also report early or partial differentiation events, 
potentially leading to a high proportion of false positive conditions in screens.  
 
Only one existing study systematically compares the sensitivity and specificity of lentiviral 
cardiomyocyte reporters based on a range of tissue specific promoter sequences (Barth et 
al., 2008). Barth et al. examined a range of promoter sequences with established cardiac 
specificity in transgenic animal models (Myh6, MLC-2v and TnI promoter sequences). They 
demonstrate significant expression from lentiviral constructs based on these promoters in 
non-cardiac cell lines, and attribute this phenomenon in part to residual activity of the viral 3’ 
LTR. By comparison, the performance of the Myh6-mCherry/ PGK-BSNr construct was 
superior when tested in differentiated cell types (Chapter 4), however significant ectopic 
expression was apparent here under conditions of directed differentiation (Screen 2, Chapter 
5). These findings suggest that the Myh6-mCherry/ PGK-BSNr construct is not suitable for 
use in exploratory screens of cardiomyocyte differentiation in adult cardiac progenitors. An 
alternative approach might be to use a knock-in reporter gene at the endogenous locus, 
preserving the native regulatory elements (Moses et al., 2001). Potential disadvantages to 
this approach include haploinsufficiency that inevitably results and the lack of applicability to 
human cardiac progenitor cells, the ultimate target for screening assays.  
 
Absence of cardiomyocyte differentiation in exploratory in vitro screening studies of 
CSP clones 3 and 16 
A range of exploratory protocols for in vitro cardiomyocyte differentiation of CSP, based on 
the methods reported for other adult mouse cardiac progenitors were explored here. These 
studies are preliminary and in the absence of positive control conditions for CSP clones 3 
and 16, it is not possible to make any determination of innate in vitro lineage capacity of the 
cells or the of the adequacy of the differentiation protocols.  
 
Clonal CSP populations were employed based on the hypothesis that clonogenicity would 
potentially purify the stem/ progenitor cells from a heterogeneous population of cells. It is 
possible however that the cloned cells inherently lack, or have lost the capacity for 
differentiation through the process of expansion and maintenance. Alternatively, associated 
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populations of stromal cells, (which may be essential mediators signals directed CSP 
differentiation), have been excluded through clonal isolation of cells from the heterogeneous 
parent population.  
 
Noseda et al. have demonstrated genomic instability in cultured Sca1+ and CSP, using array 
comparative genome hybridization (Noseda et al., unpublished data), as is known to be true 
for embryonic stem cells (ESCs), induced pluripotent cells (iPSCs), and other cell types (Li 
and Marban, 2010; Lund et al., 2012). It is possible that such instability leads to the selection 
of cells carrying mutations that promote survival in cell culture whilst selecting against 
capacity for differentiation, although no aberrations were detected in known regulators of 
cardiac myogenesis (Noseda et al., unpublished data).  
 
However, CSP clone 3 and 16 were amongst clones for which in vivo grafting data 
demonstrated tri-lineage potential (cardiomyocyte, endothelial and smooth muscle) (Figure 
1.6). Cell grafting following experimental infarction is the best-agreed method for evaluating 
lineage capacity. In this assay system, cell fusion represents a potential confounding factor, 
though it is unlikely to account for the total number of newly generated cardiomyocytes (Oh 
et al., 2003). Hence, limitations of the exact in vitro conditions tested best account for the 
lack of differentiation in the present study. It is notable that the efficiency of cardiomyocytes 
generation from ESCs is highly variable and sensitive to perturbation despite the highly 
refined conditions and reagents available for differentiation.  
 
Smooth muscle genes induction under conditions of low serum 
Analysis by gene expression array demonstrated induction of smooth muscle genes Cnn1 
and Myh11 for all cells (CSP clones 3 and 16; cardiac Sca1+) in response to the low serum 
conditions of the differentiation medium and coculture was not observed to significantly 
increase expression. In a number of cases, supplementation of culture medium with BMP4 
increased smooth muscle gene expression. Smooth muscle differentiation under the 
conditions of coculture used here is reported for cCFU-Fs (Chong et al., 2011); this 
observation is explored further in Chapter 6.  
 
Future work  
In future studies, it would be instructive isolate cardiac progenitor populations from transgenic 
animals harbouring cardiomyocyte reporter constructs with established specificity (Tallini et 
al., 2009). An alternative approach to optical reporter based screening is primary screening 
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based on qRT PCR analysis of gene expression (Bittker, 2012). To eliminate the potential 
negative effects of adaptation to cell culture on the capacity for differentiation, in future 
experiments it would be useful to examine differentiation of freshly isolated cells. Given the 
paucity of CSP in adult mouse hearts, the scope for examining fresh cells is limited by cell 
number. Therefore, future experiments should seek to use freshly isolated cardiac Sca1+ 
cells to investigate methods for differentiation not reliant upon azacytidine treatment or 
admixture coculture.  
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Chapter 6: Exploration of smooth muscle differentiation  
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Background 
In Chapter 5, gene expression array demonstrated smooth muscle marker (Cnn1 and 
Myh11) induction under conditions of low serum for all progenitor populations tested (CSP 
clones 3 and 16; cardiac Sca1+); in a number of cases supplementation of the culture 
medium with BMP4 increased the levels of expression. Here an extended analysis of CSP/ 
Sca1+ derived smooth muscle cells is reported, examining expression of other smooth 
muscle associated genes, along with an assessment of the protein products of these genes 
by immunocytochemistry. 
 
Smooth muscle lineage potential is described for a number of developmental (Kattman et al., 
2006; Moretti et al., 2006; Wu et al., 2006) and post-natal cardiac progenitor populations 
(Beltrami et al., 2003; Chong et al., 2011; Noseda et al., 2012). However in vitro 
differentiation of CSP is not reported. In the heart, smooth muscle forms an essential 
component of the coronary vasculature where it mediates tone (Lanza et al., 2011). Whilst 
the primary function of adult smooth muscle cells (SMC) is contractility, under certain stimuli 
(such as tissue injury), the phenotype is modulated to a synthetic mode which is 
characterised by the proliferation and synthesis of extracellular matrix components (Owens, 
1995). Post-natal renewal of smooth muscle cells by the proliferation of pre-existing 
differentiated cells is well described (Nguyen et al., 2013); however others report a stem/ 
progenitor cell origin (Tang et al., 2012).  
 
Definitive markers of the smooth muscle fate have been elusive; the best candidates are the 
myosin heavy chain Myh11 and calponin, which are expressed in the later stages of 
differentiation (Owens, 1995). Identification of differentiated smooth muscle cells relies upon 
more than one smooth muscle associated gene, along with the assessment of contractile 
function. It is important to distinguish smooth muscle cells from myofibroblasts that are 
generated from a range of sources in response to injury. Myofibroblasts are characterised by 
the expression of several smooth muscle markers, including SMA and sm22α, but not Myh11 
(Powell et al., 1999; Sartore et al., 2001). This pattern of gene expression is shared by SMC 
that have adopted the synthetic phenotype, as well as by embryonic precursor SMC. In 
development, SMA and sm22α are expressed at embryonic day 9.5, whereas calponin and 
Myh11 expression only begins later (Miano et al., 1994; Owens, 1995). Given a lack of 
sufficient specific or unique markers of their differentiation, the identification of SMC depends 
upon the concurrent analysis of the expression of multiple markers. The expression of SMA, 
sm22α, Cnn1 and Myh11 was examined in the research reported herein.  
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Smooth muscle actin (SMA) is the predominant isoform of actin in smooth muscle and one of 
the principal thin filament proteins that form part of the contractile apparatus. This isoform is 
not exclusively expressed in smooth muscle cells, and is also induced in a range of 
mesodermal cell types during development and disease. For example, SMA is expressed in 
myofibroblasts following wound healing (Darby et al., 1990), in cardiac and skeletal muscle 
following injury (Black et al., 1991; Li et al., 1996b) and in developmental cardiac progenitors 
(Ruzicka and Schwartz, 1988). Many cultured cells can be induced to express SMA under 
TGFβ stimulation (Arciniegas et al., 1992).  
 
Calponins are actin and tropomyosin binding proteins that inhibit the actomyosin ATPase 
activity, thereby regulating SMC contraction. Proteins of this family share a 26 amino acid 
calponin homology domain, and include Calponin-1 (Cnn1) and sm22α (transgelin) which are 
both abundantly expressed in SMC. Both are highly restricted to the smooth muscle fate in 
the adult, although they are expressed transiently in other muscle types during development 
(linear heart tube and skeletal myocytes) (Li et al., 1996b; Miano and Olson, 1996). Of the 
two, Calponin -1 is considered to be of greater specificity for the smooth muscle lineage 
(Miano et al., 1994; Owens, 1995).  Myh11 is another essential component of the contractile 
apparatus in smooth muscle cells and mutations of the gene are associated with familial 
thoracic aortic disease. As a marker of differentiation, Myh11 is recognised to show the 
highest specificity for the cell type; however expression in the adult is also reported in 
activated myofibroblasts following injury (Popova et al., 2010).  
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Aims  
 (i) To determine whether CSP clones 3 and 16 differentiate to smooth muscle under 
 conditions of low serum by gene expression analysis and quantitative 
 immunofluorescence 
 
(ii) To determine whether BMP4 supplementation increases smooth muscle 
 differentiation of CSP clone 3 and 16  
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Results 
To investigate further the observation of smooth muscle associated gene expression under 
conditions of low serum observed in Chapter 5, an extended selection of smooth muscle 
genes were analysed. For all cell types (cardiac Sca1+, CSP clones 3 and 16), culture in low 
serum resulted in the induction of all smooth muscle associated markers (Figure 6.2: SMA, 
sm22α, Cnn1 and Myh11; p ≤ 0.001). For CSP clone 16, BMP4 supplementation resulted in 
the augmented of the induction of sm22α, Cnn1 (p ≤ 0.01) and Myh11 (p ≤ 0.001); for CSP 
clone 3, no such relationship was observed. For all genes tested, transcript abundance was 
greater in CSP clone 16 relative to CSP clone 3 and approached those observed in the 
mouse aorta: SMA ~ 53%, sm22α ~ 30%, Cnn1 ~ 22% and Myh11 ~ 2%.  
 
To investigate whether treatment with low serum and BMP4 supplementation resulted in 
protein expression of markers of differentiated smooth muscle cells, a timecourse analysis by 
immunofluorescence was performed (Figure 6.2). The antibodies used in this study were 
optimised and validated for sensitivity and specificity against relevant positive and negative 
cell controls (Figure 6.3). Example images for cardiac Sca1+, CSP clone 3 and CSP clone 16 
treated in the presence of BMP4, are presented demonstrating qualitative differences in 
cellular morphology and in expression of smooth muscle markers across the cells tested 
(cardiac Sca1+, Figure 6.4A, 6.5A, 6.6A; CSP clone 3, Figure 6.4B, 6.5B, 6.6B; CSP clone 
16, Figure 6.4C, 6.5C, 6.6C). A high degree of morphological heterogeneity was observed 
between cardiac Sca1+, CSP clone 3 and 16 cells following treatment. CSP Clone 3 cells 
adopted a cuboidal morphology whereas CSP Clone 16 remained fibroblast-like in 
appearance.  
 
The proportion of cells expressing smooth muscle markers was quantified by automated 
microscopy and image analysis (Figure 6.6). Protein expression data for sm22α and Cnn1 
were concordant with previous studies of gene expression (Figure 6.1) but not for SMA. SMA 
was detected by immunofluorescence at baseline for CSP clones 3 and 16 and for CSP 
clone 16, and a paradoxical decrease in the proportion of positive cells for this marker was 
observed. In all cases, conditions of low serum resulted in an increase in the proportion of 
cells staining positive for sm22α and Cnn1 (p ≤ 0.001) and the majority of cases, expression 
levels plateaued after 7 days treatment (Figure 6.6).  
 
For cardiac Sca1+ and CSP clone 16, after 7 days treatment, BMP4 supplementation 
increased the proportion of cells expressing sm22α (p ≤ 0.001) and Cnn1 (p ≤ 0. 01); this 
differentiation was no longer evident at 18 days. For these two factors, at all time-points, the 
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proportion of positive cells arising from CSP clone 16 were greater than observed for CSP 
clone 3, and were equivalent to those observed for cardiac Sca1+ cells (Figure 6.7). For 
example, 67.4 ± 1.39 % of cells derived from CSP clone 16 were positive for Cnn1 following 
7 days treatment in low serum with BMP4, compared with 4.31 ± 0.57 for CSP clone 3.  
 
Myh6-mCherry reporter gene expression is mutually exclusive with SMA in CSP 
clones treated with low serum and BMP4 supplementation 
As reported in Chapter 5, CSP clone 16 transduced with Myh6-mCherry/ PGK-BSNr 
expressed the reporter gene under conditions of low serum and BMP4. To determine 
whether reporter positive cells co-expressed smooth muscle cell markers, co-staining for 
SMA and mCherry (to amplify signal) was performed (Figure 6.8). Due to antibodies against 
mCherry and other smooth muscle markers being raised in the same species, the 
assessment for coincidence of expression was limited to SMA. The Myh6-mCherry reporter 
gene expression was mutually exclusive with SMA in CSP clone 16 treated with low serum 
and BMP4 supplementation. 
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Discussion  
Smooth muscle differentiation of cardiac Sca1+ and CSP cells in vitro 
For cardiac Sca1+ cells and CSP clone 16, robust induction of smooth muscle markers was 
observed in response to serum withdrawal, and this effect was augmented by BMP4 
supplementation. Significant induction was observed for all genes tested (SMA, Cnn1, 
sm22α and Myh11) and protein expression was confirmed where suitable antibodies were 
available (SMA, Cnn1, sm22α). This pattern of marker expression is compatible with 
differentiated smooth muscle. For CSP clone 3, marker induction was also observed but at 
levels dramatically lower than for Sca1+ and Clone 16.  
 
For CSP clone 16 and the cardiac Sca1+ parent population, BMP4 was observed to increase 
the proportion of marker positive cells and overall transcript abundance. Although TGFβ is 
known to drive SMC differentiation in relevant progenitors (Chong et al., 2011) and to 
activate fibroblast expression of SMC genes (Sime et al., 1997); the role of BMP4 is not as 
well established in this context. However, BMP4 is reported to induce SMC differentiation by 
ureteral mesenchymal cells (Airik et al., 2006; Yu et al., 2002) and was essential along with 
TGFβ for SMC differentiation by adipose-derived stem cells (Wang et al., 2010). 
 
During embryonic development, adoption of the vascular smooth muscle fate is marked by 
expression of SMA, Cnn1, and Myh11 (Miano et al., 1994; Owens et al., 2004). SMA and 
Sm22α are also expressed transiently in the developing heart (Li et al., 1996b). As a 
preliminary investigation of whether smooth muscle markers expression in treated CSP 
clones reflects an intermediate stage towards cardiomyocyte differentiation, cultures of CSP 
clone 16 carrying the Myh6-mCherry reporter gene were examined for co-expression of 
SMA. Interestingly, mutually exclusive expression of SMA and Myh6-mCherry was observed 
suggesting the possibility of divergent lineage commitment.   
Baseline gene expression may indicate prediliction for smooth muscle differentiation 
Under the conditions tested, smooth muscle marker differentiation markers were expressed 
robustly in cardiac Sca1+ cells and CSP clone 16, but at significantly lower levels for CSP 
clone 3. These observations contrast with pattern of Myh6-mCherry induction with neonatal 
cardiomyocyte coculture (Chapter 5) where the proportion of cells expressing the reporter 
was higher in the CSP clone 3 compared with the CSP clone 16. At baseline, CSP Clone 3 
expressed a more complete repertoire of cardiogenic transcription factors compared with 
CSP Clone 16 (Figure 3.7) and it is possible that these differences are reflecting in differing 
lineage propensities.  
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Recently, (Tang et al., 2012) have challenged the hypothesis that phenotypic switching and 
proliferation is the basis for expansion and renewal of the smooth muscle cell compartment 
in health and disease. Using Myh11 Cre/ Lox lineage fate mapping they demonstrated the 
genesis of smooth muscle cells that were not descended from existing differentiated cells 
and instead suggest an origin from a previously unknown population of multi-potent vascular 
stem cells (MVSCs).  
 
A number of populations of vascular progenitors residing in the vessel wall are described 
(Majesky et al., 2011), including adventitial Sca1+ cells (Hu et al., 2004). For all adult cardiac 
progenitor populations yet described, isolation involves the enzymatic digestion or other 
manipulation of whole heart or myocardium and enrichment using non-specific markers of 
adult stem cells (Beltrami et al., 2003; Chong et al., 2011; Oh et al., 2003; Smart et al., 
2011). It is possible that heterogeneity of these populations is explained in part by the 
presence of vascular as well as cardiac progenitors, perhaps accounting for observed 
differences in baseline gene expression and lineage predilection. However it is notable that 
when grafting in vivo, CSP clones 3 and 16 were found to be equipotent for cardiac lineages 
(Figure 1.6).   
Future work  
These experiments to examine SMC differentiation of cardiac Sca1+ and CSP clones are 
preliminary and warrant further study. To investigate further the apparent smooth muscle 
differentiation it would be instructive to examine for Myh11 protein expression and to perform 
functional studies such as contraction assays (Chen and Lechleider, 2004; Xie et al., 2007). 
It is probable that induction of smooth muscle markers may be enhanced by optimization of 
treatment protocol to incorporate stimulatory factors known to be important in SMC 
differentiation. For example, transforming growth factor-beta (TGFβ) and Notch are well-
established mediators of stem cell differentiation into smooth muscle cells (Kurpinski et al., 
2010; Mack, 2011). To determine whether baseline differences in cardiac transcription factor 
expression in CSP clones reflect differences in lineage propensity, follow-up studies with 
more clones of complimentary characteristics are required.  
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Chapter 7: General discussion 
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Introduction 
In this Chapter, progress towards the research objectives is evaluated and findings 
contextualised with research findings that have emerged since the inception of this study.  
In order to harness the therapeutic potential of adult cardiac progenitor cells and permit the 
elaboration of methods to enhance function, a more complete understanding of the networks 
regulating cell fate is required. By analogy with developmental cardiogenesis, it is anticipated 
that the networks will be complex (Noseda et al., 2011). High-content, high-throughput in 
vitro platforms represent one approach to investigating this biology. This thesis describes the 
progress made towards the establishment of CSP cell based screening, including 
investigation of conditions for in vitro differentiation and the development of reporter gene 
assays for image based detection of differentiation events.  
 
In vitro lineage potential of CSP cells 
Adult CSP cells were clonally purified and characterised with respect to transcriptional 
signature and differentiation potential in vitro. For the clonal lines studied (CSP clones 3 and 
16), in vivo grafting studies indicated multi-potency for cardiomyocyte, endothelial and 
smooth muscle cell lineages, both in the injured and uninjured heart, however conditions for 
the in vitro differentiation for clonally isolated CSP cells were unknown. To confirm in vitro 
lineage potential and to establish positive control conditions for large-scale high-content 
screens, protocols reported to be effective in the parent cardiac Sca1+ population were 
investigated, including azacytidine and oxytocin treatment described by Matsuura et al. and 
Oh et al., and coculture with neonatal cardiomyocytes as described by Chong et al., (Chong 
et al., 2011). 
 
Cardiomyocyte lineage potential of CSP in vitro 
As a first step, treatment with the demethylating agent azacytidine was investigated for 
potential inductive effects. Cardiomyocyte differentiation was not observed for the CSP main 
population or in CSP clones 3 and 16 in response to azacytidine treatment, in a range of 
conditions despite reports of efficacy for the parent cardiac Sca1+ population (Oh et al., 2003; 
Smits et al., 2009b). In the absence of suitable positive control conditions for the 
differentiation of CSP cells, the protocols investigated were replicated as precisely as 
possible according to the method described in published reports. As a consequence, the 
differentiation media and the azacytidine treatment regime differed between experiments 
limited the scope for comparison between studies. None of the azacytidine-based protocols 
resulted in changes in gene expression consistent with cardiomyocyte differentiation. When 
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azacytidine was combined with FGF2 (Screen 3, Chapter 5), non-specific patterns of gene 
expression were observed in CSP clones 3 and 16. Taken together these results do not 
support the utility of azacytidine for the in vitro differentiation of adult cardiac progenitor cells. 
 
Coculture is the best-agreed method for the in vitro differentiation of adult cardiac progenitors 
(Chamuleau et al., 2009). However, coculture protocols based on cellular admixture are 
vulnerable to the confounding effects of marker exchange and cell fusion (Koyanagi et al., 
2005; Zaruba et al., 2010). Instead, a coculture methodology was adopted in which 
cocultured cells are segregated by a permeable membrane (Chong et al., 2011). CSP clones 
3 and 16 harbouring a Myh6-mCherry reporter transgene were used to facilitate monitoring of 
differentiation events in live cells. Although robust reporter gene expression was observed 
with coculture for both clonal lines, this observation did not correlate with the induction of 
endogenous genes associated with the cardiomyocyte lineage.  
 
The absence of in vitro cardiomyocyte differentiation of CSP and CSP clones under the 
conditions tested represents an unexpected finding, given previous reports of the efficacy of  
the parent Sca1+ population (Matsuura et al., 2004; Oh et al., 2003). It is of note that the list 
of protocols tested was not exhaustive, and other reported methods might be effective 
(Gaetani et al., 2009; Smits et al., 2009b). However, it is also possible that the process of 
culture, adaptation and expansion required to generate sufficient material for study (both for 
CSP and CSP clones), led to a loss of differentiation capacity, as has been reported for other 
cardiac progenitor populations (Smits et al., 2009b). Alternatively, the serial passage of cells 
may negatively select against cells with the greatest cardiomyocyte lineage potential. 
Nevertheless  cardiomyocyte (and also endothelial and smooth muscle cell) differentiation 
was demonstrated by in vivo grafting suggesting that it the in vitro methods, rather than the 
inherent capacity of the cells themselves, determined the outcome. 
 
To account for the seemingly contradictory findings from cardiomyocyte differentiation 
studies in vivo and in vitro, it is possible that the isolation of CSP clones from the cardiac 
Sca1+ population leads to the exclusion of stromal cell types that are essential for 
differentiation. Such ancillary cell types may be required to provide the appropriate 
microenvironment for CSP cell differentiation or alternatively to respond to and transmit 
inductive signals. The regulatory effects of stromal cells on the proliferation and 
differentiation of adult stem/ progenitor cells is well described (Aoyama et al., 1999; Jing et 
al., 2010); furthermore, cell therapy with bone marrow-derived Kit cells was observed to 
augment the contribution of stem cells to cardiomyogenesis following injury (Loffredo et al., 
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2011). The interplay between different cell types to determine cardiac progenitor cell fate 
may take the form of juxtacrine signalling through cell-to-cell or cell-to-matrix interactions 
(Ieda et al., 2009) or act remotely in a paracrine fashion (Lavine et al., 2005). In 
development, the essential nature of such signalling for normal cardiac progenitor cell 
function and myocardial development is established (Ieda et al., 2009; Lavine et al., 2005) 
 
In the coculture experiments described herein, CSP cells were physically isolated from the 
inductive cells, potentially negating essential juxtacrine signalling between the cell types 
reported elsewhere to be essential (Pfister et al., 2005). Although Chong et al. (2011), report 
cardiomyocyte differentiation following segregated coculture, the cells generated were non-
contractile and only expressed two markers of the differentiated cardiomyocytes, namely 
cardiac α-actin and connexin 43. For methods for admixture-based cardiomyocyte coculture 
it is not certain whether inductive signals arise from cardiomyocytes or stromal cell 
populations that are liable to contaminate this fraction during isolation (Pfister et al., 2005). 
Laugwitz et al., demonstrated that co-culture with cardiac stromal cells is necessary for the 
maintenance of multi-potency and expansion of Isl+ cardiac progenitors (Laugwitz et al., 
2005). 
 
For the differentiation studies reported in this thesis, cells were treated as monocultures on 
collagen or fibronectin coated tissue culture vessels. It is well described that the micro-
environmental aspects of cell culture relating to the spatial orientation of cells and the 
extracellular matrix components can significantly impact stem cell differentiation capacity 
(Daley et al., 2008; Guilak et al., 2009). Laugwitz et al., were able to isolate the micro-
environmental contribution and signal-independent effects of cardiomyocyte co-culture by 
demonstrating cardiomyocyte differentiation from culture with pre-fixed myocytes (Laugwitz 
et al., 2005). 
 
Smooth muscle lineage potential of CSP in vitro 
Smooth muscle marker expression was observed under conditions of low serum for CSP 
clones 3, 16 and cardiac Sca1+ cells (gene expression: Myh11, Cnn1, sm22α, SMA; protein 
expression: Cnn1, sm22α, SMA). For CSP clone 16 and Sca1+ marker induction was 
potentiated by BMP4 supplementation and the levels of transcript abundance approached 
those observed for the mouse aorta. Endothelial differentiation was not observed, although 
specific conditions to direct differentiation to this particular lineage were not assessed. In vivo 
grafting studies demonstrated equivalent rates of smooth muscle differentiation between 
CSP clones 3 and 16, whereas in vitro CSP clone 16 was found to have a higher predilection 
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for this fate in vitro. Further studies are required to unravel the lineage relationship of these 
cells and to explore the significance of heterogeneity of cardiac transcription factor 
expression, particularly with respect to cardiomyocyte differentiation. 
 
In vivo lineage tracing of cardiac Sca1+ cells 
Although cell grafting experiments and in vitro differentiation are informative in determining 
the lineage potential of adult cardiac progenitor populations, it is acknowledged that in vivo 
lineage tracing experiments are essential to corroborate these findings under physiological 
conditions of homeostasis and/ or injury response (Mummery and Lee, 2013).  Recent 
reports employing Cre/ LoxP lineage fate mapping have gone some way to address this 
question; such studies are reported for EPDCs (Smart et al., 2011), cardiac Kit+ (Ellison et 
al., 2013) and Sca1+ cells (Uchida et al., 2013).  
 
Ellison et al., report robust cardiomyocyte differentiation in vivo from endogenous Kit+ cells 
using a lentivirally delivered Cre recombinase under the control the Kit upstream regulatory 
element (Ellison et al., 2013). Whilst these data support the functional role for Kit+ cells as 
the effectors of regeneration following injury, concerns over the specificity of the Kit-Cre 
complicate the interpretation of these findings (Molkentin and Houser, 2013). Similarly, Smart 
et al. (2011) were able to perform in vivo lineage tracing of adult EPDCs, based on the 
selective expression of WT1 in this population following experimental myocardial infarction. A 
tamoxifen dependent WT1-Cre mouse crossed with a Cre dependent reporter strain was 
used permit the tracing of adult WT1 positive EPDCs. The activation of EPDCs was found to 
be enhanced by pretreatment with parenteral thymosin ß4, an actin sequestering protein with 
moonlighting properties as a signaling factor that promotes wound healing (Goldstein et al., 
2005). Under these conditions, a small number of cardiomyocytes descended from WT1 
expressing adult EPDCs were identified. Of note, 80% of cardiac cells expressing WT1 
following treatment with thymosin ß4 also co-expressed Sca1. 
 
Similarly, the lineage fate of cardiac Sca1+ cells in vivo was recently reported (Uchida et al., 
2013). Here, a tet-off mouse line (Sca1-tTA) was generated to investigate the fate of cardiac 
Sca1+ cells in vivo, based on the 14 kb promoter fragment of the Sca1 gene (Ma et al., 
2002). Immunohistochemical analysis and the Sca1-GFP reporter mouse (Ma et al., 2002) 
were used to demonstrate the absence of Sca1 expression in cardiomyocytes under 
conditions of normal homeostasis and pressure overload (transverse aortic constriction). 
Interestingly, Sca1-GFP+ cells were found under the basal lamina of a minority of individually 
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isolated cardiomyocytes (8.55%), reminiscent of relationship of satellite cells to skeletal 
myocytes (Gunther et al., 2013).  
 
To facilitate lineage tracing of Sca1+ cells in vivo, the Sca1-tTA mouse line was crossed with 
the Z/ AP (Lobe et al., 1999) and LC1-Cre (Schonig et al., 2002) mouse lines to generate 
Sca1-tTA//LC1-Cre//Z/AP mice. In the absence of doxycycline, Sca1 expressing cells are 
permanently labelled with human placental alkaline phosphotase. By this method, they 
confirmed cardiomyocytes are derived from a Sca1+ cells in development. Further by 
crossing with the R26R confetti reporter mouse line, these investigators were able to perform 
a retrospective clonal analysis of Sca1+ cells in vivo (Snippert et al., 2010). In this system, 
Cre expressing cells are marked stochastically with one of four fluorescent proteins (green, 
yellow, red or mCerulean fluorescent protein). By this method, it was determined that the 
majority of clonally derived cells were of a single lineage (cardiomyocyte, endothelial or 
smooth muscle cell) suggesting limited lineage potential of individual cardiac Sca1+ cells in 
vivo. Furthermore, only a small subset of Sca1+ clones generated cardiomyocytes when 
compared to other lineages (endothelial and smooth muscle cells). These data suggest that 
the majority of Sca1+ cells in the heart have a more restricted lineage potential compared 
with that of developmental progenitors such as Isl1+ cells of the second heart field (Laugwitz 
et al., 2008). If confirmed, these observations might be compatible with the heterogeneity of 
gene expression observed within the CSP population and account for the predilection of CSP 
clone 16 over clone 3 for the smooth muscle fate. 
 
Collectively these studies provide strong evidence that adult cardiac Sca1+ cells mediate 
postnatal cardiogenesis in the mouse. The finding that EDPC function could be enhanced by 
treatment with thymosin β4 provides a compelling example of how endogenous progenitor 
function may be favourably modulated to augment cardiac regeneration following injury 
(Smart et al., 2011).  
 
The potential of cardiac progenitor cell-based phenotypic screens as a 
discovery platform 
Since cardiomyocyte replenishment is established as the limiting factor in cardiac 
regeneration, understanding the signals driving the cardiomyocyte differentiation of resident 
stem/progenitor cells may help to identify novel targets for therapies aimed at enhancing 
repair. Despite considerable advances in the understanding of the signals that direct the 
specification of cardiac progenitors in development, the molecular cues that guide 
subsequent cardiomyocyte differentiation and maturation remain elusive (Noseda et al., 
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2011); still less is known about the signals that direct these processes in adult cardiac stem 
cells (Mercola et al., 2011). Conceptually, phenotypic screens based on cardiomyocyte 
differentiation of adult stem cells represent an attractive and tractable approach to 
uncovering these signals.  
 
As described above, the potential for therapeutic modulation of endogenous progenitor 
function is exemplified by finding that treatment with thymosin β4  improves outcomes from 
experimental infarction, at least in part, by stimulating EPDC mobilization and cardiomyocyte 
formation (Smart et al., 2011). Similarly Hsueh et al., demonstrated that prostaglandin E2 is 
essential for cardiomyogenesis from grafted Sca1+ cells (Hsueh et al., 2014). Using 
tamoxifen treated Cre-LoxP MerCreMer/ ZEG (M/ Z) transgenic mice as the recipients for 
grafts, investigators were able to quantify the genesis of cardiomyocytes from grafted Sca1+ 
cell (negative for LacZ and GFP). They inferred that approximately 10% of all cardiomyocytes 
in the border zone were derived from grafted cells and subsequently showed that this 
contribution was negated when the experiment was repeated with cells that were null for the 
prostaglandin E2 receptor. The potential for therapeutic translation of these findings was 
highlighted by the observation that prostaglandin E2 supplementation, improved the 
differentiation of Sca1+ cells in vitro and restored the diminished regenerative capacity of 
aged cells. The potentiating effect of thymosin β4 and prostaglandin E2 on endogenous 
cardiac progenitors were discovered by hypothesis driven research based knowledge 
(Hoggatt et al., 2013; North et al., 2007; Smart et al., 2007). In vitro screening of adult 
cardiac progenitors has the potential to serve as a useful platform for the discovery of 
previously unknown pathways regulating cell fate.  For this ambition to be realised, highly 
defined cell populations will be required for which the endogenous function is well described. 
 
Although the case for cardiac Sca1+ cells contributing to adult cardiomyogenesis continues to 
strengthen (Hsueh et al., 2014; Uchida et al., 2013), it is also clear that this population is 
heterogeneous and the cardiogenic sub-population is yet to be conclusively defined. In this 
thesis, clonal populations derived from the SP sub-population have been investigated for in 
vitro differentiation as candidate cells for future screens. Gene expression profiling 
demonstrated heterogeneity with respect to baseline gene expression, perhaps reflecting 
heterogeneity of the parent cardiac Sca1+ population.  Of the two clones tested, CSP clone 
16 which did not express Gata4 or Nkx2.5 had a greater predilection for the smooth muscle 
fate over CSP clone 3 for which these factors were present. Although in vivo grafting studies 
had previously demonstrated tri-lineage potential for CSP clones 3 and 16 (cardiomyocyte, 
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endothelial and smooth muscle), cardiomyocyte differentiation was not observed in vitro 
under a range of conditions.  
 
The elaboration of robust and reproducible methods for the cardiomyocyte differentiation of 
cardiac Sca1+ / CSP cells are a pre-requisite for use in large-scale screens and further work 
is required to achieve this. It is postulated that coculture with relevant companion cell types 
may be essential to recapitulate the function of the cardiac Sca1+ population and CSP in 
vitro. The heterogeneity inherent in the cardiac Sca1+ population is unlikely to be optimal and 
rather it is suggested that specifically defined admixtures of cell types such as cardiomyocyte 
and stromal cells may better recapitulate function in vivo. 
 
Toward this goal, it is likely that methods for cell culture will be required that better 
recapitulate the cellular and extracellular matrix constituents of the endogenous micro-
environment if stem cell behaviour is to be modelled faithfully in vitro. Existing methods for 
differentiation of cardiac Sca1+ and CSP in vitro are based on treatment of cells in monolayer 
on coated cell culture vessels which poorly models the native milieu (Matsuura et al., 2004; 
Oh et al., 2003). It is possible that the shortcomings of these culture methods in part explain 
the low incidence of cardiomyocyte differentiation and the relative immaturity of the cells 
generated.  
 
Considerable progress has been made towards the ‘bioengineering’ of myocardial tissue in 
vitro using a variety approaches, including collagen (Zimmermann et al., 2006), fibrin (Schaaf 
et al., 2011), alginate (Dar et al., 2002) gel-based scaffolds, as well as micro-topographically 
engineered culture substrates (Patel et al., 2011). Tulloch et al., 2011, report the 
development of highly organised cardiac tissue derived from cocultured iPSC 
cardiomyocytes, MSCs and endothelial cells. In this system, cells were seeded onto collagen 
based scaffolds and exposed to programmed mechanical stress which was essential to 
achieve cardiomyocyte alignment and coordinated function. It is also of note that the 
efficiency with which vascular cord structures were formed was reduced 10-fold when MSC 
were omitted from the coculture. Analogous approaches are appropriate for the modelling of 
adult cardiac progenitor populations in vitro and the establishment of phenotypic screens as 
a discovery platform.  
 
Given the number of potential variables, new approaches are required for the optimisation of 
cardiac progenitor cell differentiation in vitro. In this report, the development of the Myh6-
mCherry/ PGK-BSNr reporter has been described towards enabling optical-based, large-
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scale screening of cardiogenic factors. Desbordes et al., and Willems et al., have used 
similar approaches to discover novel small molecule regulators of embryonic stem cell self-
renewal and differentiation (Desbordes et al., 2008; Willems et al., 2012). However, for these 
approaches to be successful for adult cardiac progenitors, it may be necessary to first 
establish conditions for cell culture that better simulate the micro-environment in vivo. 
Although the number of potential variables is large, a number of novel enabling technologies 
for optimisation are available. One approach is the miniaturisation of cell culture platforms 
using microfabrication techniques facilitating high bandwidth testing of conditions (Kobel and 
Lutolf, 2010). Flaim et al., developed a technology to generate extracellular matrix micro-
arrays to study the relationship between matrix composition and stem cell function in a high 
throughput process (Flaim et al., 2005). They have since extended this method to include the 
application of soluble growth factors to conduct optical screens of the conditions for ESC 
cardiomyocyte differentiation based on an Myh6 reporter gene, similar to that described in 
this thesis (Flaim et al., 2008). A similar approach could be envisaged for the adult cardiac 
progenitor populations described here.  
 
In such screens, the choice of assay system for reporting stem cell fate is determined in part 
by the constraints inherent in the approach. Optical gene reporters have been used widely in 
this context (Dixon et al., 2011; Flaim et al., 2008; Willems et al., 2012; Willems et al., 2011). 
In this report, the development of a lentiviral fluorescent reporter, based on the Myh6 
promoter for use in CSP cells, is described. Whilst the reporter was found to distinguish 
cardiomyocytes from other differentiated cell types with high sensitivity and specificity, in 
screens of CSP differentiation activation was found not to accurately reflect expression of 
endogenous Myh6. As discussed above, ectopic expression of transgenic Myh6-promoter 
based reporters in differentiation screens is not unprecedented (Bruneau, 2012; Chen et al., 
2012; Song et al., 2012). However, utility in future work may be limited to the short-listing of 
conditions for driving cardiomyocyte differentiation and for the enrichment of differentiated 
cells for analysis. Perhaps the most robust approach for the generation of adult cardiac 
progenitor reporter cell lines is to derive the cells from transgenic animals in which tissue-
specific expression has been extensively validated.  
 
Engineering BAC (bacterial artificial chromosome) constructs for mouse transgenesis has 
enabled the creation of reporter genes incorporating large regulatory sequences that are 
insulated from the effects related to the genomic context of integration (Fu and Maye, 2011). 
Stringency of tissue specificity is of paramount importance in investigation of stem cell 
function, particularly for in vivo lineage tracing using the Cre/ LoxP system. Although Ellison 
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et al., report robust cardiomyogenesis from cardiac Kit+ precursors labelled with lentivirally 
delivered Kit-Cre (Ellison et al., 2013) these findings were not reproduced in similar studies 
using a Kit(BAC)-GFP transgenic mouse (Jesty et al., 2012). These approaches are however 
not translatable to human primary cells, and alternative approaches are required which may 
include image-based methods to measure calcium kinetics (Cerignoli et al., 2012) and high 
throughput gene expression profiling (Haining et al., 2008). 
 
Finally, to realise the potential for phenotypic screening based on adult cardiac progenitors it 
is likely that human cells will be required. In the absence of a known ortholog of Sca1, an 
alternative strategy for the isolation of cardiac progenitors is needed; the SP assay may 
represent a tractable approach (Sandstedt et al., 2012). Given the challenges of obtaining 
human myocardial tissue from which to isolate progenitor cells, an alternative approach 
might be to generate adult progenitors in vitro from iPSC or ESC for use in screens (Braam et 
al., 2009; Li et al., 2012). 
 
In conclusion, this work has demonstrated the challenges inherent in using cardiac 
progenitor populations in high content screens for the discovery of novel cardiogenic factors. 
The discrepancy between the in vivo and in vitro lineage capacity of clonal CSP cells 
suggests that monolayer culture of homogenous cell types may not be sufficient to for the 
cells to recapitulate endogenous function in vitro. It is likely that cell culture methods will be 
required that better recapitulate the microenvironment will be required if CSP function is to be 
investigated fruitfully in vitro. The application of fluorescent reporter gene assays to facilitate 
optimisation of these aspects is an attractive strategy; however, the findings here reiterate 
the importance of rigorous testing for tissue specificity. Although the technical hurdles are 
high for the realisation of CSP based screens for the discovery of novel regenerative signals, 
the level of unmet need and the promise that this approach holds mandates perseverance.  
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